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Sammendrag på norsk 
DNA er et tilsynelatende stabilt molekyl, som overføres så å si uten endringer fra 
unnfangelse til alderdom og fra generasjon til generasjon. Men arvestoffet vårt er ikke så 
uforanderlig som det kan se ut som. DNA kan endres kjemisk ved å reagere med en rekke 
stoffer som er påført utenfra eller som normalt finnes inne i enhver celle. DNA består av 
repeterende enheter av nukleotider, som igjen består av fosfat-, sukker- og basegrupper. Fosfat- 
og sukkergruppene danner en ryggrad, mens basene parer med andre baser på en motstående 
DNA-tråd. Fokus for denne avhandlingen er baseskadene uracil og 5-fluorouracil. Uracil dannes 
ved at den normale basen cytosin reagerer med vann. Dette resulterer i et uracil:guanin base-par. 
Eventuelt kan både uracil og 5-fluorouracil inkorporeres i stedet for den normale basen thymin 
under DNA-replikasjon. Dette resulterer i uracil paret med adenin, mens 5-fluorouracil kan pare 
med adenin eller guanin.  
For å unngå at skader på DNA resulterer i mutasjoner finnes det flere mekanismer i 
cellen som erstatter og reparerer skadd DNA. En av de viktigste reparasjonsmekanismene er 
base eksisjonsreparasjon (BER). BER initieres ved at en DNA-glykosylase kutter en skadd eller 
unormal base fra DNA. Hos mennesker er det identifisert fire forskjellige glykosylaser som alle 
kan initiere reparasjon av uracil og 5-fluorouracil: UNG, SMUG1, TDG og MBD4. En AP-
endonuklease kutter så sukker-fosfat ryggraden ved å kutte ved siden av den nå base-løse 
sukkergruppen, og et nytt nukleotid settes inn av en DNA polymerase. Restene av 
sukkergruppen kan så fjernes direkte av DNA-polymerasen, før ryggraden på DNA-tråden 
bindes sammen av en DNA ligase. I sum blir dermed en skadd base erstattet med en normal (en-
nukleotid BER). I enkelte tilfeller klarer imidlertid ikke polymerasen å fjerne det som er igjen 
av sukkergruppen, dette skjer gjerne når sukkergruppen har blitt redusert eller oksidert. Da vil 
polymerasen sette inn flere nukleotider, slik at den skadde sukkergruppen fortrenges. Dette 
skaper en spesiell struktur som gjenkjennes av en flap endonuklease, som kutter ut den 
fortrengte biten, før en DNA ligase knytter DNA-tråden sammen igjen. Dermed fører reparasjon 
av en skadd base til at flere nukleotider erstattes (fler-nukleotid BER).  
Inntil nylig har ikke fler-nukleotid BER vært observert i cellenes mitokondrier, som har 
sitt eget DNA å ta vare på. Hvordan ville i så fall mitokondriene håndtere skader som i 
cellekjernen repareres av fler-nukleotid BER? Dette har vi undersøkt i det første arbeidet, hvor 
vi fant at også mitokondriene kunne utføre fler-nukleotid BER.  
Uttrykket av glykosylasen UNG varierer mellom forskjellige mennesker, organer og 
cellelinjer. I det andre arbeidet viser vi at hastigheten til BER sporet som helhet kontrolleres på 
det første trinnet, det vil si av mengde og aktivitet av DNA-glykosylasen som initierer 
reparasjonen. UNG initerte all observerbar reparasjon av uracil paret med adenin, mens 
reapasjon av uracil paret med guanin ble initiert hovedsakelig av UNG, med et relativt stort 
bidrag fra TDG i en av cellelinjene.  
I det tredje arbeidet har vi studert hvordan 5-fluorouracil repareres i DNA og hvilken 
betydning DNA-reparasjon har å si for virkningsmekanismen for 5-fluoruracil. Vi fant at BER, 
initiert av UNG2, står for det aller meste av reparasjonen når 5-fluorouracil er paret med adenin. 
Når 5-fluorouracil er paret med guanin utfører BER, initert av UNG2, SMUG1 eller TDG det 
meste av reparasjonen, mens mismatch-reparasjon ser ut til å være av mindre betydning. 
Nedregulering av de nevnte glykosylasene og hemming av BER-sporet påvirket imidlertid ikke 
kreftcellelinjers følsomhet for 5-fluorouracil. Dermed later det til at i dette tilfellet spiller ikke 
inkorporering i DNA og påfølgende DNA-reparasjon noen stor rolle for celledød. I stedet ser 
det ut som om 5-fluorouracil heller dreper celler via inkorporering i RNA, samt ved at 
dannelsen av thymidin-nukleotider hemmes. 
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1. INTRODUCTION 
 
A human embryo develops from a single cell at the time of conception into a multitude 
of different cells that comprise the adult body. Decades later, these cells will 
collectively have the experiences of a lifetime, while the genetic material will remain 
essentially unchanged. Genetic information is also stable at far longer timescales, as the 
genetic information that constitutes a human, chimpanzee, mouse or whale show far 
more similarity than morphology would suggest. Yet, while DNA is apparently 
exceedingly stable, it is far from chemically inert. The chemical structure of DNA is 
altered through chemical reactions with a multitude of exogenous chemicals such as 
those found in cigarette smoke, as well as the exposure to ionising and ultraviolet 
radiation. Furthermore, compounds found in the cellular environment may also damage 
DNA. The most abundant of these is water, which is present at a concentration of ~55 
M.  
1.1 Base loss  
 
Water can react with DNA in several ways. The N-glycosidic bond between base and 
sugar is particularly susceptible to hydrolysis, resulting in base loss and the generation 
of an exposed deoxyribose site called an apurinic/apyrimidinic (AP) site in DNA [1]. 
Purines are lost from DNA at a higher rate than pyrimidines. Guanine hydrolyses at a 
slightly higher rate than adenine, while the loss of pyrimidines is ~20 times slower than 
that of guanine. The rate of depurination is 4 times higher in ssDNA than in dsDNA [2]. 
It has been estimated that this takes place approximately 10000 times per human diploid 
cell per day [2,3].  
1.2 Deamination 
 
Water can also react with exocyclic amino groups in DNA bases, most frequently at 5-
methylcytosine and cytosine to produce thymine and uracil, respectively. The former 
deaminates at a four times higher rate than the latter, and the deamination rate is several 
hundred-fold increased in single-stranded DNA (ssDNA). Estimates on the formation of 
uracil from cytosine range from 70 to a few hundreds per cell per day, depending on 
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how much of the DNA is assumed to be single-stranded ([4] and references therein). 
While 5-methylcytosine deaminates at a higher rate than cytosine, it is much rarer in the 
human genome. Thus, approximately 10% of cytosine deaminations occur at 5-
methylcytosines [1]. In addition, the exocyclic amino groups of adenine and guanine are 
vulnerable to hydrolytic deamination, producing xanthine and hypoxanthine, 
respectively. However, these products are formed at only about 2-3% the rate of 
cytosine deamination. These exocyclic amino groups are involved in Watson-Crick base 
pairing, so the products of deamination will be mutagenic. Deaminated (5-methyl) 
cytosine pairs with adenine, while hypoxanthine pairs with cytosine. Xanthine is non-
coding (Figure 1) [1].  
N
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(Guanine)
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(Adenine)
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(Cytosine)  
Figure 1: Hydrolytic deamination of DNA bases generates base analogues that are mis- or non-coding. The 
preferential base-paring partner is given in parentheses. Note that the deamination of 5-methylcytosine results in a 
base normally present in DNA.  
 
1.3 Reactive oxygen species 
 
Many processes produce reactive oxygen species (ROS) in the cell. Up to 0.2% of the 
oxygen consumed in normal oxidative respiration in mitochondria are converted to 
superoxide ions (O2-) [5], which is further converted to hydrogen peroxide (H2O2) and 
the very reactive hydroxyl radicals (•OH) inside the cell. Furthermore, similar ROS are 
created as a consequence of ultraviolet light, inflammation, cell injury, phagocytosis, 
and the hydroxylation of steroids and drugs [6]. ROS oxidation of DNA results in 
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single- and double-strand breaks, AP-sites, as well as a multitude of modified bases 
[6,7]. For pyrimidines, the double bonds between 5 and 6 positions are especially 
vulnerable, as are methyl groups in thymine and 5-methylcytosine. Purines are 
frequently oxidised in the 8-position, which may create ring-opened 
formamidopyrimidines (FaPyA and FaPyG), and a multitude of other lesions [7]. Many 
of these appear to be generated in large amounts endogenously in mammalian cells, and 
may be mis- or non-coding, mutagenic and/or cytotoxic. Quantitation of these lesions is 
problematic, however, and estimates vary by several orders of magnitude. Furthermore, 
reactions of ROS with polyunsaturated membrane lipids produce potent DNA-reactive 
agents as by-products. These yield several mutagenic etheno- and propanobase adducts 
[8], the best studied is malondialdehyde (MDA), which predominantly produces 
pyrimido[1,2-a]purin-10 (3H) -one, abbreviated M1G, in DNA [9]. Additionally, 
ionising radiation (IR) produces ROS in large amounts. IR is naturally present in the 
environment, as a result of the disintegration of naturally occurring radionuclides, or 
may be extra-terrestrial in origin. IR damages DNA directly through the excitation and 
ionisation of bases and sugars in DNA or indirectly through the generation of ROS. IR 
induces localised base damage, single- and double-strand breaks, and is used in the 
treatment of cancer [10].  
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Figure 2: Susceptibility of alkylation at extracyclic oxygens and ring nitrogens in DNA bases. Many alkylations 
interfere with Watson-Crick hydrogen bonding, and generates mis- or non-coding adducts. 
1.4 Alkylating agents 
 
Endogenous alkylating agents participate as methyl-donors in many biochemical 
reactions, and are ubiquitous in mammalian cells. Exogenous alkylating agents exist in 
cigarette smoke, environmental toxins and products of incomplete burning of biomass. 
Many are carcinogens, such as benzo(a)pyrene. Both endo- and exogenous alkylating 
agents may interact and adduct nucleophilic centres in DNA bases, i.e. at positions 
occupied by oxygen and nitrogen atoms (Figure 2) [10,11]. One of the most abundant 
endogenous methyl donors is S-adenosyl-L-methionine, which has the potential to 
alkylate bases in DNA, predominantly resulting in 4000 7-methylguanines, 600 3-
methyladenines, as well as 10-30 O6-methylguanines per human cell per day [12]. 
These, and other examples of methylated bases, are found in samples from human cells 
at steady state levels at around one per 107 nucleotides, give or take an order of 
magnitude [13]. The biological consequences of these lesions are diverse. While 7-
methylguanine is thought to be rather harmless, 3-methyladenine blocks replication and 
is highly cytotoxic, and O6-methylguanine is highly mutagenic and cytotoxic [1]. While 
 13
many of the alkylating agents are carcinogenic, such as the tobacco-specific 
nitrosoamines [14], they may also be used to treat cancer. Monofunctional agents (e.g. 
carrying one reactive group) such as temozolomide (TMZ) methylate DNA bases, while 
bifunctional agents, i.e. those carrying two reactive groups such as melphalan, also have 
the capacity to crosslink two different bases that can be on the same or different strands 
of DNA [10]. Thus, exogenous alkylating agents are of vital importance for both the 
generation and treatment of human cancer. 
1.5 Misincorporation by polymerases 
 
In addition to the threats posed by reactive compounds constantly present in the cellular 
environment, enzymes that exert their normal function may also alter or damage the 
sequence of DNA. One example of this includes the introduction of mismatches by 
DNA polymerases, which has a small probability of introducing mismatched 
nucleotides during DNA synthesis. A suboptimally balanced nucleotide pool may 
further decrease the replication fidelity. Under these conditions, a high or low 
concentration of one or more nucleotides may lead to the formation of non-Watson-
Crick base pairing (reviewed in [15]). Furthermore, replicative DNA polymerases tend 
to incorporate dNTPs carrying a base with similar structure as the four canonical bases. 
Hence, dGTP which is easily oxidised in the 8-position (8-oxo-dGTP) is readily 
incorporated into DNA. During replication, its incorporation is precluded by MutT-
homolog 1 (MTH1), which hydrolyses 8-oxo-dGTP to 8-oxo-dGMP [16].  
 
A similar preclusive mechanism acts on dUTP, which is a normal intermediate during 
de novo synthesis of dTTP. dUTPase hydrolyses dUTP to dUMP, which is in turn is 
converted to dTMP by reaction with N5,N10-methylenetetrahydrofolate (THF) 
catalysed by thymidylate synthase (TS). The inhibition or lack of either enzyme or THF 
due to dietary factors, results in an increased dUTP/dTTP ratio. As the replicative 
polymerases have a similar KM towards these nucleotides, dUTP is readily incorporated 
into DNA resulting in U:A base pairs according to standard Watson-Crick base pairing. 
These are not mutagenic by themselves, but because the repair of U:A to T:A may 
employ a polymerase with a higher error frequency than replicative polymerases, the 
resulting repair of U:A may well result in mutagenesis [17]. Furthermore, the 
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replacement of uracil with thymine in DNA alters the binding of transcription-factors 
[18]. While substantial amounts of thymine can be replaced with uracil in the genomes 
of genetically engineered E. coli and S. cerevisiae, they will eventually stop dividing 
due to a “general failure of macromolecular biosynthesis” [19,20]. Furthermore, 
replacing about ~1% of thymines with uracil in S. cerevisiae results in a mutator 
phenotype characterised by AT to CG transversions [21].  
 
Mammalian cells accumulate uracil in their genomes too. This is aggravated by 
treatments which result in a higher dUTP/dTTP ratio, i.e. methotrexate inhibits 
dihydrofolate reductase (DHFR), thus reducing the availability of THF to be used as a 
methyl-donor in dTMP synthesis [22]. Folic acid and vitamins B6 and B12 are all 
required for the biosynthesis of THF. THF will not be replenished if the supply of these 
nutrients is low enough, ultimately leading to an increased uracil misincorporation into 
DNA of mammalian cells. Importantly, folate deficiency in humans are linked to several 
disorders including colon cancer, neurodegeneration and birth defects ([23]; reviewed 
by [24]).  
 
The manipulation of TS activity is exploited in the treatment of cancer, as treatment 
with fluoropyrimidines leads to inhibition of TS. The fluoropyrimidines are inter-
converted to a variety of fluorinated ribonucleotides and deoxyribonucleotides inside 
the cell. 5-fluoro-2-deoxyuridine monophosphate (5-FdUMP) binds with high affinity to 
TS and inhibits the enzyme. This depletes the level of dTTP, necessary for DNA 
synthesis, Moreover, the dUTP/dTTP ratio increases, which results in insertion of 
dUMP into DNA. Finally, imbalanced nucleotide pools may lead to the generation of 
mispairs by replicative polymerases [25,26,27]. However, this is not the only proposed 
cytotoxic mechanism of fluoropyrimidines, as 5-FU is incorporated into both RNA and 
DNA [28]. 5-FU pairs most efficiently with adenine, but may also pair with guanine 
through a pH-dependent ionisation of the base [29]. The removal of 5-FU by DNA 
repair processes could contribute to the cytotoxicity of the drug [25] either as a 
consequence of repair, or indirectly as a consequence of utilising a skewed nucleotide 
pool for repair [15]. Finally, the incorporation into RNA disrupts rRNA, tRNA and 
mRNA, as well as the processing of uridine into pseudouridine [30,31,32,33,34,35]. All 
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of these mechanisms can probably contribute to cytotoxicity to some extent, but even 
after half a century of clinical use the relative contribution of each is still a matter of 
dispute.  
 
While the examples mentioned so far have described damage to DNA due to interaction 
with endogenously occurring reactive substances in a more or less random manner, 
endogenously encoded enzymes may also specifically damage DNA. Human cells 
contain a number of enzymes in the apolipoprotein B-editing catalytic polypeptide 
(APOBEC) family, that deaminates cytosine to uracil in nucleic acids, thus potentially 
yielding a CG->TA mutation [36]. The best studied of these is the activation-induced 
deaminase (AID), which specifically deaminates cytosine residues in immunoglobulin 
loci in maturating B-cells. This is required for class-switch recombination (CSR) as well 
as somatic hypermutation (SHM) [37,38]. Others, e.g. APOBEC3G, deaminates 
retroviral genomes in the cytosol, thereby restricting their replication [39]. 
 
Thus, even if we disregard exogenous threats such as IR and environmental chemicals, 
the DNA of human cells are under constant assault from reactive components of the 
cellular environment, in sum totalling at the very least a few ten thousands DNA lesions 
per cell per day, most of which are potentially mutagenic. Yet the DNA of human cells 
are replicated with an impressive accuracy - less than one of the 3.2·109 base pairs in the 
human genome are mutated per replication [40]. However, several DNA repair 
mechanisms maintain the chemical and sequential integrity of the genome by removing 
DNA damage prior, during and after replication. 
1.6 DNA damage and cancer 
 
In contrast to somatic cells, which replicate their DNA with high fidelity, are cancer 
cells characterised by the accumulation of mutations of all types. The most striking 
examples are provided by the fact that most cancer cells are not diploid, i.e. they carry 
an abnormal number of chromosomes, which in turn alters the expression of thousands 
of genes [41]. Alternatively, chromosomes may also contain insertions, deletions, 
amplifications, rearrangements or translocations of large chromosomal segments. These 
may generate oncogenic fusion proteins, or put normally coding genes under the control 
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of different promotors [42]. Such chromosomal changes are referred to as chromosomal 
instability (CIN). Yet another example of genetic instability is hereditary non-polyposis 
colon cancer (HNPCC). HNPCC is characterised by a rather stable number and 
structure of chromomsomes, but is associated with changes in the number of simple 
repetitive sequences 1-6 nucleotides in length. This may potential result in inactivating 
frameshift mutations. Such repetitive sequences are called microsatellites and hence, 
variation in the number of repeats is referred to as microsatellite instability (MSI) [43]. 
Additionally, tumour cells tend to accumulate point mutations more frequently than 
normal tissue [44,45,46]. And even when the nucleotide sequence is preserved, 
epigenetic changes in methylation status may very well alter the expression of genes 
that promote tumourigenesis, as demonstrated for the human MLH1-gene [47].  
 
Is the documented genomic instability a cause of or consequence of cancer? Is it an 
early or late event in carcinogenesis? It has been argued that the sheer volume of genetic 
changes observed in cancer cells is so large that it could not have arise as a result of a 
normal mutation rate. Thus, an enhanced mutation rate brought about by random 
mutations in genes responsible for the stability of DNA (e.g. DNA repair genes) could 
well be an early event in tumourigenesis [46,48]. This hypothesis is, however, debated 
[49]; some maintain that an instability at the chromosome-level is sufficient to explain 
cancer [41], others argue that a mutator phenotype – at any level – is not necessary at 
all. In this scenario, rare mutations in genes that confer some kind of growth advantage 
to the cell will be selected for. Thus, given enough cell divisions and natural selection, 
they argue that normal mutation rates may well account for the genetic variability of 
human cancers [50]. 
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2.0 DNA REPAIR MECHANISMS 
 
The DNA in a human cell is continuously challenged by various modifications and 
alterations even in the absence of exogenous DNA damaging agents. Yet, human cells 
are able to cope with these challenges and replicate with high fidelity by employing 
enzymatic systems that detect and repair damaged DNA. In many cases the repair is 
error-free, returning DNA to the state it was in before the lesion. Repair may, however, 
also be error-prone, thus ’repairing’ DNA to something else than the original state. 
About 150 human genes are currently identified as or (suspected to be) implicated with 
DNA repair. A frequently updated table summarising these genes, and containing links 
to relevant databases are found at http://www.cgal.icnet.uk/DNA_Repair_Genes.htm 
[51,52]. 
2.1 Direct reversal of DNA damage 
The simplest imaginable mechanism of direct damage reversal is demonstrated by 
ligases, which re-join strand breaks generated by e.g. oxidative damage [10]. 
The AlkB-homologue family, of which there are at least nine members in the human 
genome, provides an example of direct repair of methylated bases in nucleic acids 
[53,54]. The bacterial AlkB-enzyme removes alkyl-groups from N-1 position of 
adenine, and the N-3 position of cytosine, in a process requiring Fe2+, 2-oxoglutarate 
and molecular oxygen. The offending alkyl group is oxidised to an unstable 
hydroxyalkyl-moiety, which spontaneously de-associates from the base as 
formaldehyde. This restores DNA to its original state, at the energetic expense of the 
concurrent conversion of 2-oxoglutarate to succinate and CO2 [55], reviewed in [56]. 
All the nine known human AlkB-homologues are expressed [54,57], but biochemical 
activities have hitherto only been identified for the fat and obesity associated protein 
(FTO), ALKBH1, 2 and 3 [54,58,59,60].  
The protein O6-methylguanine-DNA methyltransferase (MGMT) recognises and repairs 
guanine alkylated at the O6-position or thymine alkylated the O4-position. These lesions 
are formed by reaction with endogenous and exogenous alkylating agents. These are 
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pre-mutagenic and pre-toxic lesions, as they preferentially form base pairs with thymine 
and guanine, respectively [61,62]. MGMT removes the offending alkyl-group by 
permanently transferring it to a cysteine residue in the active reaction site. As a 
consequence, the protein is inactivated, ubiquitinylated [63] and swiftly degraded by the 
proteasome [64]. Thus, the repair of a single alkylation requires the synthesis and 
degradation of a whole 22 kDa protein. It follows from this that the number of MGMT 
molecules per cell dictates the capacity to repair such alkylated lesions directly. MGMT 
upregulation increases the cells’ tolerance to alkylating agents significantly [65]. On the 
other hand, if MGMT is knocked down [66,67] or out [68] the cells become 
hypersensitive (reviewed in [69]). 
2.2 Repair of double strand breaks 
 
Double-strand breaks (DSB) are cytotoxic lesions where the backbones of both DNA 
strands are cleaved. DSBs come in two forms; two-ended DSBs describe a simple 
fracture of DNA, where one DNA double helix is broken in two. This may happen at 
any stage of the cell cycle, as a consequence of IR, physical stress or the repair of 
closely positioned lesions at opposite strands. On the other hand, one-ended DSBs are 
generated during S-phase or G2, and happens when a replication fork encounters a 
single-strand break (SSB) [70]. The severity of DSB can be seen when there is a failure 
to repair them, which may lead to cell death or large scale chromosomal rearrangements 
in the form of insertions, deletions and translocations [71].  
 
Human cells have at least two distinct mechanisms for the repair of DSBs, non-
homologous end-joining (NHEJ) and homology-directed repair (HR). As the names 
may suggest, the former process is less accurate than the latter, and is simpler 
mechanistically. In NHEJ, a heterodimer of Ku70 and Ku80 binds to each DSB. These 
in turn recruit DNA-dependent protein kinase (DNA-PK), which becomes activated and  
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Figure 3: Repair of double-strand breaks. (A) Non-homologous end-joining of a double strand break. Ku70/Ku80 
heterodimers and DNA-PK are sequentially recruited to the double strand breaks, followed by (auto)phosphorylation 
of DNA-PK and nearby proteins. The two broken strands are brought together and ligated by a complex containing 
LIG4, XRCC4 and XLF. (B) Homology-directed repair of a double-strand break. 5’ ends are degraded, and the 
resulting 3’ overhang invades a DNA strand containing a homologous sequence, e.g. in the sister chromatid. DNA is 
synthesised past the break point (blue lines), followed by branch migration. The nascent DNA is released and allowed 
to anneal to the other side of the strand break, thus connecting the two ends of DNA. After the Holliday junction has 
been resolved, flaps, gaps and nicks are processed. 
 
phosphorylates itself and other proteins when two ends of DNA are positioned opposite 
each other. Finally, the two DNA ends are joined by a complex containing DNA ligase 
IV (LIG4), XRCC4 and XLF [70]. If the DSBs arose from IR it is likely that both 
strands of DNA contain multiple lesions (so-called dirty ends), in which case additional 
processing is required to rejoin ends. Several proteins seem to be involved in processing 
of dirty ends, including – among others - Aprataxin, the Werner syndrome protein 
(WRN), Artemis, Mre11-Rad50–Nbs1 (MRN) -complex and DNA polymerases µ and λ 
[70,72]. NHEJ has limited specificity in that it joins two ends of DNA, thus potentially 
joining ’wrong’ ends, which may lead to gross chromosomal rearrangements. 
Additionally, a few base pairs may be lost during the joining process. HR, on the other 
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hand, is able to rejoin ends in an error-free manner and even restores missing sequence 
information. It achieves this by using a homologous template located elsewhere in the 
cell, preferentially on the sister chromatid. The MRN-complex, which degrades one of 
the strands in the 5'->3' direction initiates this process [73]. RAD51 and associated 
proteins then bind the remaining ssDNA and guide it to a homologous sequence 
elsewhere in the genome [74,75]. The free 3' end on the invading strand primes DNA 
synthesis, which continues past the break point of the original homologous sequence, 
thus generating a Holliday-like structure. This allows the recessed side of the other 
strand break to anneal to the newly replicated strand. The original sequence is restored 
after the Holliday junction has been resolved by symmetrical nicking of both strands by 
Gen homolog 1 (GEN1) [76], then if necessary followed by removal of flaps, gap 
resynthesis and nick ligation [10,70]. The examples given above are, however, only one 
of several possible DSB-repair mechanisms.  
2.3 Mismatch repair (MMR) 
DNA is usually replicated at a very high fidelity, with the four canonical bases in DNA 
binding to each other in a manner described by Watson-Crick base pairing [77]. That is, 
however, not always the case, as mispairing can be introduced by incorporating the 
wrong nucleotide during DNA synthesis, strand slippage during replication of repeat 
sequences, recombination involving non-identical sequences or chemical alteration of 
bases [78]. These lesions are all potentially mutagenic and substrates for mismatch 
repair, which removes the mismatch along with a relatively large fragment of DNA 
followed by re-synthesis. Furthermore, MMR is involved in many diverse processes, 
including antibody diversification, regulation of recombination and crossovers, as well 
as the DNA damage response [79]. Mechanistically, the obvious challenge for MMR is 
to distinguish the newly replicated strand containing an erroneous base from the 
template strand. The human MMR system is initiated by a MutS heterodimer, of which 
there are at least two in human cells. MutSα comprises the MutS homologues (MSH) 2 
and 6 and recognises simple base-base mismatches and small insertion-deletion loops (≤ 
2 bases), while MutSβ 
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Figure 4: Correction of replicative mismatches by MMR. Mismatches are generated during semi-
conservative DNA synthesis (red). They are recognised and bound by MutSα followed by recruitment of MutLα. 
These genereate sliding clamps which translocates along DNA until a strand discontinuity is encountered. In the 
leading strand this strand discontinuity is located 3' to the mismatch, while in Okazaki fragments, the strand 
discontinuity may be 3' or 5' to the mismatch. If the closest strand discontinuity is located 5' to the mismatch (left), 
EXO1 will be loaded onto the SSB and degrade the all DNA between the discontinuity and ~150 nucleotides past the 
mismatch. However, EXO1, which is exclusively 5'→3', can not act directly if the closest discontinuity is located 3' 
to the mismatch (right). Here, MutLα will generate one or more incisions around the mismatch in the strand that 
harbours the discontinuity and load EXO1, which then degrades the strand containing the mismatch in the 5'→3' 
direction. In both cases resynthesis (blue) and ligation are performed by POLδ, PCNA, RPA, RFC and LIG1. 
 (containing MSH2 and 3) recognises larger insertion-deletion loops [78]. The binding 
of a MutS-heteroduplex to a mismatch leads to the recruitment of one of three MutL-
heteroduplexes, and the formation of a ternary complex containing the mismatch and 
the MutS-MutL heteroduplexes. This forms a sliding clamp that translocates along the 
DNA in either direction at the expense of ATP hydrolysis until it encounters a strand 
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break that acts as a signal to discriminate the nascent and template strands [79]. If the 
strand break is positioned 5' to the mismatch, the strand between the nick and the 
mismatch, as well as some 100-150 nucleotides past the mismatch, is degraded by 
exonuclease 1 (EXO1) [80,81,82]. If the strand break is 3' to the mismatch, an 
endonuclease in the PMS2 subunit of MutLα is activated, which incises the nascent 
strand ~150 nucleotides 5' to the mismatch [80,83] followed by EXO1 degradation. 
Repair is then completed by the synthesis of a new strand by DNA polymerase δ or ε, 
aided by proliferating cell nuclear antigen (PCNA), replication factor C (RFC) and 
replication protein A (RPA), followed by ligation by DNA ligase I (LIG1). The proteins 
mentioned above are sufficient to reconstitute both 5' and 3' nick-directed MMR in vitro 
(Figure 4). However, many additional factors are shown to interact with the central 
MMR machinery [84], and the mechanisms briefly outlined above are therefore 
probably more intricate in vivo. 
Deficiencies in the core MMR components are mutagenic, and may lead to point 
mutations as well as MSI, characterised by variations in the number of repeats at 
repetitive sequences. The consequence of this at the level of the mammalian organism is 
HNPCC [43]. In addition, MMR deficient cells tolerate many DNA damaging agents. 
Examples include SN1-alkylating agents (MNNG, MNU), intrastrand cross-linking 
agents such as cisplatin [85,86], antimetabolites such as 6-thioguanine [87,88] and 
fluoropyrimidines [89,90,91,92]. When challenged with these agents, MMR proficient 
cells arrest in G2/M [93,94] and may eventually undergo apoptosis [95], while MMR 
deficient cells continue to divide at the expense of genomic stability. Two not mutually 
exclusive hypotheses exist to explain this. The first notes that many of these agents 
damage both strands of DNA. Since MMR is directed towards the newly replicated 
strand, it is unable to repair damage in the template strand. Thus, MMR may excise and 
try to repair the non-damaged strand, leading to the generation of another mismatch, 
thus initiating a cascade of repeated misincorporations opposite the offending base [96]. 
This concept has been termed futile repair (reviewed in [27]). Alternatively, the 
recognition (and repair) of lesions by MMR may initiate ATM- and/or ATR-mediated 
signalling cascades, which in turn arrest the cell in G2/M, and may guide the cell 
towards apoptosis [93,94]. 
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2.4 Nucleotide excision repair (NER) 
 
NER excises DNA lesions as part of an oligonucleotide, which is about 30 nucleotides 
in length in humans. NER does not appear to recognise DNA damage in itself, rather it 
detects distortions of the DNA double helix. These tend to be pyrimidine dimers 
introduced by UV-light, or bulky lesions introduced by chemotherapeutics or 
environmentally encountered chemicals (e.g. benzo(a)pyrene) [10]. Inactivating 
mutations in human NER genes are associated with xeroderma pigmentosum (XP), a 
cancer-prone syndrome resulting in epithelial skin cancer induced by exposure to 
sunlight, as well as Cockayne syndrome (CS) and trichothiodystrophy (TTD) [97].  
NER is a multi-step process, where 20 to 30 known proteins participate in a well 
defined and orderly fashion (Figure 5) (reviewed in [10,98,99]. Global genomic NER 
(GG-NER) is initiated by recognition of the helix distortion by a heterotrimer consisting 
of XPC, RAD23 homolog B (HR23B) and centrin 2 [100,101], followed by binding of 
XPA and RPA to the damaged area (reviewed in [98]). Alternatively, if RNA 
polymerase II is blocked by a DNA lesion in actively transcribed genes, the CS genes A 
and B recruit the rest of the NER machinery and remove the stalled RNA polymerase. 
This mode of NER is called transcription-coupled NER (TC-NER) (reviewed in [102]). 
Irrespective of how repair was initiated, the next steps are thought to be identical for 
GG- and TC-NER. Following damage recognition, the multi-protein complex that is 
transcription factor IIH (TFIIH) unwinds the DNA sequence surrounding the lesion 
using XPB and XPD helicases, which are part of the TFIIH complex. The resulting 
single-stranded bubble-structure is stabilised by RPA. Then endonucleases XPG and 
XPF cuts the DNA backbone 5 or 6 nucleotides 3' to the lesion and 20 to 22 nucleotides 
in the 5' direction, respectively, thus releasing an oligonucleotide. Replicative DNA 
polymerases then fill in the resulting gap, using the un-damaged strand as template 
[103,104]. 
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Figure 5: Nucleotide Excision Repair of bulky lesions in DNA. Bulky, helix distorting lesions anywhere in nuclear 
DNA are recognised by a complex of XPC, HR23B and centrin 2 (upper left branch), which then recruits core NER 
protein complexes (middle branch). Additionally, these bulky lesions stalls RNA polymerase on actively transcribed 
DNA strands (upper right branch), in which case CSA and CSB replaces the stalled RNA polymerase with core NER 
components (middle branch). XPB and XPD helicases unwinds the double helix surrounding the lesion, followed by 
incisions on either side of the lesion by endonucleases XPF and XPG. The damaged DNA is then removed as part of 
an oligonucleotide, followed by resynthesis and ligation.  
2.5 Base excision repair (BER) 
 
BER is initiated by a damage specific glycosylase, which recognises and excises an 
offending base, resulting in a free base and an AP-site. It is thought to be the 
quantitatively most important mode of DNA repair in mammalian cells [105]. A few 
glycosylases are bifunctional, in that they display an additional lyase activity that 
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incises the DNA backbone 5' and/or 3' to the deoxyribose (β and δ-elimination, 
respectively) (Figure 6).  
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Figure 6: Gap tailoring during BER. Monofunctional glycosylases generate a natural AP-site (top), at which point 
the DNA backbone still is intact. The resulting AP-site is then incised by APE1 at the 5' side of the phosphate, 
generating a 3'OH group and a 5' deoxyribosephosphate (dRP) fragment (middle, left). Bi-functional glycosylases 
carry associated lyase activity able to incise the DNA backbone by β-elimination, resulting in the generation of a 
3'phospho-α,β-polyunsaturated aldehyde (PUA) and a 5' phosphate group (middle, middle). The PUA is released by 
the 3'-phospho-diesterase activity of APE1, again generating a 3'OH group. Glycosylases of the NEIL-type, are able 
to carry out β,δ-elimination, leaving a 1-nucleotide gap flanked by phosphates on either side (middle, right). While 
APE1 may act on this lesion as well, through its associated 3' phosphatase activity, it is more likely that this may be 
mediated by the more potent PNKP [106], or aprataxin [107]. 
 
Next, AP endonuclease 1 (APE1) incises the DNA backbone 5' to the deoxyribose, 
followed by the incorporation of one or several nucleotides, removal of the remaining 
deoxyribose fragment and ligation. This may take place by at least three slightly 
different sub-pathways, defined by the number of nucleotides that are incorporated 
(Figure 7). 
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Figure 7: Replacing the excised nucleotide: SN and LP. Following gap tailoring, BER may be completed by the 
insertion of one or several nucleotides followed by ligation. POLβ inserts the first nucleotide in all cases. Provided 
that the dRP-fragment can be removed by the inherent dRP-lyase activity of the polymerase, the resulting nick can 
then be closed by XRCC1/Ligase IIIα complex. This is the single nucleotide pathway (left branch). If, however, the 
dRP-fragment is resistant to dRP-lyase removal, POLβ may insert a second nucleotide. This allows the dRP-fragment 
to be removed as part of a small flap (middle branch). Alternatively, a switch to replicative POLδ or ε may occur, and 
these may insert a longer patch of nucleotides (in this case, three) downstream of the original lesion. The displaced 
strand is then cleaved off by FEN-1, and the resulting nick ligated by DNA ligase I (right branch). The latter (right) 
pathway is exclusive to proliferating cells, while the single- and two-nucleotide pathways are employed in both 
proliferating and non-proliferating cells. 
 
Single-nucleotide (SN) and long patch (LP) pathways have been successfully 
reconstituted in vitro using purified proteins. In the SN-pathway, one nucleotide is 
incorporated by POLβ, followed by the generation of a ligatable end by 3' deoxyribose 
lyase (dRPase) activity residing in the 8 kDa fragment of the same polymerase. Finally, 
DNA ligase IIIα in conjunction with XRCC1 ligates the nick [108]. Alternatively, the 
dRP-fragment may be removed as part of a single-stranded ‘flap’ generated by strand-
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displacement synthesis. This happens if the dRP-fragment is modified in such a way 
that it becomes resistant to the dRPase activity of POLβ. In non-proliferating cells this 
is performed by POLβ, which inserts another nucleotide, followed by flap removal by 
flap endonuclease 1 (FEN-1) and ligation (two-nucleotide pathway) [17,108]. 
Alternatively, POLδ or ε (together with RFC and PCNA) may incorporate an even 
longer patch. The dRP-fragment is removed by FEN-1, along with the displaced 
nucleotides, followed by ligation by LIG1 (LP-pathway) [109,110]. The latter pathway 
is apparently exclusive to proliferating cells, while single- and two nucleotide pathways 
can be carried out in non-proliferating cells as well [17]. 
2.5.1 Human uracil-DNA glycosylases 
 
The human genome contains four known genes encoding glycosylases capable of 
removing uracil from DNA. These are uracil-DNA glycosylase (UNG), single-strand 
selective monofunctional uracil-DNA glycosylase 1 (SMUG1), thymine-DNA 
glycosylase (TDG) and methyl-CpG binding domain protein 4 (MBD4). UNG, SMUG1 
and TDG adopt the same α/β core fold and belong to the same super family [111].  
2.5.2 Uracil-DNA glycosylase (UNG)  
 
The human UNG gene encodes two open reading frames driven by separate promotors 
and encodes the 304 amino acids in UNG1 and 313 amino acids in UNG2. They share 
the C-terminal 269 amino acids that are necessary and sufficient for catalytic activity, 
but differ in their N-terminal sequences that contain mitochondrial (UNG1) and nuclear 
(UNG2) localisation signals, respectively [112,113]. 
 
Uracil in both single and double-stranded DNA are the main substrates for the UNG-
proteins, and they are exceptionally active relative to other glycosylases [114]. UNG-
enzymes may also excise uracil-analogues with modifications in the 5' and/or 6' position 
that are small enough to fit into the catalytic active site of the enzyme, although at lower 
efficiency. Examples include 5-fluorouracil (5-FU), isodialuric acid, 5-hydroxyuracil 
and alloxan [115,116]. Among the biologically relevant substrates, the catalytic domain 
of the human UNG are most active on uracil in ssDNA, followed by uracil in dsDNA 
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opposite guanine, then adenine [117]. However, the surrounding base sequence has a 
significant effect on catalytic efficiency [117,118]. 
 
UNG1 mRNA is expressed in all tissues examined, whereas UNG2 mRNA is mainly 
associated with proliferating tissues [119]. Following serum starvation, both mRNA’s, 
as well as total activity are upregulated at the entry of S-phase, seemingly independent 
of ongoing DNA synthesis [119,120,121]. The protein level of UNG2 is upregulated in 
S-phase and degraded in G2/M or early G1. hUNG1, on the other hand, is apparently 
expressed rather stably through the cell cycle [119,122,123,124,125,126]. UNG2 co-
localises with PCNA and RPA in replication foci, where UNG2 probably acts on 
misincorporated uracil [122]. Co-immunoprecipitation experiments support these 
observations, as not only proteins necessary for SN- and LP-pathways co-
immunoprecipitate with UNG2, but also the replication-associated proteins cyclin A, 
MCM7 and DNA polymerase α [127,128]. Furthermore, specific inhibition of UNG-
proteins remove nearly all activity on U:A base pairs in extracts from human cells 
[116,127,129]. In addition, the apparent inverse expression pattern of TDG and UNG2 
[124], suggests that UNG2 may be the major activity acting on deaminated cytosines 
during S-phase. UNG1 appears to be the only uracil-DNA glycosylase in mitochondria 
[129], and would therefore be responsible for uracil repair in all contexts. 
 
UNG2 is modified by post-translational phosphorylation at Ser23, Thr60 and Ser64 
[123]. These phosphorylations regulate cellular turnover, as the two latter residues 
appears to form part of a phosphodegron, which is a signal for ubiquitinylation and 
proteosomal degradation subsequent to phosphorylation. Furthermore, phosphorylation 
at any of these sites increases activity by up to 30%. Finally, the binding to RPA is 
increased by phosphorylation at Ser23, and diminished by phosphorylation at Thr60 and 
Ser64, while binding to PCNA is relatively unaffected by phosphorylation at any of 
these sites [123]. 
 
Gene-targeted Ung-/- knockout mice appear to develop normally, but display lymphoid 
hyperplasia early in life and a 22-fold increase in B-cell lymphomas at a later age 
compared to wild type [130,131]. A variety of cells derived from Ung-/- mice 
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accumulate genomic uracil and display a slight increase in mutation rate and frequency 
[130,132,133,134,135,136,137]. Omitting folate from the growth medium results in a 
mild increase in genomic uracil and mutation rate in cultured Ung -/- MEFs, compared to 
wild type [135]. While brain cells (but not colon epithelial cells) from Ung-/- mice fed 
with a folate-deficient diet also accumulated genomic uracil, they did not display the 
(mild) mutator phenotype. Nevertheless, they appear more vulnerable to 
neurodegeneration, which may be consistent with some cognitive and behavioural 
changes displayed by Ung-/- animals that were fed a folate-deficient diet [135]. 
Moreover, following brain damage provoked by cerebral ischemia, murine Ung-mRNA 
and protein activity were upregulated, especially in the cytoplasmic/mitochondrial 
fraction. Moreover, in Ung–/– mice, brain ischemia and reperfusion resulted in an 
increase in infarct size compared with wild type [133]. This was further aggravated 
when the animals were fed a folate-deficient diet [138]. These results suggest that 
murine UNG may protect neurons from tissue damage brought about by folate 
deficiency or ischemia. 
 
Another deviation from wild type is apparent in the acquired immune system of Ung-/- 
mice. Here, B-cells from Ung-/- mice display an altered mutation spectrum at dC and dG 
sites during somatic hypermutation (SHM). Moreover, Ung -/- mice exhibit defects in 
class-switch recombination (CSR), i.e. an altered balance of serum immunoglobulin 
isotypes, with higher levels of IgM and lower levels of IgG3 compared to wild type 
[139]. These defects in the murine acquired immunesystem may be explained 
mechanistically by UNG2-mediated excision of uracil, generated through cytosine 
deamination by AID [139]. However, since the overexpression of mutants of UNG2 
with <1% wild type activity in Ung-/- B-cells efficiently restores CSR, the canonical 
catalytic activity of UNG2 may not necessarily be required for CSR [140,141]. Thus, it 
has been suggested that UNG2 may play a structural rather than catalytic role in CSR, 
possibly acting as a scaffold for other repair factors [142,143]. Humans that carry 
recessive inactivating mutations in the UNG-gene show a similar phenotype as Ung-/- 
mice, especially with respect to CSR and SHM. Together these defects manifest 
themselves as a form of hyper-IgM syndrome (HIGM), interestingly similar to that 
caused by deficiencies in the AID-gene. In humans, however, the CSR defect is more 
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severe than in Ung-knockout mice, while the SHM mutation spectrum is affected in a 
similar manner in both species, i.e. only at cytosine and guanine [144]. These 
inactivating mutations either result in UNG2 proteins that are catalytically inactive or 
that are excluded from the nucleus [145].  
 
The activity of the UNG proteins shows considerable variation between tissues as well 
as individuals [146,147,148]. Furthermore, cancer cells appear to display a large 
variation in the level and activity of both total UNG and UNG2 proteins, in contrast to 
un-transformed fibroblast cell lines that show a quite low and uniform expression of 
UNG proteins. The variation between cancer cell lines is not caused by polymorphisms 
in the coding regions of the UNG-gene, but rather reflects variations in the level of 
protein expression of UNG2 [149]. The effect of this variation on BER is unclear, 
although a single study suggests that forced overexpression of UNG2 results in a 
significant growth inhibition as response to inhibitors of TS at short – but not long – 
incubation times. Concurrently, a significantly elevated level of single-strand breaks as 
estimated by the comet assay was observed. This indicates that overexpressed UNG2 
removed misincorporated uracil in excess of what the rest of the BER pathway could 
process, thus resulting in an accumulation of repair intermediates [150]. This was not 
sufficient to affect cell death or clonogenicity, but nevertheless suggests that high 
expression levels of UNG-proteins could contribute to genetic instability.  
2.5.3 Single-strand selective monofunctional uracil-DNA glycosylase 1 
(SMUG1) 
 
SMUG1 has a broad substrate specificity, recognising uracil as well as a number of 
different uracil-analogues with substitutions in the 5' and 6' positions. Major substrates 
for SMUG1 are ethenocytosine, 5-fluorouracil and in particular 5-hydroxymethyluracil, 
for which it is the major activity in human cells [116]. When APE1 and Mg2+ are 
present in the reaction mixture the preferred substrate for SMUG1 is actually uracil in 
double-stranded DNA, in spite of the nomenclature [116]. SMUG1 is localised in nuclei 
with high levels in nucleoli and is constitutively expressed throughout the cell cycle 
[116] and similarly expressed in both proliferating and non-proliferating tissues [132]. 
Knocking down Smug1 in MEFs with siRNA results in a mutator phenotype, especially 
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G:C to A:T transitions, in a manner which is non-redundant with UNG2 [136]. 
Additionally, Smug1-knockdown MEFs are sensitive towards ionizing radiation and 5-
FU [136,151]. SMUG1 forms foci with DNA polymerase λ (POLλ) in irradiated mouse 
cells, and these enzymes co-immunoprecipitate, indicating that the glycosylase is 
involved in repair of oxidised pyrimidines, in addition to repair of deaminated cytosines 
[152]. 
2.5.4 Thymine-DNA glycosylase (TDG) 
 
The search for an enzyme able to repair deaminated 5-methylcytosines, which results in 
the canonical base thymine mispaired with guanine, led to the discovery of TDG. This 
glycosylase binds and excises thymine in T:G mispairs, thus initiating BER [153,154]. 
While the activity on the T:G mispair is rather small, TDG is up to ~100 times more 
active on uracil in U:G mispairs. The highest known activity is that of 5-FU opposite 
guanine, for which the turnover number is up to ~1000 times higher than on T:G 
mispairs [155]. This is to a large degree sequence specific, with the highest activity 
when a guanine is present 3' to the mispaired thymine (or other lesion), thus mimicking 
a deaminated 5-methylcytosine in a CpG context [155]. In addition to deamination 
products, TDG can also excise oxidised bases (hydroxyuracil, 5-methylhydroxyuracil) 
and products of lipid peroxidation (ethenocytosine) [156]. Once TDG has excised its 
target base it binds extremely tight to the product AP-site [157,158], to such an extent 
that the purified enzyme does not turn over (reviewed in [159]). The full product 
inhibition is alleviated by the next enzyme in the BER pathway, APE1, which displaces 
TDG from the AP-site [158], and by the covalent addition of a Small Ubiquitin-like 
Modifier (SUMO, 1 or 3) [160] to the C-terminus of TDG [161]. This induces a 
conformational change in TDG, which radically alters the way it interacts with DNA. 
The SUMO-conjugated protein can no longer bind AP-sites, thus facilitating catalytic 
turnover and resulting in an enhanced processing of U:G. Concurrently, however, the 
ability to process T:G is reduced [162]. Release from the AP-site is aided by physical 
interaction with the XPC-HR23B complex [163]. The T:G glycosylase activity is further 
stimulated by the physical association with the RAD9-RAD1-HUS1 heterotrimer 
(abbreviated 9-1-1 complex) [164]. 9-1-1 is similar to PCNA in that it acts as a sliding 
clamp and interacts with many downstream BER proteins [165,166,167,168,169]. 
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While TDG-mRNA is expressed at similar levels in all tissues studied [170], and at 
similar levels throughout the cell cycle [121], the protein level is tightly linked with the 
progression of the cell cycle. TDG is highly expressed in G1 and G2/M, but is degraded 
at the entry of S-phase by the proteasome. This is the opposite expression profile to that 
of UNG2 [124]. TDG has so far not been implicated in carcinogenesis. Unlike most 
other mice with targeted deletions of other glycosylases, Tdg-/- mice lose viability 
halfway through the gestational period [159]. However, cells derived from knockout 
embryos are tolerant to 5-FU, indicating that the TDG could mediate fluoropyrimidine 
cytotoxicity. Overexpression and knockdown of TDG in HeLa-cells exposed to 5-FU 
results in sensitation and tolerance, respectively, thus mirroring the murine phenotype 
[171]. Furthermore, forced expression of TDG during S-phase is apparently harmful to 
the cell and results in S-phase arrest [124]. While one might invoke several explanations 
why TDG-initiated DNA repair in S-phase would be detrimental, one should keep in 
mind that TDG is also established as a regulator of transcription. TDG interacts with 
transcription factors such as c-Jun, retinoic acid receptor (RAR) and retinoid X receptor 
(RXR), estrogen receptor α, p53 and others [172,173,174,175] (reviewed in [159]). 
Furthermore, recent evidence hints at a role for TDG in the maintenance of methylated 
CpG sequences, as TDG interacts with DNMT3b (DNA (cytosine-5-) -
methyltransferase 3β) [176].  
2.5.5 Methyl-CpG binding domain 4 (MBD4) 
 
Two different groups discovered MBD4 independently. One group found the protein in 
a database search for candidate proteins that could bind to methylated CpG-sequences 
[177], and another in a yeast two-hybrid screening that used human MLH1 as bait [109]. 
It later turned out that these two studies had identified one and the same protein, which 
contains an N-terminal methyl-CpG binding domain that targets the protein to 
methylated CpG-sequences in vivo and in vitro [177] and a C-terminal domain similar 
to bacterial glycosylase/lyases. The C-terminal domain harbours monofunctional 
glycosylase activity on thymine, uracil and 5-FU when paired with guanine, which is 
especially active in methylated CpG contexts [178,179]. Like most other glycosylases, 
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the activity of MBD4 is strongly inhibited by its slow dissociation from the AP-site 
[180]. 
 
The human MBD4-gene contains a polynucleotide stretch of 10 adenines that is 
frequently mutated in human MSI-positive cancers (reviewed in [109,179,181,182]. The 
loss or gain of an extra adenine results in a premature stop codon in the mRNA, which 
is translated to a truncated protein that lacks the glycosylase domain. However, the 
methyl-CpG binding domain is still intact and able to bind methylated CpG-sequences. 
In vitro, the truncated MBD4 acts as a dominant negative inhibitor of the wild type 
MBD4 activity as well as other UDGs, most likely through steric hindrance. When the 
truncated MBD4 is transfected into human cell lines, it confers an increase in mutation 
frequency, a predisposition to structural chromosomal rearrangements and altered 
clonogenic response to cisplatin and etoposide [183]. Knockout mice have an increased 
mutation frequency, especially at CpG-sequences [184,185]. They also display reduced 
apoptosis in the murine intestine in response to several DNA damaging agents, 
including 5-FU, to which Mbd4-/- MEFs were considerably more tolerant [186,187]. The 
absence of apoptosis and tolerance to cytotoxic agents are thought to be mediated by 
interactions with Fas-associated death domain protein (FADD) and/or MLH1 [109,188]. 
2.5.6 8-oxoguanine DNA glycosylase (OGG1) 
 
A major mutagenic DNA-lesion induced by oxidative damage is 7, 8-dihydro-8-
oxoguanine (8-oxoG), which may form base pairs with adenine and result in G:C → 
T:A transversion mutations [189,190,191]. OGG1 excises 8-oxoG from DNA when 
paired with cytosine, thus initiating BER. It carries an additional lyase activity cause 
incision at the DNA backbone 3' to the AP-site, and is therefore classified as a 
bifunctional glycosylase [192]. Alternative splicing of OGG1-mRNA generates two 
major isoforms in human cells. The α-isoform is targeted to the nucleus, and the β-
isoform is targeted to mitochondria [193]. OGG1 expression is apparently not cell cycle 
regulated, at mRNA or protein levels [121,194], and OGG1 is not induced by oxidative 
stress [195].  
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OGG1 binds tightly to the AP-site after base excision, and there is consequently little 
turnover of the purified enzyme. However, APE1 stimulates dissociation of OGG1 from 
the AP-site, thus allowing the enzyme to turn over. The presence of APE1 results in an 
increase in glycosylase activity [196] and uncoupling of glycosylase and lyase activities 
[197]. SN-BER of 8-oxoG has been reconstituted using only four enzymes (OGG1, 
APE1, POLβ and LIG1) [198], and studies on extracts suggest that this is the 
predominant mode of repair for this lesion [172,199]. 
 
Gene-targeted Ogg1-knockout mice have an increased level of 8-oxoG in DNA, 
increased G:C to T:A transversion mutations, and a predisposition to lung 
adenoma/carcinoma in old animals [189,200,201]. Polymorphisms in the human OGG1-
gene are present in the human population and may contribute to lung carcinogenesis, 
although the literature is rather ambiguous (see review in [183,202]). Regulating the 
expression of OGG1 in human cells exposed to oxidative stress modulates survival. 
Overexpression of OGG1 in irradiated human cells is apparently harmful, while 
suppression of expression leads to increased survival. This is thought to be caused by 
double strand breaks created by simultaneously occurring repair processes close to each 
other on opposite strands, as overexpression of OGG1 protects against H2O2, and 
suppression of OGG1 sensitises cells [203,204].  
2.5.6 MutY homolog (MUTYH) 
 
8-oxoG that escapes excision and repair by OGG1 is premutagenic because replicative 
polymerases may incorporate an adenine opposite this lesion [205]. This generates the 
substrate for the MUTYH glycosylase, which excises the normal adenine base when it is 
paired with 8-oxoG [206,207]. This initiates BER, which cause insertion of a cytosine 
opposite the 8-oxoG, generating the substrate for OGG1, thus eventually resulting in a 
repaired G:C base pair [208]. In addition, the human MUTYH excises adenine when 
mispaired with guanine [209,210], although the functional significance of this activity is 
not clear. MUTYH is a bifunctional glycosylase, but the lyase activity of the enzyme is 
dramatically lower than the glycosylase activity. Human cells contains at least two 
different isoforms localised in the nucleus and mitochondria and no less than 10 
different mRNAs, indicating that even more isoforms could be present [211].  
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APE1 stimulates the glycosylase activity of MUTYH by alleviating AP-site product 
inhibition, and these two proteins interact directly [210,212]. Expression of MUTYH is 
upregulated in G1/S and MUTYH co-localises and interacts directly with PCNA and 
RPA in replication foci [212,213]. However, the steps following APE1 incision are not 
known at present, as no direct interactions between MUTYH and POLβ or δ have so far 
been observed [212]. These polymerases would, however, tend to re-incorporate 
adenine rather than cytosine opposite 8-oxoG, and thus probably initiate a futile repair 
cycle [214]. Rather, DNA POLλ may be a good candidate to ensure the incorporation of 
cytosine opposite 8-oxoG, as the presence of PCNA and RPA increases both the 
selectivity for cytosine opposite 8-oxoG , as well as the efficiency of POLλ. 
Concurrently, PCNA and RPA repress the efficiency of POLβ at an 8-oxoG template 
[215]. Consistent with this, murine POLλ is localised to sites of oxidative damage, and 
Poll-knockout MEFs are hypersensitive to oxidative DNA damage [152]. MUTYH has 
also been shown to interact and co-localise with MSHα [216] as well as the 9-1-1 
complex, especially after oxidative stress [10].  
 
Mutyh-/--mice show no obvious phenotype, with a lifespan and tumour frequency close 
to the wild type [217]. However, when crossed with Ogg-/- animals to generate the 
double knockout, the offspring have reduced lifespan, an accumulation of 8-oxoG in 
lung tissue, small intestines and liver and a dramatic increase in tumour incidence in 
lungs, small intestines and ovaries [217,218]. This demonstrates in principle that the 
repair of 8-oxoG is important to prevent carcinogenesis in mammals. Consistent with 
this, variants of the human MUTYH-gene coding for catalytically weakened proteins 
confer a recessive predisposition to colorectal cancer, as well as an accumulation of G:C 
to T:A transversions in the gene encoding Adenomatous polyposis coli (APC) [219]. 
This disorder has been termed MUTYH-associated polyposis (MAP) (reviewed in 
[220]). Biallelic inheritance of MUTYH-variants results in a 93-fold excess risk of 
colorectal cancer, and may account for ~2% of colorectal cancers diagnosed before 40 
years of age, and less than ~1% of patients diagnosed before 55 years of age [221]. 
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2.5.7 Nth endonuclease III-like 1 (E. coli) (NTHL1) 
 
NTHL1 is a bifunctional glycosylase that excises oxidised pyrimidines from DNA, most 
notably thymine glycol, 5-hydroxycytosine, FaPyG and dihydrouracil 
[222,223,224,225,226]. The β-lyase activity is several-fold lower than the preceding 
glycosylase activity [227]. NTHL1 interacts directly with PCNA, p53 and XPG, and its 
glycosylase activity is stimulated by the two latter enzymes [228], as well as by APE1 
and Y-box binding protein 1 (YB-1) [227,229]. Interestingly, NTHL1 also stimulates 
itself through a DNA-independent dimerisation [230].  
 
The expression of NTHL1 is cell cycle regulated, with the highest level of mRNA 
observed during S-phase [226]. It is localised in the nucleus as well as mitochondria 
[225,231]. Mice with targeted disruptions in the Nthl1-gene have been generated, but 
show no overt phenotype compared to wild type even when exposed to IR or H2O2 
[232,233]. However, the expression level of NTHL1 is an important determinant for 
cellular survival in irradiated human cells. Here, induced overexpression of NTHL1 
leads to an increased mutation frequency, double strand breaks and lower survival 
[203]. Downregulation of NTHL1-mRNA and protein by siRNA results in fewer double 
strand breaks in response to IR, but a survival similar to that of overexpressing cells, 
indicating that the protein level of NTHL1 has to be tightly regulated. Interestingly, the 
response to H2O2  is different, as overexpression increases survival while 
downregulation sensitises cells [204]. 
2.5.8 Nei endonuclease VIII-like 1 & 2 (E. coli) (NEIL1 and 2) 
 
Like the well-characterised bacterial endonuclease VIII (Nei; endonuclease eight), the 
NEILs are bi-functional glycosylases that excise oxidised bases from DNA. They have 
the ability to carry out β- and δ-elimination on the resulting AP-site, resulting in a 1-
nucleotide gap flanked by 3' and 5' phosphates [234,235,236]. The resulting 3' 
phosphate must me removed prior to nucleotide insertion, but this is a very poor 
substrate for APE1. Instead, polynucleotide kinase 3' phosphatase (PNKP) removes the 
3' phosphate. Thus, BER can be performed independently of APE1 [106,236,237]. It has 
also been suggested that NEIL1 and NEIL2 could participate in the removal of 
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deoxyribose-fragments in short patch BER, a task which is normally performed by 
POLβ [238]. 
 
NEIL1 recognises and excises a large variety of oxidised pyrimidines. It is the only 
known enzyme able to act on FaPyA [223], and it can also excise thymine glycol, 5-
hydroxycytosine, 5-hydroxyuracil, 5,6-dihydrothymine and 5,6-dihydrouracil 
[233,234,236]. It is present in the nucleus as well as mitochondria [239]. The expression 
of NEIL1 is strongly induced during S-phase [235]. Furthermore, it is active in fork- 
and bubble-structures, unlike OGG1 and NTHL1. NEIL1 interacts with PCNA, which 
also stimulates its activity [240,241]. Hence, it is likely to play a role in genomic 
surveillance at or near the replication fork. NEIL1 is also shown to interact with and – 
in most cases - be stimulated by all subunits of the 9-1-1 complex as well as WRN, 
CSB, FEN-1, POLβ and LIG3α [106,164,241,242,243]. 
 
Downregulation of NEIL1-mRNA and protein in human and hamster cells by siRNA 
results in an increased level of oxidative DNA damage and mutation rate, both 
spontaneously and after oxidative stress [244]. SiRNA-mediated knockdown of Neil1 in 
MEFs results in sensitation to IR. Neil1-knockout mice develop normally until 7 months 
of age, when males, and to a lesser extent females, have been reported to develop severe 
obesity along with obesity-associated ailments, but not cancer [245]. Furthermore, 
Nthl1-/-Neil1-/--double knockout mice show a very high incidence of lung and liver 
tumours compared to either single knockout. This was accompanied by an accumulation 
of FaPyA and to a lesser extent FaPyG in DNA from mice lacking Neil1, while the level 
of 8-oxoG in DNA was rather similar [246]. However, the latter group did not observe 
the obese phenotype in Neil1-/- mice. Although these groups report conflicting 
phenotypes for the Neil1-knockout animals, they both report that the observed 
phenotype (be it cancer or obesity) is less severe for females than for males [245,246].  
 
NEIL2 excises oxidised pyrimidines, with the most pronounced activity towards 5-
hydroxyuracil, and somewhat less on 5,6-dihydrouracil and 5-hydroxycytosine. It is 
localised exclusively in the nucleus [234,236]. Like NEIL1, it is active in bubble 
structures of varying sizes, indicating that it could be active in transcription and/or 
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replication [240] and its expression is rather unaffected by the cell cycle [236]. NEIL2 
appears to interact directly with POLβ and LIG3α, and co-immunoprecipitates with 
these two as well as with PNKP and XRCC1 – but not APE1. These proteins are in 
concert able to repair 5-hydroxyuracil in plasmid DNA in an APE1-independent 
manner, either when added together as recombinant proteins or as a multi-protein 
complex immunoprecipitated from cells [237]. Furthermore, NEIL2 interacts with YB-
1, which also stimulates NEIL1 activity [247]. 
 
While NEIL3 has extensive homology to E. coli Nei, NEIL1 and NEIL2 [234], no 
glycosylase activity has so far been associated with the protein. The only known activity 
of NEIL3 is an AP lyase-activity on ssDNA. Thus, it might be relevant in the response 
to oxidative damage, as the protein can partially rescue Nei- and Fpg-deficient E.Coli 
from oxidative stress [248].  
2.5.9 N-methylpurine-DNA glycosylase (MPG) 
 
MPG is a monofunctional glycosylase that removes purine bases methylated in N3- and 
N7-positions, as well as hypoxanthine, N6-ethenoadenine and 3-ethenoguanine 
(reviewed in [105,249]. MPG-mRNA and activity are up-regulated during the S-phase 
[121]. MPG interacts with PCNA, which also stimulates its activity [121]. Furthermore, 
its glycosylase activity is stimulated by APE1 and HR23B [250,251] and it interacts 
with Methyl-binding domain 1 protein (MBD1) and XRCC1 [252,253]. 
 
Monofunctional methylating agents such as methyl methanesulfonate (MMS) and TMZ 
induce methylations at purine bases, with the relatively harmless 7-methylguanine as the 
quantitatively most important lesion [254,255]. The direct cytotoxicity is mediated by 
generation of another cytotoxic and mutagenic lesion, 3-methyladenine. Although rather 
counter-intuitive, induced overexpression of MPG does not protect against these agents, 
but confers a sensitation to the cells [256,257,258]. This effect is, however, not seen 
when exposed to methylating agents that yield almost exclusively 3-methyladenine 
[258]. Thus, it would appear that the accumulation of toxic BER intermediates 
stemming from the repair of relatively harmless adducts by overexpressed MPG 
mediates cell death. Agents that target BER intermediates, such as methoxyamine (MX) 
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and PARP-1 inhibitors, aggravates the cytotoxicity of methylating agents (reviewed in 
[259]), also when MPG is overexpressed [257]. Furthermore, while Polb-/- MEFs are 
hypersensitive to alkylating agents, they are as sensitive as wild type when the Mpg-
gene is knocked out as well [260,261].  
 
2.5.10 APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1, 
APE1) 
 
APE1 is a multi-functional enzyme that modifies DNA with several known activities on 
damaged DNA. It was first identified as an AP-endonuclease that incises the DNA 
backbone at AP-sites, generating a 3'OH and a 5' deoxyribosephosphate (dRP) –
fragment [262,263]. APE1 also contains a 3' phosphodiesterase activity generating a 
3'OH from 3’phospho-α,β-polyunsaturated aldehyde (PUA), the product of bifunctional 
glycosylases and a 3' phosphatase activity which releases phosphate and generates a 3' 
OH (reviewed in [264]). Furthermore, APE1 contains a 3'->5' exonuclease activity that 
excises mismatches at 3' nicked or gapped DNA structures [216]. It also contains an 
endonuclease activity acting on oxidised bases, which incises the DNA backbone in a 
glycosylase-independent manner, generating a 3'OH group and a “dangling” 5' damaged 
base. The latter process has been termed nucleotide incision repair (NIR) [265,266]. 
Additionally, APE1 is a regulator of transcription factors, including AP-1, NF-κB, p53 
and numerous others. In many cases the transcription factors are actively kept in an 
active reduced state through interaction with the N-terminal redox domain of APE1 
(reviewed in [264,267]). 
 
Given the many roles of APE1, it comes as no surprise that attempted generation of 
knock-out Apex-/- mice results in embryonic lethality [268]. Haploinsufficient Apex+/--
mice are viable, but they have increased spontaneous mutation rates [269] and an 
increased cancer incidence when exposed to oxidative stress [270]. Furthermore, 
reducing the APE1 expression level by anti-sense RNA results in hypersensitivity to a 
range of different DNA damaging agents, but not UV [271]. SiRNA-mediated silencing 
of APE1-mRNA and protein in human cells results in an accumulation of AP-sites, 
followed by blocked cell proliferation and apoptosis. This may be reversed by the 
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expression of S. cerevisiae Apn1, that has a similar AP endonuclease activity, but are 
structurally unrelated to human APE1 and unable to regulate transcription factors or 
interact with other human BER proteins [272]. On the other hand, an increase in the 
already high endogenous level of APE-1 leads to resistance against many DNA 
damaging agents, again with UV as an exception ([273], reviewed in [264]). APE-1 is 
furthermore upregulated during S-phase [274], and as a consequence of genotoxic stress 
(reviewed in [264]). 
 
Most of the known human glycosylases bind tightly to the product AP-site and are 
inhibited by them, including SMUG1, TDG, MBD4, MUTYH, OGG1, NTHL1 and 
MPG [158,180,196,210,227,251,275]. APE1 alleviates the product inhibition and 
stimulates the turnover of most of these glycosylases by displacing them from the AP-
site. If bifunctional glycosylases are displaced prior to the relatively slow β-elimination 
reaction, then they act as being monofunctional and hand over an intact AP-site to 
APE1 [197,210,227]. This type of glycosylase stimulation by displacement may be a 
“passive” process, in which APE1 decreases the amount of AP-sites available for 
glycosylases through its enzymatic mechanism [197], or alternatively an active process 
that displaces glycosylases from the AP-site through formation of a temporary 
glycosylase-APE1-DNA complex [276,277]. These models are not mutually exclusive. 
While APE1 stimulation of glycosylases is well established, the effect of a glycosylases 
on APE1 activity has not been thoroughly examined. A few studies show that the 
presence of a glycosylase tightly bound to the AP-site weakly inhibits endonuclease 
activity of APE1 [158,275], in effect slowing down repair of AP-sites. UNG2 does not 
bind to AP-sites but its activity is nevertheless reported to stimulate APE1 [116,275]. 
 
Similar to the glycosylases, APE1 remains bound to the product of its reaction, the 5' 
dRP-fragment [278,279]. APE1 promotes binding of POLβ, the next enzyme in the SN 
BER pathway, to nicked AP-sites, and stimulates its dRP-ase activity. Reciprocally, 
POLβ stimulates the AP-endonuclease activity of APE1 [278,280]. These bilateral 
interactions between glycosylases and APE1, and APE1 and POLβ prompted the 
suggestion that BER intermediates are bound by the preceding enzyme in the pathway 
until the next protein arrives, at which point the intermediate is shuttled from one repair 
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enzyme to the other, much like the baton in a relay [281]. In addition to DNA 
glycosylases and POLβ, there is evidence for a rather extensive network of protein-
protein interactions regarding APE1 and BER proteins. APE1 is shown to stimulate 
and/or physically interact with PCNA, LIG1 and FEN-1 (all involved in LP-BER) 
[282,283], as well as the 9-1-1 complex, XRCC1, p53, high mobility group box 1 
protein (HMGB1), Heat-shock protein 70 (Hsp70) and WRN 
[167,284,285,286,287,288]. Many of these factors are associated with APE1 as part of 
BER-competent multi-protein complexes, which may be formed even in the absence of 
DNA damage [127,128]. Negative regulators of APE1 include BCL-2, which inhibits 
endonuclease activity and disrupts the APE1-XRCC1 complex [289], and granzyme A, 
which degrades APE1 by proteolytic cleavage, directing the cell towards apoptosis 
[290]. 
 
Several polymorphisms in the APE1 gene have been identified in the human population, 
some in the coding regions of the gene [291]. As the phenotype of Apex+/- mice and 
downregulation by siRNA may suggest, inactivating mutations could play a role in 
mutagenesis and carcinogenesis. However, results from epidemiological studies are so 
far too ambiguous to suggest a causal relationship between APE-1 polymorphisms and 
cancer (reviewed in [259,292]).  
2.5.11 Polynucleotide kinase 3'phosphatase (PNKP) 
 
As mentioned, the phosphate-flanked 1-nt gaps generated by NEIL glycosylases are 
poor substrates for APE1. Here, the 3' phosphatase-activity of PNKP comes into play, 
thereby unveiling the 3'OH group required for nucleotide-insertion by polymerases 
[106]. A multi-protein complex proficient in SN BER has been isolated from human 
cells, containing (among others) NEIL2 and PNKP but not APE1 [237]. The ‘end-
cleaning’ properties of PNKP are also involved in the repair of double- and single-
strand breaks [293,294]. PNKP-mRNA and protein downregulation by siRNA confers 
sensitivity to several genotoxic agents as well as a ~7-fold increase in spontaneous 
mutation frequency [295].  
 
 42 
2.5.12 DNA polymerase β (POLβ) 
 
POLβ has two main activities in BER, localised in two different domains. The 
polymerase activity is contained in the 31 kDa C-terminal domain. This activity is the 
main polymerase in SN BER [296,297,298], and may also be responsible for 
incorporation of the first nucleotide in LP-BER [299]. In addition, POLβ contains lyase 
activity in an 8 kDa N-terminal domain required for removing the dRP fragment 
generated by APE1 during SN BER [298,300]. As this latter activity is the catalytically 
slowest of the BER enzymes it was proposed that excision of dRP is the rate-limiting 
step in SN-BER [301]. Furthermore, it appears to be the clearly dominant dRPase 
activity in mammalian cells [302,303]. POLβ takes part in an extensive network of 
interactions with BER proteins, among them APE1, PNKP, PCNA, XRCC1, PARP1 
and 2, LIG1, and FEN-1 (reviewed in [304]) also as part of multi-protein complexes. 
XRCC1 and LIG1 seem to inhibit strand-displacement synthesis by POLβ [108,198], 
while WRN and FEN-1 stimulates it [305,306]. This may suggest that the presence of 
BER proteins close to the repair site affects the extent of LP strand-displacement. The 
functional significance of PCNA and PARP-1 and 2 on POLβ is unclear, or there are 
conflicting results in the literature (discussed in [307]). 
 
While attempted generation of Polb-/-mice results in embryonic lethality [308], Polb-/- 
embryonic fibroblasts are able to grow in culture. They show an extreme sensitivity to 
MMS, which can be reversed by expressing the 8 kDa-lyase domain of the murine 
POLβ alone [302]. Haploinsufficient (i.e. Polb+/-) mice are viable, with an increased 
mutation rate when exposed to alkylating agents [309]. The spontaneous mutation 
frequency is not affected, but increased tumour formation and CIN are observed in the 
heterozygous animals [310]. POLβ is frequently overexpressed in human cancers 
(compared to normal tissue) [311]. POLβ overexpression confers a mutator phenotype 
and an enhanced tumour formation to chinese hamster ovary cells [312,313]. 
Furthermore, POLβ is frequently mutated in a range of different human tumour 
specimens, and some of these mutations are in coding regions of the gene [314]. This 
may result in proteins with altered properties, such as lower replicative fidelity and/or 
dRPase-activity [315,316]. Expression of some of these are mutagenic and sufficient for 
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cellular transformation of mouse cells [317]. Additionally, deletion mutants found in 
human cancers lead to a dominant negative phenotype, where the truncated protein 
hinders the wild type from binding to DNA [318].  
2.5.13 DNA Polymerase δ and ε (POLδ and ε) 
 
In addition to their roles in semi-conservative DNA synthesis, these polymerases are 
also involved in gap filling in long-patch BER, MMR and NER. In extracts from Polb-
deficient murine cells, both POLδ and ε can perform both LP and slow SN BER, in a 
process requiring PCNA and RFC [319,320]. The current understanding of the process 
is that POLβ inserts the first nucleotide in both sub-pathways, followed by the insertion 
of several more by POLδ or ε resulting in LP repair [299]. LP-BER has been 
reconstituted with APE1, POLδ or ε, PCNA, RFC, FEN-1 and LIG1 as necessary and 
sufficient factors [110,321]. Furthermore, both polymerases co-immunoprecipitates with 
core BER factors in a BER competent multi-protein complex [128]. 
2.5.14 Flap Structure-specific endonuclease 1 (FEN-1) 
 
When replicative polymerases encounter another strand of nucleic acid on the template, 
they can continue replicative DNA synthesis by displacing the obstructing strand. This 
generates a structure with a protruding single-stranded 5'end. This structure arises 
during lagging strand DNA synthesis, LP BER and HR. The single-stranded protruding 
5' fragment can be removed by FEN-1 by cleaving at the junction between double- and 
single-stranded structures, thus generating a ligatable end [322]. FEN-1 also contains a 
5'→3' exonuclease activity that degrades nicks, gaps and recessed ends [323], and a gap 
endonuclease activity that cleaves the single-stranded regions of gaps (e.g. stalled 
replication forks), thus generating a double-strand break [324]. 
 
Oxidised or reduced AP-sites in the BER-pathway cannot be processed by the lyase 
activity of POLβ [325]. Instead, FEN-1 removes these modified AP-sites as part of an 
oligonucleotide, which is generated by strand-displacement synthesis by POLβ, δ or ε 
[306,326]. FEN-1, alone or in conjunction with PARP-1, stimulates POLβ-mediated 
strand-displacement synthesis at modified AP-sites [327]. PCNA stimulates FEN-1 
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binding to substrate and subsequent catalysis [328], an effect which is antagonised, at 
least in vitro, by the expression of the PCNA binding protein p21 [329]. FEN-1 activity 
is also stimulated by APE1, POLβ, PARP-1, WRN and 9-1-1 [165,282,327,330]. 
 
Fen1-/- knockout mice are not viable, but heterozygotes display an apparently normal 
phenotype. However, when an additional Apc-allele is mutated in a Fen+/- background, 
the animals develop MSI-positive tumours [331]. Many human cancers frequently 
overexpress FEN-1 [332], and furthermore, cancer-associated mutations in the human 
FEN1-gene have been identified. Many of these mutations lead to a protein that is 
inactive for 5' exonuclease and gap endonuclease activities. Mice homozygous for these 
partially inactive proteins have increased autoimmunity, chronic inflammation and 
cancer incidence [333].  
2.5.15 DNA ligases in BER 
 
Two of the three known DNA ligases in humans have been implicated in BER. These 
are DNA ligase I (LIG1) and DNA ligase III (LIG3), in PCNA-associated excision 
repair and XRCC1-associated short patch repair, respectively. The third known ligase 
(DNA ligase IV, LIG4) appears to function only in NHEJ and V(D)J recombination 
[334]. All human ligases derive their energy from ATP, in contrast to bacterial ligases, 
which are dependent on NAD+ [10]. 
 
LIG1 interacts with the DNA clamps 9-1-1 complex and PCNA. The latter protein 
recruits LIG1 to replication foci, where it functions to join Okazaki-fragments in 
lagging strand synthesis [335]. LIG1 is present in both proliferating and non-
proliferating cells, but the mRNA level increases markedly when cells are induced to 
proliferate [336]. The discovery of the PCNA interaction led to the notion that LIG1 
was involved in PCNA-dependent LP BER, a position which was strengthened by 
reconstitution experiments with purified proteins [110,321,326] and its presence in 
multi-protein BER-competent complexes [128,337]. Furthermore, a mutant cell line 
defective for LIG1 has significantly longer in vitro repair tracts in LP BER, while SN 
BER is unaffected [338]. Finally, LIG1 has been proposed to be a patch size mediator 
for POLδ and ε [110]. The 9-1-1 complex interacts in vitro and in vivo with LIG1, an 
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interaction that is stimulated by UV light. The 9-1-1 complex coordinates and stimulates 
the sequential activities of FEN-1 and LIG1 [339], suggesting that it functions as a 
DNA damage-induced PCNA-like factor in DNA repair. LIG1 also interacts with APE1 
and POLβ [283,337]. 
 
The LIG3-gene encodes two isoforms, referred to as α and β. The LIG3β isoform is 
apparently specific for testis, while the LIG3α isoform is expressed in all other cells and 
tissues as well [340]. Furthermore, the α-mRNA contains two translation start codons. 
These result in proteins with different N-termini that specifically directs them to the 
nucleus or mitochondria [341]. Most of the nuclear LIG3α is in a complex with 
XRCC1, and this interaction is apparently required for its stability, as unbound LIG3α is 
swiftly degraded in the absence of XRCC1 [342,343]. Thus, cells deficient for XRCC1 
are also functionally deficient for LIG3α. Both XRCC1 and LIG3α binds to PARP-1 
and poly(ADP-ribose), and are thus recruited to DNA with strand-breaks [344]. LIG3α 
is thought to perform DNA ligation in SN BER and single-strand break repair. 
Consistent with this, LIG3α is found in BER-competent multi-protein complexes 
[237,293,345], and it is one of four core proteins sufficient for complete SN BER in 
reconstitution experiments [108].  
 
2.5.16 X-ray repair complementing defective repair in Chinese hamster 
cells 1 (XRCC1) 
 
The XRCC1 protein harbours no known enzymatic activity, but cells deficient in this 
protein are nevertheless sensitive to a range of DNA damaging agents, e.g. IR as well as 
oxidative and methylating agents (reviewed in [346]). XRCC1 binds rapidly to sites of 
damaged DNA in vivo [347] and purified XRCC1 binds to BER intermediates in vitro 
including small gaps and nicks [348], natural AP-sites as well as 5' and 3' incised AP-
sites (i.e. the product of monofunctional glycosylases, APE1 and bifunctional 
glycosylases, respectively) [349].. Extracts from XRCC1-deficient Chinese hamster 
ovary (CHO) cells have a 2 to 4 fold reduced ligation efficiency [350]. Furthermore, 
XRCC1 has the ability to interact with and/or stimulate BER proteins at all steps of the 
pathway, including MPG, OGG1, NEIL2, APE1, POLβ, LIG3α, PCNA, PARP-1 and -2 
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and PNKP [108,237,253,286,293,342,351,352,353,354]. XRCC1 has also been found as 
a member of several multi-protein complexes, at least some of which are probably 
formed independent of DNA damage [127,128,355]. Together these observations 
suggest a role in single-strand break repair and BER as a scaffolding protein, which 
stimulates, orchestrates and recruits other repair proteins to the site of DNA damage. 
 
Gene-targeted mice deficient for Xrcc1, or for that matter mice that overexpress murine 
XRCC1, have not been obtained due to embryonic lethality [356,357], thus underlining 
the importance of a tightly regulated expression of XRCC1 in murine cells. In the 
human population, single-nucleotide polymorphisms in the coding regions of the 
XRCC1-gene are relatively widespread, but the epidemiological significance regarding 
cancer is rather ambiguous [292,358].  
2.5.17 Proliferating cell nuclear antigen (PCNA) 
 
PCNA is a donut-formed homotrimeric protein that encapsulates DNA and acts in 
replication forks as a sliding clamp for replicative polymerases. It is loaded onto DNA 
by RFC. Like XRCC1, PCNA do not contain any (known) enzymatic activities, but 
rather seem to function as a scaffolding protein that keeps various replication and repair 
factors in close proximity to DNA. PCNA interacts with numerous BER proteins, 
including UNG2, MUTYH, NTHL1, NEIL1, APE1, XRCC1, POLβ, FEN-1, DNA 
LIG1, PARP-1 and WRN [122,212,228,241,251,282,328,329,354,359]. PCNA is 
required for LP BER by POLδ and ε [110,321]. When the cyclin-dependent kinase 
inhibitor p21 is expressed, it binds to PCNA and sequesters it from repair factors, thus 
inhibiting LP repair [329].  
 
2.5.18 Poly(ADP-Ribose) Polymerase 1 and -2 (PARP-1 and -2) 
 
PARP-enzymes catalyse the polymerisation of NAD+ to chains of poly(ADP-ribose) 
(PAR), which may be elongated up to 200 units in length. PARP-1 is responsible for 
most of the PARP-activity in mammalian cells, and binds as a dimer with high affinity 
to DNA containing strand-breaks. This activates the enzyme [360], leading to auto-
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ribosylation of PARP-1 itself, as well as nearby acceptor proteins (e.g. a number of 
histones, p21, p53, XRCC1, POLβ and LIG3α). Auto-ribosylation of PARP-1 leads to 
its dissociation from DNA due to charge repulsion between the negatively charged PAR 
and the phosphate groups in DNA [361]. This dissociation is necessary for DNA repair 
enzymes to access the lesion. Thus, in the absence of NAD+, or in the presence of 
PARP-1 inhibitors, the binding of PARP-1 to damaged DNA inhibits repair. This leads 
to accumulation of DNA repair intermediates in the form of strand-breaks [346,362]. 
Furthermore, it has been shown that PARP-1 binding to DNA recruits and stabilises 
XRCC1 and associated proteins into nuclear foci at strand-breaks [363]. PARP-1 
inhibitors sensitises cells to any agent that directly or indirectly produces strand-breaks 
[346], an effect which can be exploited in cancer chemotherapy. Following the 
dissociation of auto-ribosylated PARP-1 from DNA, PAR is rapidly degraded by PAR 
glycohydrolase (PARG), thus allowing re-binding of PARP-1 to damaged DNA. The 
binding of PARP-1 to damaged DNA is therefore a rather transient and dynamic 
phenomenon. If this process is allowed to repeat itself, for instance if the strand-break is 
not easily repaired, or the number of strand-breaks is so large that they overwhelm the 
cellular repair capacity, PARP-1 will soon consume all intracellular NAD+. This is a 
signal for cell death, which may be dependent or independent of caspases, depending on 
the metabolic status of the cell in question (reviewed in [364]). 
 
While PARP-1 modifies several BER proteins covalently, it can also interact with them 
directly, as demonstrated for POLβ, PCNA, XRCC1, WRN and LIG3α, thereby 
recruiting them to sites of damage (reviewed in [304]). Several of these are stimulated 
by this interaction. Furthermore, under conditions where ATP is scarce it has been 
suggested that ATP for ligation are derived from the PAR-polymer, and that this 
constitutes the rate-limiting step of BER [365]. 
 
Eighteen proteins in the PARP-family have so far been identified in humans, of which 
PARP-1 is the most abundant and accounts for at least 85% of the PARP-activity in 
living cells, while PARP-2 accounts for some ~10% [366,367]. These are the only 
family members that are responsive to damaged DNA. Neither Parp-1 nor Parp-2 
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knockout mice display grave aberrant phenotypes in the absence of DNA damaging 
agents, but attempted double knockouts are embryonic lethal [368].  
2.5 Mitochondrial DNA repair 
 
Each human cell contains several mitochondria, and each mitochondrion contains 
several copies of their own 16,569 bp genome (mtDNA). Each copy of the mtDNA 
genome encodes 22 tRNAs, 2 rRNAs and 13 polypeptides that participate in the 
electron transport chain. The lack of histones and the proximity to oxygen radicals 
produced by the ”leaky” electron transport chain makes the mtDNA especially exposed 
to oxidative damage. Consequently, quite a few of the estimated ~2000 proteins that 
populate mitochondria must be involved in DNA repair. The best established DNA 
repair pathway in mitochondria is BER. Five glycosylases have so far been reported in 
mammalian mitochondria: UNG1, OGG1, MUTYH, NTHL1 and NEIL1 
[112,193,211,231,239]. Furthermore, mitochondria contain APE1, APE2 and LIG3α. 
Together with the only known polymerase activity in mitochondria, DNA polymerase γ 
(POLγ), which also contains a dRP-ase activity, these enzymes are sufficient to 
complete BER by the insertion of a single nucleotide, while LP BER requires FEN-1 or 
DNA2 to excise the flap generated by strand displacement [129,369]. 
 
Other excision repair pathways are not as well characterised. NER is not thought to be 
active in this organelle, as pyrimidine dimers are apparently not repaired in mtDNA 
[370,371,372]. HR and NHEJ may be active in mitochondria [373,374,375], although 
mitochondria are apparently unable to repair some of the lesions that are removed by 
these pathways in nuclei [376]. Direct repair proteins, specifically MGMT and 
ALKBH1, are also present and active in mitochondria [60,376]. Finally, mammalian 
mitochondrial extracts appears to harbour a functional MMR pathway [377]. However, 
none of the core MMR-proteins seem to be directed to mammalian mitochondria. 
Rather, mitochondrial MMR seems to be initiated by YB-1 [378].
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3.0 AIMS OF THE STUDY 
 
The base excision repair pathway has traditionally been subdivided into single-
nucleotide and long patch subpathways. Mechanistically, these pathways differ in two 
ways; by the number of nucleotides that are inserted, and the way in which the AP-site 
is removed. In SN-BER the AP-site is removed by beta-elimination, which is performed 
by POLβ and γ in the nucleus and mitochondria, respectively. These activities are, 
however, not able to remove modified AP-sites [325]. Instead, reduced or oxidised AP-
sites are removed as part of an oligonucleotide ‘flap’ that is displaced from dsDNA by 
long patch synthesis. The dominant activity on ‘flap’ substrates in nuclear DNA is 
FEN1. However, prior to paper I, neither FEN1 nor FEN-1 like activities had been 
demonstrated in mitochondria. Indeed, mitochondrial BER was thought to proceed 
exclusively by the SN-pathway [379,380]. Thus, the aim of this study was to examine 
the capacity of mitochondria for repair of lesions that in the nucleus require LP BER. 
This work is presented in paper I. 
 
Four uracil-DNA glycosylases have been identified in human cells. These are UNG, 
SMUG1, TDG and MBD4. Of these four, UNG is apparently the quantitatively most 
important glycosylase. There is a substantial variation in uracil-excision activity among 
different tissues, individuals and cell lines [146,147,148,149]. The significance of this 
variation on the rest of the BER pathway is not clear, especially since the rate-limiting 
step of BER have been proposed to reside at every step of the pathway, except for 
nucleotide insertion. In murine male germ cells, uracil-repair seems to be limited by the 
expression of UNG in young animals and APE1 in older [381]. Furthermore, the 
catalytically slowest process in SN-BER is the removal of the dRP-fragment by POLβ, 
so in reconstitution experiments the rate is determined by the level of POLβ [301]. 
Finally, the ligation step has also been suggested to be rate-limiting [365]. Furthermore, 
DNA glycosylase overexpression is cytotoxic and/or inhibits growth in cells that are 
challenged with treatments that specifically generates their substrates in DNA 
[150,203,204,257,258]. Using nuclear extracts from human cell lines known to vary in 
the expression of UNG2, we aimed to examine which of the known nuclear BER 
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proteins, if any, acted as bottle necks in the repair of uracil in DNA in human cell lines. 
This work is presented in paper II. 
 
5-FU has been in clinical use for over half a century, but the exact mechanism by which 
it kills cells is still a matter of debate. The current understanding of the cytotoxic 
mechanism involves inhibition of TS and incorporation of fluorinated uracils into RNA 
and DNA [26]. The latter aspect has received considerable attention in recent years, as a 
variety of cells in which DNA repair proteins are downregulated or absent display an 
altered sensitivity to 5-FU or one of its metabolites [25]. Several DNA repair pathways 
can initiate repair of 5-FU from nuclear DNA. The ability to excise 5-FU from DNA is 
demonstrated for UNG2, SMUG1, TDG and MBD4 [116,151,155,157,382,383] , which 
initiate the BER pathway. Alternatively, the MMR pathway has also been shown to act 
on 5-FU in DNA [384]. We aimed to determine the relative significance of each DNA 
glycosylase to initiate BER in vitro, and compare the efficiency of BER and MMR to 
the repair of 5-FU from DNA. Furthermore, we examined what effect downregulation 
of the DNA repair enzyme that was quantitatively dominant in vitro had on 
fluoropyrimidine cytotoxicity. This work is presented in paper III. 
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4.0 SUMMARY OF PAPERS AND GENERAL DISCUSSION 
4.1 Paper I: Mitochondrial base excision repair of uracil and AP sites takes 
place by single-nucleotide insertion and long-patch DNA synthesis. 
 
Akbari M, Visnes T, Krokan HE and Otterlei M. 
 
The mitochondrial genome is under continuous attack from ROS due to its proximity to 
the electron transport chain. ROS oxidises and modifies only bases in DNA, but also 
AP-sites that are generated by spontaneous hydrolysis or as BER intermediates. These 
modified AP-sites cannot be excised by beta-elimination employed by the dRP lyase 
activity of POLβ in nuclei and POLγ in mitochondria [325]. Hence, oxidised AP-sites 
are refractory to repair by the SN-pathway. The only known pathway to excise these 
modified AP-sites in human cells is to remove them as part of a ’flap’ oligonucleotide 
during LP-BER [299]. Yet, mitochondrial BER was thought to take place exclusively 
by SN-BER [379,380]. So how would oxidised AP-sites be repaired in mitochondria? 
 
An essential and critical factor in the study of mitochondrial BER is to prepare 
mitochondrial extracts free of nuclear contaminants, in this case especially those 
involved in DNA repair. We did this by treating partially purified intact mitochondria 
from HeLa and HaCaT cells with proteinase K. The mitochondrial double membrane 
served as a barrier that protected mitochondrial proteins from degradation. Proteinase K 
was then partially removed by centrifugation. Residual proteinase K was inhibited with 
proteinase inhibitor cocktail, thereby allowing extraction of mitochondrial proteins free 
of nuclear BER proteins. The purity of the extract and absence of nuclear contaminants 
was then confirmed by the following observations: 1) Absence of the nuclear proteins 
POLδ, PCNA, lamin A+C and UNG2, as judged by Western blot analysis. 2) Presence 
of VDAC1, COX IV and UNG1, specific for mitochondria, as judged by Western blot 
analysis 3) All UDG-activity and complete U:A BER in the extract were inhibited by 
neutralising antibody against the catalytic domain of UNG, indicating that SMUG1, 
TDG and MBD4 were not present in the extract. 4) We detected DNA polymerase 
activity in the presence of aphidicolin but not N-ethylmalemide (NEM), indicating that 
the polymerase activity stemmed from the mitochondrial POLγ. (Aphidicolin inhibits 
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POLα, δ and ε, while NEM – at the concentration used here – inhibits POLα, γ, δ, and ε 
but not β). 
 
By exposing cccDNAs containing an AP-site in a specific position to mitochondrial 
extracts from HeLa and HaCaT, we observed incorporation of labelled 
deoxynucleotides not only at the lesion site, but also at a few nucleotides 3' of the 
lesion, suggesting mitochondrial LP-BER. Omitting ATP from the reaction mixture 
resulted in an increased incorporation in the 3' fragment, indicating that DNA ligase 
activity was a patch size mediator. Furthermore, by purifying the substrate DNA after 
the reaction and treating it with T4 DNA ligase, we observed a nearly complete 
conversion of repair intermediates to ligated fragment, indicating that the LP-repair 
intermediates were ligatable and hence could not have contained any dRP- or flap-
fragments. In addition, we demonstrated the efficient repair of tetrahydrofuran, a 
modified AP-site that is resistant to dRP-lyase activity and consequently repaired 
exclusively by LP-BER. These observations were consistent with mitochondrial LP-
BER, and furthermore – suggested the presence of a flap endonuclease activity in the 
mitochondrial extract, analogous to nuclear BER. However, at the time, there was no 
such enzyme(s) associated with mitochondria. 
 
We therefore constructed a circular DNA substrate that imitated the flap-containing 
BER intermediate by annealing two overlapping oligonucleotides, to a circular ssDNA 
molecule followed by strand elongation and ligation. The oligonucleotide upstream of 
the overlap junction was radiolabelled at the 5’ end, while the other oligonucleotide 
served as a flap. The ligation of these two oligonucleotides would be indicative of 
complete repair, which requires the removal of the overlapping flap. After treating the 
substrate with mitochondrial extract and cutting the DNA 18 and 33 nucleotides on 
either side of the flap, we detected a shift in gel migration of the radiolabelled oligo, 
which was inhibited by the addition of EDTA. This shift indicated that the two 
oligonucleotides had been ligated, and that the obstructing flap must have been 
removed. Furthermore, this strongly suggested that mitochondria harboured an enzyme 
that could resolve flap-structures from DNA. We could, however, not detect the 
quantitatively dominant nuclear flap endonuclease, FEN-1, in the mitochondrial extracts 
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by Western blot analysis, although we were able to detect FEN-1 by Western blot 
analysis in a nuclear extract. In order to increase sensitivity, we also attempted to 
immunoprecipitate FEN-1 from mitochondrial extract. However, even after 
immunoprecipitation we were still not able to detect mitochondrial FEN-1, whereas this 
was easily done in nuclear immunoprecipitates. In addition, the FEN-1-
immunoprecipitate from nuclear extracts was active on flap-DNA substrates, while the 
FEN-1-immunoprecipitate from mitochondrial extracts was not. Finally, we showed that 
the flap-removing activity in mitochondrial extracts was of an endonucleolytic nature, 
as it released the expected 5-mer from a substrate containing a 5 nucleotide flap, similar 
to nuclear extracts and FEN-1 immunoprecipitate. In addition to the 5-mer flap, we also 
detected smaller fragments, which probably represent exonucleic digestion after the flap 
release. However, we cannot exclude the possibility that at least some of the flap-
removing activity processively digested the flap from the 5’ end prior to ligation. 
Nevertheless, together these observations are consistent with LP BER in mitochondrial 
extracts that do not stem from nuclear contaminants, and that an activity similar to FEN-
1 is involved in mitochondrial LP-BER.  
 
Shortly after publication, three independent papers confirmed our initial observation of 
LP-BER in extracts from protease-treated mitochondria [369,385,386]. Furthermore, 
they all detected FEN-1 in mitochondria by Western blot analysis, although the 
significance of FEN-1 in LP-BER varied between the studies. One group isolated a 
multi-protein complex that was proficient in LP-BER, but which did not appear to 
contain FEN-1. Moreover, siRNA-mediated downregulation of FEN1-mRNA and 
protein had little effect on flap endonuclease activity, and the product of a flap 
endonuclease assay yielded a product that was smaller than expected, although the 
possibility of exonucleic digestion of the released flap could not be ruled out. Thus, 
Szczesny et al argued that while FEN-1 was present in mitochondria, it was not 
involved in LP-BER [385]. On the other hand, Liu et al demonstrated that FEN-1 
immunodepletion from mitochondrial extracts significantly reduced both flap 
endonuclease-activity and LP-BER. Furthermore, they demonstrated that FEN-1 
downregulation by siRNA resulted in delayed repair of oxidative damage in 
mitochondrial, but not nuclear DNA [386]. Finally, Zheng et al detected mitochondrial 
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FEN-1, but also identified another flap endonuclease in mitochondria, the DNA 
replication helicase 2 homolog (yeast), abbreviated DNA2. This protein has ATPase, 
helicase and nuclease domains, the latter active on 5' flap structures. In yeast, it is 
involved in the resolution of certain secondary structures during replication, as well as 
the removal of Okazaki fragments. In human cells, DNA2 appears to be localised in 
mitochondria as well as the nucleus [387]. Moreover, Zheng et al reported a physical 
interaction between DNA2 and POLγ. Both DNA2 and FEN-1 were apparently 
involved in the removal of a 5' flap by slightly different mechanisms. FEN-1 cleaved the 
flap at the ssDNA/dsDNA junction, whereas DNA2 cleaved one to ten nucleotides at 
the 5' end of the flap. Importantly in the context of LP-BER, the immunodepletion of 
either protein lead to a lower ligation efficiency, and simultaneous immunodepletion of 
both abolished ligation completely. The addition of purified DNA2 or FEN-1 reversed 
these effects. Furthermore, reconstituted LP-BER with purified APE1, POLγ and LIG3α 
displayed only very low ligation efficiency when either DNA2 or FEN-1 was present 
and a high efficiency when both were present [369]. 
 
Taken together, the available evidence suggests that LP-BER takes place in human 
mitochondria. DNA2 and FEN-1 are both able to create ligatable ends during strand 
displacement synthesis, perhaps synergistically. Additionally, one or both enzymes are 
probably involved in the replication of mtDNA, an issue that is far from settled 
mechanistically [388,389]. Thus, several models are open for speculation. DNA2 and 
FEN-1 may be specific for either LP-BER or replication, with little or no functional 
overlap or they may operate synergistically in one or both pathways. The generation of 
mutants that are not imported into mitochondria would probably be an important step 
towards elucidating the roles of DNA2 and FEN-1 in mammalian mitochondria. It is, 
however, not likely that additional flap endonucleases are present in human 
mitochondria, since immunodepletion of both endonucleases abolished all detectable 
flap endonuclease activity in the mitochondrial extract [369].  
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4.2 Paper II: The rate of base excision repair of uracil is controlled by the 
initiating glycosylase. 
 
Visnes T, Akbari M, Hagen L, Slupphaug G and Krokan HE  
 
UDGs catalyse the first step in BER, in which a minimum of four enzymes cooperates 
to replace a damaged with a normal base. Interestingly, the intermediates in the process 
are strand-breaks that could be far more dangerous to the cell than the original base 
lesion. Thus, as suggested by the extensive network of protein-protein interactions 
documented for BER proteins, the process must be well coordinated and orchestrated to 
avoid accumulation of BER intermediates. However, the identity of the rate-limiting 
step of mammalian BER has so far remained elusive, every step of the pathway have 
been suggested to be rate limiting, with the exception of nucleotide insertion. Uracil-
repair seems to be limited by the expression of the initiating glycosylase in male germ 
cells derived from young mice, while in cells from older mice the limiting factor seems 
to be Ape1 [381]. In reconstitution experiments, the rate of BER is apparently 
determined by the rate of the catalytically slowest process, i.e. the removal of the dRP-
fragment by POLβ [301]. Finally, the ligation step has also been suggested to be rate-
limiting [365]. If, however, the rate of the pathway were determined at any of the 
intermediate steps, then one would expect large amounts of base damage to be 
converted to the intermediate that precedes the rate-limiting step. Thus, if the lyase 
activity of POLβ were rate limiting, most of the base damage would be converted into a 
strand-break containing a newly inserted base at the 5' side, and a dRP-fragment at the 
3' side. Such processes seem to be responsible for the cytotoxicity conferred by induced 
overexpression of OGG1, NTHL1 and MPG to agents that produce their substrates in 
DNA [203,257,258].  
 
There is a substantial variation in uracil-excision activity among different tissues and 
individuals [146,147,148]. This variation is apparently not caused by variation in 
genotype, as a screen of 62 cell lines from human sources revealed no polymorphisms 
in the coding region of the UNG-gene [149]. However, extracts prepared from these cell 
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lines varied several-fold in the ability to remove uracil [149]. With all this in mind, how 
would the large variations in UDG-activity documented in human cell lines affect BER? 
 
For this purpose, we prepared nuclear extracts from eight cell lines of human origin. Of 
these cell lines there were seven cancerous and one untransformed fibroblast. We did 
not detect any mitochondrial UNG1, which indicates that the nuclear extracts were 
essentially free of mitochondrial contaminants. We found great variation in UDG-
activity among the extracts, as measured on a substrate containing [3H]U:A base pairs. 
The measured UDG-activities corresponded roughly to those measured by Kvaløy et al 
(R2=0.45, P=0.051) [149]. Furthermore, we found large variations in the content of 
other BER proteins according to Western blot analysis, with the exception of PCNA and 
POLδ, which were rather similar in all extracts. Furthermore, we observed a highly 
significant correlation between content of UNG2 in the extracts and measured UDG-
activity. Only two of the proteins showed significant correlation with each other, 
namely POLδ and LIG1. No correlation, neither positive nor negative, was observed 
between TDG and UNG2, in spite of their inverse regulation through the cell cycle 
[124]. This suggests that UNG2 and TDG are truly differentially regulated from cell line 
to cell line, and the variations observed here are not only consequences of different cell 
cycle profiles at the time of harvest. 
 
We furthermore subjected the eight nuclear extracts to in vitro BER-analysis, using 
cccDNA containing a single uracil opposite adenine or guanine. We also generated the 
AP-site and nicked AP-site (nAP) intermediates, by pre-treating the substrates with the 
purified catalytic domain of UNG, or UNG and APE1, respectively. The efficiency of 
repair was Uracil < AP < nAP in all eight extracts, and the repair of U:A and U:G 
showed a striking highly significant correlation with the level of UNG2 and UDG-
activity, especially for the U:A substrate. These observations indicate that the rate of 
U:A repair – and to some extent the U:G substrate - was determined by the protein 
content and activity of the initiating glycosylase UNG2, and that overall rate of repair is 
determined at the first step of the pathway.  
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The lower correlation between UDG-activity and U:G repair was essentially caused by 
one outlier, the AGS extract, which repaired U:G substrate with disproportionately high 
efficiency. If data from this extract were excluded from the data set, the correlation 
between U:G repair and UNG2 was as good as that between U:A and UNG2. This 
suggests that UNG2 was the major initiator of U:G repair in the other cell lines, and that 
the rate of U:G BER was controlled at the first step for this lesion as well. Furthermore, 
the AGS extract contained the second lowest level of UNG2 in our panel and the 
highest content of TDG. We therefore decided to investigate the relative contribution of 
uracil-DNA glycosylases to U:G repair in three extracts. Using inhibitory antibodies 
against UNG2, SMUG1 and TDG we were able to silence >95% of U:G repair in AGS, 
SW480 and T-47D extracts, indicating that the fourth known UDG in human cells, 
MBD4, was of quantitative minor importance, and that the other three were 
quantitatively dominant. By omitting one of the three inhibitory antibodies, we 
estimated the contribution from each glycosylase to U:G repair. This revealed that 
UNG2 still accounted for most of the U:G repair in the AGS extract, but also that TDG 
was able to repair U:G very efficiently. In the two other cell lines, which contained 
more UNG2 and less TDG than the AGS extract, UNG2 was responsible for ~90% of 
repair while TDG only accounted for ~5%. SMUG1 appeared to be of low importance 
in all extracts, and UNG2 initiated >95% of U:A repair in all three extracts. Thus, the 
disproportionate efficient U:G repair in the AGS extract is most likely explained by a 
high expression level of TDG. This was a rather unexpected finding, as previous studies 
indicated that all detectable U:G excision activity in mammalian cells can be quenched 
by inhibiting UNG and SMUG1 [116,132]. However, TDG depends on SUMOylation 
to alleviate the extremely tight product inhibition by the AP-site. This process, in turn, 
requires Mg2+ and ATP, factors that are not included in oligonucleotide cleavage assays. 
Thus, using a BER assay on plasmid DNA allowed us to observe a hitherto unsuspected 
high activity of TDG in nuclear extracts of human origin. TDG is highly expressed in 
G1 and subsequently degraded in S-phase, and vice versa for UNG2. TDG could 
therefore be a major contributor to U:G repair outside of S-phase. UNG2, on the other 
hand, is probably the major activity on uracil in all contexts during the S-phase.  
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Intriguingly, we found the content of LIG3α to correlate with U:G repair equally well as 
UNG2. However, if we hypothesise that LIG3α is the rate-limiting factor for U:G 
repair, then one would expect it to be rate-limiting for AP-site and nAP-substrates as 
well. That was, however, not the case. Furthermore, ligation efficiency of U:G substrate 
was rather similar in all extracts. We found no other significant correlations between 
repair of the intermediate substrates and any of the BER factors studied. This raises the 
question of imbalanced repair of AP-sites, as some of the extracts that contained the 
most APE1 repaired AP-sites with low efficiency. One should keep in mind that APE1 
has cellular functions that are independent of BER. Discrepancy between APE1 content 
and AP-site repair in extracts suggests that the expression level of APE1 in nuclei of 
human cell lines may be dictated by other factors than cellular repair capacity. 
However, another possible explanation for the discrepancy between APE1-level and 
AP-site repair is that Western blot analysis may not necessarily reflect the AP-site 
incision activity in the extracts. APE1 activity is likely to be affected by inhibitory 
proteins such as BCL-2 [289], post-translational modifications and complex formation. 
  
We furthermore observed that uracil and AP-site substrates were repaired with higher 
efficiency when the lesion was positioned opposite guanine, rather than adenine. In 
contrast, the repair efficiency of nicked AP-site substrate was similar in both contexts. 
Therefore, specificity for the opposite base is likely to reside at the AP-site incision 
stage of the pathway, although purified recombinant human APE1 displayed a rather 
similar activity for both AP:A and AP:G, as also observed by others [390]. These 
observations suggest that there are other factors not considered in this paper that may 
direct AP-site incision in different contexts. A speculative notion is that DNA 
glycosylases, which display specificity to the opposite base and bind to AP-sites 
[158,180,196,210,227,251,275] can stimulate or inhibit the access of APE1 to the AP-
sites. These interactions have been postulated to recruit APE1 to the AP-site and 
”protect” it [391], but in the few cases where this has been studied, the presence of a 
glycosylase bound to the AP-site inhibits incision activity of APE1 [158,275].  
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4.3 Paper III: Cytotoxicity of 5-fluoropyrimidines is mainly through RNA 
incorporation and thymidylate synthase inhibition rather than DNA 
fragmentation from DNA excision repair 
 
 Pettersen HS, Visnes T, Vågbø CB, Doseth B, Kavli B and Krokan HE  
 
The exact mechanism causing 5-fluoroyracil (5-FU) cytotoxicity is still a matter of 
debate, even though it has been in clinical use for half a century. Already from the very 
start it was clear that 5-FU was internally metabolised and incorporated into RNA and 
DNA [392]. Incorporation into RNA perturbs the general metabolism of RNA in several 
different ways. It disturbs processing of rRNAs [33,393], post-transcriptional 
modification of tRNAs [30,31] as well as snRNA-protein complexes, thus inhibiting 
splicing of pre-mRNA [32,34], as well as post-transcriptional conversion of uridine to 
pseudouridine present in rRNA, tRNA and snRNA [35]. Another metabolite, 5-FdUMP, 
strongly inhibits the action of Thymidylate synthase (TS), which methylates dUMP at 
the 5' position of the base, thus generating dTMP. During inhibition of TS, less dTTP is 
generated, leading to an inhibition of DNA synthesis. When the level of dTMP is 
reduced, the levels of dAMP, dCMP and dGMP are perturbed as well, since the 
individual dNTP levels in the cell are regulated through various feedback mechanisms. 
Consequently, the DNA synthesis that does go on may be expected to be error prone, 
generating mismatches at a much higher frequency than under normal conditions [15]. 
The replicative polymerases may also incorporate analogues of dTTP into DNA. 
Incorporation of dUTP results in a U:A base pair, which may be repaired by UNG2 or 
SMUG1 [116], while incorporation of 5-FdUTP results in 5-FU:A or 5-FU:G base pairs 
[29,394]. Purified recombinant UNG2, SMUG1 and TDG are all able to recognise 5-
FU:A in DNA, while 5-FU:G may be recognised by UNG2, SMUG1, TDG and MBD4 
[116,151,155,157,382,383]. Furthermore, as 5-FU:G is a mismatch it can be repaired 
through the MMR pathway [384]. It has also been suggested that MMR may recognise 
and repair 5-FU:A [384].  
 
While at least five different mechanisms may be involved in the repair of 5-FU from 
DNA, their relative significance in repair and cytotoxicity has so far not been 
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determined. Nevertheless, the role of DNA repair in 5-FU cytotoxicity has recently 
received considerable attention. Cells derived from knockout mice deficient in various 
DNA repair genes are generally less sensitive to fluoropyrimidines compared to wild 
type. This includes the MMR genes Msh2 and Mlh1 [89,187], as well as the BER genes 
Tdg, Mbd4 and Polb [171,186,395]. Cells from gene-targeted mice deficient for these 
genes are all less sensitive to fluoropyrimidines. However, cells from Ung-/- mice are as 
sensitive to fluoropyrimidines as wild type [130,151]. Finally, MEFs that express 
siRNA against Smug1-mRNA constitutively are more sensitive to 5-FU than control 
cells [151]. Human cells deficient in MMR reflect these findings, as they are less 
sensitive to fluoropyrimidines [89,90,91]. Less evidence is available for BER deficiency 
in human cells, as neither downregulation of POLβ by siRNA [311] nor expression of 
the UNG-specific inhibitor Ugi [396] has any apparent effect on fluoropyrimidine 
cytotoxicity. However, silencing of human UNG2 by siRNA are reported to increase 
resistance towards 5-F(dU) [397]. 
 
Primarily, we wanted to clarify the relative significance of DNA glycosylases and 
MMR to 5-FU-DNA repair. Using nuclear extracts from several human cancer cell 
lines, we found that the excision of 5-FU opposite adenine and in single-strand context 
depended entirely on UNG2, as the addition of Ugi abolished these activities 
completely. However, when 5-FU was opposite guanine, the relative contribution from 
UNG2, SMUG1 and TDG were all rather similar and varied from extract to extract. A 
similar analysis using BER-incorporation assays mirrored the oligonucleotide cleavage 
assays in that 5-FU:A repair was completely inhibited by Ugi, while endogenous levels 
of UNG2, SMUG1 and TDG were all able to initiate repair of 5-FU:G. However, there 
was an apparent discrepancy between oligonucleotide cleavage and BER assays, in that 
TDG seemed a lot more active in the latter assays. One should keep in mind that TDG 
binds with strong affinity to the product AP-site, an interaction that abrogates enzymatic 
turnover [157,158]. This is alleviated by SUMOylation, which releases TDG from the 
AP-site [161,162]. SUMOylation in vitro requires ATP and Mg2+, factors that were 
absent from the oligonucleotide cleavage assays. While ATP could potentially be 
included in the oligonucleotide cleavage assays, the presence of Mg2+ is not possible as 
it activates potent exonucleases in the extracts. TDG activity is therefore not favoured in 
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oligonucleotide cleavage assays, and its more dominating presence in BER assays could 
perhaps be expected. 
 
We also wanted to clarify the roles of BER and MMR in the repair of 5-FU, as a recent 
paper suggested involvement of MMR in both 5-FU:A and 5-FU:G repair [384]. MMR 
assay strategies are usually depended on restriction enzymes that specifically 
differentiate between damaged/mismatched DNA and normal base pairs [79]. Because a 
5-FU:A base pair is so similar to T:A that no known restriction enzyme can distinguish 
between them, the study of 5-FU:A using restriction enzymes alone is not possible 
[384]. Nevertheless, an MMR proficient extract incorporated more radioactivity into 
plasmid DNA containing 5-FU:A than an MMR-deficient control extract. The authors 
therefore suggested that MMR could be involved in the repair of 5-FU:A, in spite of the 
inability of the MutSα heterodimer to bind 5-FU:A base pairs in electrophoresis 
mobility shift-assays [384]. We were, however, able to monitor 5-FU:A-repair using the 
restriction enzyme HincII to distinguish between repaired and un-repaired DNA. The 
repaired DNA contained normal base pairs, which was recognisable for HincII. 
Unrepaired substrates contained 5-FU, which was removed by the catalytic domain of 
UNG after the reaction, thus generating an AP-site. This AP-site was further adducted 
with MX, which HincII could not recognise. Using this strategy, we were able to show 
that 5-FU:A was repaired exclusively by BER in HeLa and SW480 nuclear extracts. 5-
FU:G could also be repaired by MMR, as we observed a nick-dependent conversion of 
5-FU:G to C:G when UNG2, SMUG1 and TDG were inhibited and/or immunodepleted. 
The process was, however, rather slow compared to BER, which repaired >85% of 5-
FU:G within 30 minutes of the reaction. This indicates that BER, initiated by UNG2, 
SMUG1 or TDG, is the predominant mode of repair in HeLa and SW480. However, the 
role of MMR is most likely underestimated using this assay, since it depends on the 
presence of nick in the DNA substrate, which is likely to be sealed directly by ligase 
activity in the nuclear extracts. 
  
Having established that the majority of 5-FU-repair in vitro was performed by UNG2, 
SMUG1 and TDG we performed siRNA-mediated knockdown of these glycosylases in 
HeLa and SW480. Using specific siRNAs we reduced the protein levels of UNG2 and 
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TDG by >75% for several days. SMUG1 was reduced with at least 60% and this 
conferred tolerance to the drug 5-hydroxymethyl-2’-deoxyuridine (5-hm(dU)) in both 
cell lines. 5-hm(dU) is incorporated into DNA and the excision of this erroneous (but 
still rather innocent) base by SMUG1 mediates cytotoxicity through the generation of 
strand-breaks and probably DNA damage signalling. [398,399,400,401,402]. Thus, 5-
hm(dU) cytotoxicity is rather similar to the DNA repair-mediated cytotoxicity proposed 
for 5-FU. However, it is not incorporated into RNA, and its metabolites does not inhibit 
TS [403], so it serves as a good control for BER-mediated cytotoxicity. However, all 
knockdown cells were as sensitive to varying concentrations of 5-FU, 5-F(dU) as 5-
F(rU) as control cells in both cell lines. Thus, fluoropyrimidine cytotoxicity was 
apparently of a different nature than the DNA repair mediated cytotoxicity of 5-hm(dU), 
suggesting that other mechanisms than DNA repair mediated fluoropyrimidine 
cytotoxicity. Furthermore, downregulation of SMUG1 in cells exposed to 5-hm(dU) 
shifted the cells from G1/S arrest to G2-arrest, while downregulation of UNG, SMUG1 
or TDG in cells exposed to 5-FU and 5-F(dU) had no such effect.  Adding BER 
inhibitors MX and the PARP-1 inhibitor 4-amino-1,8-naphthalimide (4-AN) modulated 
the cytotoxicity of 5-hm(dU), but not of 5-F(dU). Again, this suggest that BER is not 
involved in 5-F(dU) cytotoxicity. 
 
If DNA repair did not mediate the cytotoxicity of fluoropyrimidines, then what did? We 
observed that 5-FU, 5-F(dU) and 5-F(rU) inhibited TS with similar efficiencies in HeLa 
and SW480. Since the two cell lines displayed large variations in the sensitivity to these 
compounds, especially so for 5-F(dU), this indicated that other factors, in addition to 
TS-inhibition, modulated cytotoxicity in these cell lines. Using quantitative LC-MS/MS 
we found that cells exposed to 5-FU preferentially incorporated 5-FU into RNA rather 
than DNA, at a ~3000:1 ratio. For cells exposed to 5-F(dU), however, the RNA/DNA 
ratio was about ~6:1. Furthermore, we attempted to rescue the cells by adding 
increasing amounts of the nucleosides that presumably were in short supply during 
fluoropyrimidine exposure. The addition of uridine to 5-F(rU)-exposed cells had the 
greatest effect, and this treatment rescued both cell lines from the toxic effects of 5-
F(rU). Concurrently, 5-FU incorporation into RNA was greatly reduced. This indicates 
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that incorporation into RNA mediated the cytotoxicity of 5-F(rU). Conversely, 5-F(dU) 
cytotoxicity was alleviated by the addition of thymidine and deoxyuridine, indicating 
that a lack of these DNA precursors is vital for the toxic effects of this drug. Finally, 
cytotoxicity of the clinically relevant 5-FU was partially reversed by high 
concentrations of uridine, but not thymidine or deoxyuridine. This indicates that 
incorporation of 5-FU into RNA plays at the very least some part in cytotoxicity, 
although addition of increasing levels of uridine did not reduce incorporation of 5-FU 
into RNA notably. The lack of uridine reversal for 5-FU is most likely explained by the 
fact that 5-FU may take two slightly different pathways into RNA. One is the sequential 
addition of ribose- and phosphate-groups by uridine phosphorylase (UP) and uridine 
kinase (UK), respectively, generating 5-F(rU) as intermediate product. The other 
pathway is the direct addition of both these groups by orotate phosphoribosyltransferase 
(OPRT). Both pathways generate 5-FUMP, but only the former pathway could be 
expected to be affected by addition of uridine to the medium. 
 
Taken together, our in vitro data suggests that genomic 5-FU is primarily repaired via 
the BER pathway, initiated by UNG2, SMUG1 and TDG. However, the specific 
downregulation of these glycosylases had little effect on fluoropyrimidine cytotoxicity. 
Rather, the cytotoxicity of 5-FU in HeLa and SW480 is most likely mediated by TS-
inhibition and incorporation into RNA, and not excessive DNA repair. This is based on 
the following lines of evidence: 1) Knockdown of the three quantitatively dominant 5-
FU glycosylases had no effect of fluoropyrimidine cytotoxicity or cell cycle arrest. This 
was in contrast to the cytotoxicity and cell cycle arrest seen with 5-hm(dU), which both 
were affected by SMUG1 downregulation. 2) Cells exposed to 5-FU incorporated 5-FU 
into RNA rather than into DNA. 3) Inhibition of BER using MX or 4-AN did not affect 
the cytotoxicity of 5-F(dU). 4) Rescue experiments using nucleotide precursors 
suggested that 5-FU cytotoxicity was mediated through TS inhibition and incorporation 
into RNA. 
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These results are apparently in conflict with recent publications that implicate BER in 
fluoropyrimidine cytotoxicity. Ung-/- MEFs are as sensitive to fluoropyrimidines as the 
wild type [130,151], while downregulation of UNG2 in HeLa by siRNA conferred a 
marked tolerance to 5-F(dU) [397]. However, transfecting HeLa with the UNG-specific 
inhibitor Ugi did not affect fluoropyrimidine response [396]. Downregulation of 
SMUG1 in MEFs sensitises cells, while induced overexpression increases the tolerance 
to 5-FU [151]. Tdg-/- MEF and ES cells are more tolerant to 5-FU than wild type, 
whereas downregulation of endogenous TDG-levels in HeLa has a marginally 
protective effect. However, induced overexpression of human TDG sensitises HeLa 
cells in an apparent dose-dependent manner [171], although matters may be complicated 
by the dual role of TDG as both a DNA repair protein and transcription regulator [173]. 
Mbd4-/- MEFs are less sensitive to 5-FU compared to wild type, but also to a range of 
other cytotoxic agents that induces lesions that are not suspected to be substrates for 
MBD4 [186,187]. This indicates that this glycosylase may function as a general 
apoptosis-promoting factor rather than being directly involved in the repair of 5-FU. 
Later steps of the BER pathway are not as well characterised, although Polb-/- MEFs are 
~8-fold more resistant to 5-F(dU) than wild type [395]. On the other hand, 
downregulation of POLβ in human cancer cell lines has no apparent effect on the 
response to 5-FU [311]. Overexpression of a catalytically inactive mutant of human 
APE1, which binds to AP-sites and blocks subsequent repair steps, confers 
hypersensitivity to fluoropyrimidines in CHO-cells [404]. Finally, CHO-cells without 
functional XRCC1-genes are as sensitive as the wild type [405]. A coherent synthesis of 
these results is not easily achieved, although the results do suggest that 5-FU 
cytotoxicity, especially in MEFs, may very well take place by a mechanism that is 
partly mediated by DNA repair. Yet, there are probably quite a few differences in 5-FU 
metabolism and DNA repair between murine embryonic fibroblasts and human cancer 
cell lines. One example may be the very high preferential incorporation of 5-FU into 
RNA, compared to DNA observed for human cancer cell lines (~3000:1 in human 
cancer cell line, ~11:1 in MEFs [151]). Another example is provided by the relative 
contributions of glycosylases to 5-FU excision. Here, SMUG1 appeared to have a 
dominant role in MEFs, but not in human cell lines, in which UNG2 was the dominant 
enzyme. These species and/or cell type differences indicates that the DNA repair 
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response to 5-FU could be different in these systems. Nevertheless, the report from 
Caradonnas group clearly suggests that downregulation of UNG2 in HeLa increases the 
tolerance to 5-F(dU) [397]. Apart from technical differences (cell culture, incubation 
times), we find it hard to reconcile this result with ours, although it is conceivable that a 
cell could harbour functional mitochondrial succinate dehydrogenase (the enzyme 
responsible for colourimetric change in MTT assays) but still be unable to form colonies 
following trypsination.  
 
MMR has been proposed to mediate 5-FU cytotoxicity in human cells, although our in 
vitro data suggest that the contribution of MMR to repair of 5-FU incorporated into 
DNA is rather modest. How, then, might a minor role for MMR in 5-FU repair be 
reconciled with its role as an apparent mediator of 5-FU cytotoxicity? MMR is also 
involved in the repair of mismatches between ordinary bases, which are generated as a 
result of imbalanced nucleotide pools during TS inhibition [15]. The synthesis of long 
repair patches under these conditions could also generate novel mismatches, thus 
initiating an iterative futile repair cycle. MMR is also involved in DNA damage 
checkpoint signalling, which is likely to affect 5-FU cytotoxicity [91]. Thus, in spite of 
its modest contribution to 5-FU repair in vitro, the MMR pathway could well mediate 
fluoropyrimidine cytotoxicity through mechanisms that are independent of 5-FU DNA 
repair.  
 
If 5-FU-DNA glycosylases were important mediators of 5-FU cytotoxicity, then one 
might expect their expression (or at least the expression of some other downstream BER 
gene) to be altered in 5-FU resistant cells. This is, however, not the case in large scale 
microarray profiling of a variety of 5-FU resistant and sensitive cells, where BER genes 
tend not to be differentially regulated [406,407,408,409,410,411]. Even when we 
consider the obvious problem of false positives in these large-scale studies, the large 
variation in gene sets that characterise resistant or sensitive cells indicates that there 
may be several different mechanisms of 5-FU cytotoxicity in human cancer cells. As the 
different studies generally find different data sets, this suggests that resistance to 5-FU 
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can be achieved through several different strategies. Even so, the conspicuous absence 
of BER and DNA repair factors in these data sets indicates that modulation of DNA 
repair is not one of them. The current evidence points to TS-inhibition and RNA 
incorporation, as the main mechanisms of 5-FU cytotoxicity in human cancer cells 
[411,412,413,414,415]. 
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a b s t r a c t
Base excision repair (BER) corrects a variety of small base lesions in DNA. The UNG gene
encodes both the nuclear (UNG2) and the mitochondrial (UNG1) forms of the human uracil-
DNA glycosylase (UDG). We prepared mitochondrial extracts free of nuclear BER proteins
from human cell lines. Using these extracts we show that UNG is the only detectable
UDG in mitochondria, and mitochondrial BER (mtBER) of uracil and AP sites occur by both
single-nucleotide insertion and long-patch repair DNA synthesis. Importantly, extracts of
mitochondria carry out repair ofmodiﬁedAP siteswhich innuclei occurs through long-patch
BER. Such lesions may be rather prevalent in mitochondrial DNA because of its proximity to
the electron transport chain, the primary site of production of reactive oxygen species. Fur-ase excision repair
hort-patch
ong-patch
racil-DNA glycosylase
thermore,mitochondrial extracts remove 5′ protruding ﬂaps fromDNAwhich can be formed
during long-patch BER, by a “ﬂap endonuclease like” activity, although ﬂap endonuclease
(FEN1) is not present in mitochondria. In conclusion, combined short- and long-patch BER
activities enable mitochondria to repair a broader range of lesions in mtDNA than previously
known.
base lesions and strand breaks, which if left unrepaired may. Introduction
uman mitochondrial DNA (mtDNA) is a closed-circular
olecule of approximately 16,600 basepairs containing 37
enes which code for 13 polypeptides, 22 tRNAs and 2 rRNAs.
ll polypeptides are subunits of mitochondrial respiratory
omplexes of the inner membrane. Although mtDNA only
ncodes 13 of the ∼90 different proteins present in the respira-
ory chain, it is important for normal cellular function because
ells depleted of mtDNA (0 cells) do not respire normally [1].
∗ Corresponding author at: Department of Cancer Research and Molecu
ssons gt. 1, N-7006 Trondheim, Norway. Tel.: +47 72573075; fax: +47 72
E-mail address: marit.otterlei@ntnu.no (M. Otterlei).
Abbreviations: AP sites, apurinic/apyrimidinic sites; UNG, uracil-DN
atch; mtDNA, mitochondrial DNA; mtBER, mitochondrial BER; ROS, re
EM, N-ethylmaleimide; FEN1, ﬂap-endonuclease 1; THF, tetrahydrofur
568-7864/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
oi:10.1016/j.dnarep.2008.01.002© 2008 Elsevier B.V. All rights reserved.
Genetically engineered mutator mice that accumulated a sub-
stantial number of mutations in mtDNA showed early aging
phenotypes and reduced lifespan underlining the signiﬁcance
of mtDNA maintenance [2].
Theelectronﬂowduringmitochondrial respiration cangive
rise to reactive oxygen species (ROS) [3]. ROS can cause DNAlar Medicine, Laboratory Center, Faculty of Medicine, Erling Skjal-
576400.
A glycosylase; BER, base excision repair; SP, short-patch; LP, long-
active oxygen species; tRNA, transfer RNA; rRNA, ribosomal RNA;
an.
result in mutations and genomic instability [4]. The mutation
rate in some regions of human mtDNA, including rRNA and
tRNA sequences, is 20–100-fold higher than that of nuclear
7 ( 2606 dna repa ir
DNA [5]. Somatic and hereditary mutations of mtDNA are
associated with a variety of diseases including diabetes and
deafness [6,7] cancer [8] and neurodegenerative disorders [9].
DNA polymerase  (POL) is the only DNA polymerase
identiﬁed in human mitochondria [10]. POL is a proces-
sive DNA polymerase which consists of two subunits, a large
140kDa catalytic subunit, POLA [11] and an accessory fac-
tor, POLB [12]. The large subunit contains a 3′–5′ exonuclease
(proof-reading) as well as a dRP lyase activity that removes
5′-deoxyribosephosphate (dRP) moiety during BER [13]. The
accessory subunit stimulates the DNA synthesis activity and
processivity of POL [12,14].
BER is apparently the main mechanism for repair of ROS-
generated base lesions in DNA [4]. BER of several oxidative
base lesions and uracil have been detected in mitochondria
[reviewed in 15]. Nuclear BER in human cells occurs by replace-
ment of a single nucleotide or short-patch repair (SP) or several
nucleotides; the so-called long-patch (LP) repair [16]. It is
known that the dRP lyase activity of POL is unable to cleave
modiﬁed (oxidized/reduced) moieties [17], the repair of which
requires ﬂap endonuclease and LP BER. Given the high rate
of ROS production in mitochondria, it is likely that oxidized
moieties are continuously formed in mtDNA. How mitochon-
dria deal with DNA damage that requires LP BER in nuclei is
not known. BER by enzymes puriﬁed from Xenopus laevis mito-
chondria, or by extract from rat liver mitochondria apparently
occurs as single-nucleotide insertion [18,19].
Our main aim in conducting this study was to examine
the capacity of mitochondria for repair of lesions that in the
nucleus require LP BER. First we established an improved
method for puriﬁcation of mitochondria that enabled us to
prepare mitochondrial extracts free of detectable nuclear BER
proteins. Using these extracts we examined the role of UNG
in removal of uracil from mtDNA and carried out mitochon-
drial BER analysis including, patch-size analysis, and repair
of modiﬁed AP sites. We found that UNG is the predominant
uracil-DNA glycosylase in mitochondria and BER of uracil and
AP sites by mitochondrial extracts is in form of SP as well as
LP BER.
2. Materials and methods
2.1. Chemicals and antibodies
Synthetic oligonucleotides were purchased from MedProbe
(Oslo, Norway). [-33P]dTTP, [-33P]dCTP, and [-33P]ATP
(3000Ci/mmol) were from Amersham Biosciences. Proteinase
K, aphidicolin, N-ethylmaleimide (NEM), and Percoll® were
from Sigma–Aldrich. Complete® protease inhibitor and T4
DNA ligase were from Roche Inc. Restriction enzymes and
T4 polynucleotide kinase were from New England Biolabs.
Primary antibodies; APE1 (ab194), APE2 (ab13691), VDAC1
(ab15895), COX IV (ab16056), lamin A+C (ab8984), FEN-1 (ab
462)were all fromAbcamLtd., UK. Antibody to PCNA (PC10, sc-
56) was from Santa Cruz Biotechnology, Inc., USA, polyclonal
FEN-1 antibody was from Bethyl (BL587), and POL (D73020)
was from Transduction Laboratories. Neutralizing antibody
against the catalytic domain of UNG has been described pre-
viously [20]. Paramagnetic protein-A beads were from Dynal,
Norway.0 0 8 ) 605–616
2.2. Cell culture
HeLa and HaCaT cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium with 10% fetal calf serum, 0.03% glutamine,
and 0.1mg/ml gentamicin in 5% CO2.
2.3. Isolation of crude mitochondria
We harvested the cells by trypsination and washed the cells
once with cold PBS and once with an isotonic buffer (20mM
HEPES-KOH pH 7.4, 5mM MgCl2, 5mM KCl, 1mM DTT, and
0.25M sucrose), resuspended the cells in a hypotonic buffer
(20mM HEPES-KOH pH 7.4, 5mM MgCl2, 5mM KCl, and 1mM
DTT) and incubated themon ice for 5–10min before disruption
of the cells by aDouncehomogenizer (5–10 strokes).We imme-
diately added (1:1, v/v) 2× MSH buffer (20mM HEPES-KOH
pH 7.4, 4mM EDTA, 2mM EGTA, 5mM DTT, 0.42M mannitol,
0.14M sucrose) to the homogenate to stabilize the mitochon-
drial membrane as described previously [21]. We centrifuged
the homogenate three times at 2000× g, each time for 5min
to separate cell debris and nuclei (the pellet) from mitochon-
dria (the supernatant), and then pelleted the mitochondria at
3000× g for 30min. The mitochondrial pellet was then resus-
pended in 1ml 1× MSH/50% Percoll, the suspension loaded
on top of a 1× MSH/50% Percoll gradient (12ml) and cen-
trifuged at 50,000× g for 1h at 4 ◦C. The mitochondria were
removed from the gradient and washed once with 1× MSH
buffer to remove Percoll, once with 1ml buffer B (10mM
HEPES-KOHpH 7.4, 0.21Mmannitol, 0.7M sucrose, and 2.5mM
DTT), resuspended in buffer B containing 1mg/ml proteinase
K in a ﬁnal volume of 1ml (unless otherwise is indicated)
and incubated at 37 ◦C for 30min. The mitochondria were pel-
leted at 10,000× g for 5min and washed twice with 0.5ml of
a protease inhibitor mix (0.5ml protease inhibitor cocktail (1
Complete® tablet dissolved in 1ml water), 0.5ml 2× MSH, and
5mM phenylmethylsulphonyl ﬂuoride (PMSF)). We routinely
isolated mitochondria from 30 dishes (150mm) at 85–90% con-
ﬂuence which after proteinase K treatment yielded on average
0.6–0.8mg mitochondrial protein.
2.4. Western blot analysis of intact mitochondria
We isolated mitochondria from 30 dishes (150mm) by Percoll
gradient as described above. The crude mitochondrial pel-
let was resuspended in 0.35ml buffer B and the suspension
divided in seven tubes (0.05ml each). Proteinase K was added
to the samples at the indicated concentrations followed by
incubation at 37 ◦C for 30min. Proteinase K was inactivated
by adding 5mM PMSF and Complete® protease inhibitor to
the samples followed by addition of loading buffer (NuPage)
and heating of the samples at 85 ◦C for 10min. We separated
proteins in 10% denaturing SDS-polyacrylamide gel (NuPage),
and transferred them to a PVDF membrane (ImmobilonTM,
Millipore). The membrane was incubated with the primary
antibodies at 4 ◦C overnight, followed by incubation for 1h at
room temperature with either peroxidase-labeled polyclonal
rabbit anti-mouse IgG/HRP or peroxidase-labeled polyclonal
swine anti-rabbit IgG/HRP (DakoCytomation, Denmark). We
incubated the membrane with chemiluminescence reagent
(SuperSignali® West FemtoMaximum, PIERCE, USA), and visu-
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lized the bands in Image Station 2000R (Eastmann Kodak
ompany, USA).
.5. Preparation of nuclear and mitochondrial extracts
e used a modiﬁcation of the procedure described previ-
usly [22]. Mitochondria (pretreated with 1mg/ml proteinase
) or nuclei were resuspended at 1× packed pellet volume
PPV) in buffer I (10mM HEPES-KOH pH 7.9, and 150mM KCl)
nd 1× PPV of buffer II (10mM HEPES-KOH pH 7.9, 150mM
Cl, 2mM EDTA, 2mM DTT, 40% glycerol, 1% Nonidet P-40,
% Triton X-100, 5mM PMSF, Complete® protease inhibitor,
nd phosphatase inhibitor cocktails). The samples were then
ently rotated at 4 ◦C for 1h, followed by centrifugation at
2,000× g at 4 ◦C for 15min, and the supernatants recovered.
he protein concentration was measured using the Bio-Rad
rotein assay. We always examined the purity of mitochon-
rial extracts byWesternblot analysis for PCNA, POL, VDAC-1,
nd COX IV before using the extracts in biochemical tests. Fail-
re to inactivate proteinase K would be detected as degraded
OX IV.
.6. DNA substrates, BER assay, ﬂap-removal assay,
mmunoprecipitation, and uracil-DNA glycosylase (UDG)
ctivity assay
e prepared DNA substrates for BER assay containing
racil or a synthetic analog of an AP site, 3-hydroxy-2-
ydroxymethyltetrahydrofuran (THF) at a single position as
escribed before [23,24]. Normal AP site was generated by
ncubating the uracil-containing DNA substrate with puri-
ed catalytic domain of UNG [20]. For nick-DNA, the AP site
ontaining DNA was incubated with recombinant APE1. BER
ssays using nuclear or mitochondrial extracts were carried
ut as described before [23–25].
For ﬂap-DNA substrates, we annealed oligonucleotides
ontaining none, one, two, or ﬁve non-complementary
denines at 5′ end (Fig. 5A, underlined nucleotides) as well
s a 5′ end-labeled oligonucleotide upstream to the ﬂap-
ontaining oligo (shown in bold) to single-stranded circular
lasmid (pGEM®-3Zf(+)) and carried out DNA synthesis with
4 gene 32 ssDNA-binding protein, T4 DNA polymerase, T4
NA ligase, and dNTPs. The DNA was puriﬁed using a PCR
uriﬁcation Kit (Qiagen). Unless otherwise is indicated, the
ap-removal assay was carried out in 0.020mg mitochondrial
xtract, 50mM HEPES-KOH pH 7.4, 2mM DTT, 5mM MgCl2,
5mM KCl, 1mM ATP, 0.36mg/ml BSA, T4 DNA ligase and
pmol of the indicated DNA-substrates at 37 ◦C for 15min in
0l reaction. The reaction was stopped by adding EDTA, SDS
nd proteinase K and further incubation for 30min. The ﬂap-
emoval activity of the immunoprecipitates was carried out in
he presence of T4 DNA ligase.
For immunoprecipitation we covalently attached 0.02mg
olyclonal FEN-1 antibody to 0.2ml premagnetic beads as
escribed by the manufacturer. We incubated 0.04ml of the
eads with 0.2mg HeLa nuclear or mitochondrial extract at
◦C for 4h under constant rotation. The beads were washed
our times with wash buffer (10mM Tris–HCl pH 7.5, 100mM
Cl). The beads were then either used directly in ﬂap-removal
ssay or boiled in loading buffer and used for Western blot8 ) 605–616 607
analysis. UDG activity assay was performed as described ear-
lier [25].
3. Results
3.1. Proteinase K treatment clears isolated
mitochondria of nuclear protein contaminants
A prerequisite for analysis of mtBER in vitro is the prepara-
tion of mitochondrial extracts free of nuclear BER proteins.
During the early stage of this study we found it difﬁcult to iso-
late mitochondria completely free of nuclear proteins. In an
attempt to clear mitochondria of nuclear proteins we treated
intact mitochondria with proteinase K, a serine protease that
exhibits broad cleavage speciﬁcity. Fig. 1A shows results of
Western blot analysis of mitochondria that had been incu-
bated with different concentrations of proteinase K at 37 ◦C
for 30min. The absence of detectable nuclear lamin in mito-
chondrial extract has frequently been used to test the purity
of mitochondria. Notably, the sample not treated with pro-
teinase K was free of lamin A+C, while we detected nuclear
proteins including UNG2, POL, and PCNA (Fig. 1A, lane 1).
Traces of nuclear proteins were still detectable in the sam-
ples treated with 0.5mg/ml proteinase K (Fig. 1A, lane 2), but
at 1 and 1.5mg/ml proteinase K, the samples were cleared
of detectable nuclear proteins (lanes 3 and 4). Proteinase K
treatment degraded a fraction of the outer mitochondrial
membrane (OMM)protein, voltage-dependent anion channel 1
(VDAC-1) at concentrations of 0.5mg/ml and higher, while the
inner membrane (IMM) proteins remained seemingly intact at
proteinase K concentrations up to 2.5mg/ml as demonstrated
by the presence of full length COX IV (Fig. 1A). The amount
of APE1 was reduced considerably at 0.5mg/ml proteinase K
compared with the untreated sample (Fig. 1A, lanes 2 and
1, respectively), but a fraction remained unchanged at con-
centrations of proteinase K of 0.5–2.5mg/ml (lanes 2–6). This
supports that APE1 is both a nuclear and a mitochondrial pro-
tein [26,27]. The amount of the second human endonuclease,
APE2, did not change in the samples treated with proteinase
K, indicating that APE2 is a true mitochondrial protein [27,28].
The additional band seen above the major APE2 band after
proteinase K treatment is likely caused by cross-reaction of
the antibody with a degraded protein. As expected UNG2 but
not UNG1 was degraded by proteinase K treatment.
The ability to detect a protein by Western blot analysis
depends on the sensitivity of the antibodies. We compared
the sensitivity of antibodies against thenuclear proteins lamin
A+C and PCNA by Western blot analysis of a serial dilution of
total HeLa extract. PCNAwas detected in fourfoldmore diluted
extracts compared with lamin A+C (Fig. 1B). Next, we carried
out Western blot analysis of a serially diluted puriﬁed recom-
binant PCNA and found that the PCNA antibody was able to
detect as low as 1.8ng protein (Fig. 1C). These results together
with those shown in Fig. 1A support the use of this particular
PCNA antibody as a suitable marker for detection of nuclear
protein contaminants in mitochondrial extract. In conclusion,
the results of Western blot analysis suggest that treatment
of intact mitochondria with proteinase K enables us to pre-
pare mitochondria that are free of nuclear BER proteins. We
608 dna repa ir 7 ( 2 0 0 8 ) 605–616
Fig. 1 – (A) Western blot analysis of mitochondria isolated from HeLa cells and treated with the indicated concentrations of
seria
nanproteinase K at 37 ◦C for 30min. (B) Western blot analysis of
Western blot analysis of a serial dilution of puriﬁed recombi
therefore routinely treated intact mitochondria with 1mg/ml
proteinase K prior to preparation of extract that we used in the
following experiments.
3.2. Extracts prepared from proteinase K treated
mitochondria display POL speciﬁc DNA synthesis activity
Mammalian DNA polymerases show different sensitivity for
aphidicolin and N-ethylmaleimide (NEM). Thus, aphidicolin
inhibits DNA polymerases , , and  at 0.06mM but not poly-
merases  and , while NEM inhibits DNA polymerases , , ,
and  at 2mM but not POL even at 10mM [29–31]. POL is the
only DNA polymerase identiﬁed in human mitochondria [10].
We incubated mitochondrial extract with DNA substrate con-
taining a nick at a deﬁned position (Fig. 2A) with or without
aphidicolin or NEM in the repair reaction. We used nicked-
DNA to exclude possible inhibition of repair reactions before
the DNA synthesis step by aphidicolin or NEM. The control
sample shows that the extract is capable of carrying out DNA
synthesis and subsequent ligation of newly synthesized DNA
(Fig. 2B, lane 1). Addition of 0.1 or 0.3mM aphidicolin to the
reaction had no detectable inhibitory effect on DNA synthe-
sis activity of the extract, while NEM at 5mM dramatically
inhibited this activity (Fig. 2B, lanes 2–4). This experiment indi-
cates that our mitochondrial extract was not contaminated
with the nuclear DNA polymerases , ,  (which are inhib-
ited by aphidicolin) or  (which is not inhibited by NEM), and
that the extract displayed DNA polymerase activity compara-
ble with POL. Altogether, the results shown in Figs. 1 and 2
demonstrate that the method used allowed us to prepare a
pure mitochondrial extract.lly diluted total HeLa extract for lamin A+C and PCNA. (C)
t PCNA.
3.3. Pure mitochondrial extracts retain BER activity
and UNG is the only detectable uracil-DNA glycosylase in
HeLa mitochondria
In human cells, four uracil-DNA glycosylases (UDG) have been
identiﬁed [32]. Among these, UNG is the only known UDG tar-
geted to bothnucleus (UNG2) andmitochondria (UNG1) [33,34].
Nuclear BER in human cells has been extensively studied
and shown to occur via SP and LP BER [16]. BER carried out
by enzymes puriﬁed from Xenopus laevis mitochondria and
extract from rat liver mitochondria was reported to occur via
single-nucleotide insertion [18,19]. We tested mitochondrial
uracil-BERusing [-33P]dTTPor [-33P]dCTPandDNAsubstrate
containing uracil at a speciﬁc position (Fig. 3A, U:A).We carried
out the repair reaction in the absence or presence of neu-
tralizing antibody against the catalytic domain of UNG which
is identical in UNG1 and UNG2. Notably, repair of uracil was
in form of several-nucleotide insertion (Fig. 3B, lanes 1 and
3). Neutralizing UNG by antibody prevented uracil-dependent
repair DNA synthesis activity by mitochondrial extract (lanes
2 and 4, respectively).
Next, we used a more sensitive assay and veriﬁed the
ability of mitochondrial extract to remove uracil from single-
stranded as well as double-stranded DNA oligos containing
U:A or U:G pairs. We found that inhibition of UNG in the reac-
tion abolished all the uracil releasing activity of the extract
(Fig. 3C, lanes 10–12). These results strongly suggest that UNG
is the only DNA glycosylase responsible for removal of uracil
in human mtDNA. Notably, because U:G is also a substrate for
TDG and SMUG1 DNA glycosylases [32] the complete inhibi-
tion of removal of uracil from U:G substrate by neutralizing
dna repa ir 7 ( 2 0 0
Fig. 2 – Effect of inhibitors of DNA polymerases on
mitochondrial DNA synthesis activity. (A) Schematic
illustration of substrate for analysis of DNA synthesis
activity. X represents the site of nick in DNA. (B) We
incubated mitochondrial extract with nick-containing DNA
substrate and [-33P]dTTP in the absence or presence of
aphidicolin or NEM at the indicated concentrations at 32 ◦C
for 60min. Puriﬁed DNA was digested with XbaI and
HindIII and resolved in 12% denaturing polyacrylamide gel.
As undamaged substrate we used DNA containing T in
place of nick (T:A). High molecular weight (HMW) bands
represent nucleotide incorporation outside the short
fragments released after digestion of DNA with the
indicated restriction enzymes.8 ) 605–616 609
UNG antibody indicates that our mitochondrial extract is free
of the nuclear DNA glycosylases TDG and SMUG1, further sup-
porting that the mitochondrial extract was essentially free of
nuclear proteins.
3.4. BER DNA synthesis during repair of both uracil
and AP sites by mitochondrial extract occurs through
incorporation of several nucleotides
Next we carried out patch-size analysis of AP site BER. AP sites
were produced by incubation of uracil-containing DNA sub-
strates with recombinant UDG. A fraction of AP site repair was
apparently via LP BER (Fig. 4A, lanes 2–4). Human DNA ligases
need ATP for activity. We carried out BER in the presence or
absence of additional ATP and ATP-generating agents in the
reaction. In the absence of ATP, repair intermediates of differ-
ent sizes were readily detected (Fig. 4B, lane 2) demonstrating
the ability of the mitochondrial DNA polymerase, likely POL,
to incorporate more than one nucleotide during BER DNA syn-
thesis. Incubation of the puriﬁed DNA with T4 DNA ligase at
16 ◦C overnight resulted in close to complete ligation of repair
intermediates (Fig. 4B, lanes 3 and 4). This indicates that most
repair intermediates observed in lane 2 did not contain unpro-
cessed 5′ deoxyribosephosphate (dRP) or 5′ ﬂaps.Moreover, the
results show that the indicated repaired fragments released
by the digestion of DNA with XbaI and HindIII (see Fig. 3A)
represent short and long-patch products and are not merely
products of resynthesis of DNA past the HindIII recognition
site.
The 3′–5′ exonuclease activity of POL may result in DNA
synthesis 5′ upstream to the damage. We tested this using
U:G DNA substrate (Fig. 3A) in combination with [-33P]dTTP
(todetect possible incorporationof radioactivity 5′ upstreamto
the damage) or [-33P]dCTP (to detect incorporation of radioac-
tivity at the site of the damage). We did not detect DNA
synthesis activity 5′ upstream to the damage above the back-
ground (not shown). In conclusion, under our experimental
conditions, DNA synthesis activity 5′ upstream to the damage
either does not occur or takes place at very low frequency.
To test if the observed LP BER also takes place in cells
other than HeLa cells, we carried out patch-size analysis of
mitochondrial extract prepared from HaCaT cells. As shown
in Fig. 4C, the isolation and puriﬁcation of HaCaT mitochon-
dria with our procedure cleared residues of PCNA and POL
from mitochondria. BER analysis of the extract showed that,
like HeLa mitochondrial extract, a fraction of the repair DNA
synthesis product was between four to eight nucleotides long
(Fig. 4D, lane 2). In conclusion, under our BER assay conditions,
we found that BER by HeLa and HaCaT mitochondrial extracts
takes place through both SP and LP DNA synthesis.
3.5. Mitochondrial extract removes 5′ protruding ﬂaps
from DNA
The observed LP BER by mitochondrial extract suggests
strand-displacement during repair DNA synthesis resulting
in the formation of 5′ single-strand ﬂaps. Such ﬂaps must
be removed from DNA in order for ligation of DNA ends to
take place. To search for a possible 5′ ﬂap removal activity
in mitochondrial extract we used the DNA substrate strategy
610 dna repa ir 7 ( 2 0 0 8 ) 605–616
Fig. 3 – Role of UNG in mitochondrial uracil-BER. (A) Schematic presentation of the strategy for BER analysis of mitochondrial
extract. (B) We carried out uracil-BER analysis of mitochondrial extract in the absence or presence of a speciﬁc neutralizing
UNG antibody (anti-UNG-Ab) using U:A DNA substrate and [-33P]dCTP or [-33P]dTTP as indicated. The repaired products
(rep. prod.) were digested with XbaI/HincII (lanes 1 and 2) or HincII/PstI (lanes 3 and 4) to examine the uracil-BER patch-size
as described in (A). (C) We incubated mitochondrial extract with 5′ end-labeled single- or double-strand olignucleotides
(22-mer) containing a centrally located uracil in the absence or presence of neutralizing UNG antibody as indicated (lanes
7–12). The reaction was carried out at 37 ◦C for 60min. As control we incubated the substrates with puriﬁed catalytic domain
oligoof UNG (rec.UNG, lanes 4–6). The full length and the cleaved
outlined in Fig. 5A. A schematic illustration of DNA fragments
released after digestion of DNA with EcoRI and HindIII is pro-
vided in Fig. 5B, and the control digestion of the substrates
is shown in Fig. 5C. To facilitate the identiﬁcation of repaired
DNA fragments (fragments II and IV), we prepared DNA sub-
strate using an oligo that does not form ﬂap upon annealing
to template DNA. This “ﬂap” oligo was either phosphorylated
at 5′ position (F0-P) or not (F0). During the preparation of F0-P
substrate, the ligation of fragments I and F0-P oligo will give
rise to fragment IV. Fragment II represents restriction digested
plasmid where the in vitroDNA synthesis has been incomplete
(Fig. 5C, lane 1). The weak bands in fragments II and IV (lanes
2–5) represent synthesis extension of 33P end-labeled oligo on
single-strand circular DNA templates lacking the downstreams are shown as 22-mer and 11-mer, respectively.
ﬂap-oligo, because of incomplete annealing of these oligos to
the template DNA. Upon removal of the ﬂap and subsequent
ligation of DNA, the intensity of the bands corresponding to
fragments II and IV will increase relative to the intensity of
the initial DNA substrate concomitantly with a reduction in
the intensity of the bands corresponding to fragments I and
III. For repair analysis, DNA substrates were incubated with
mitochondrial extract in the absence (Fig. 5D, lanes 1–3 and
7–9) or presence of EDTA (Fig. 5D, lanes 4–6 and 10–12). As can
be seen in Fig. 5D, the intensity of the bands corresponding to
fragments II and IV is higher in the absence than in the pres-
ence of EDTA (compare fragments II and IV, lanes 1–3 to lanes
4–6, respectively). Single digestion of DNA with EcoRI (Fig. 5D,
lanes 7–12), further conﬁrmed the indicated migration pattern
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Fig. 4 – Patch-size analysis of mitochondrial AP-BER. (A) We incubated mitochondrial extract with [-33P]dCTP and the
indicated AP site containing DNA substrates at 32 ◦C for 60min. Then the puriﬁed DNA was digested with the indicated
restriction enzymes to examine the size of repair DNA synthesis as well as the amount of ligated (total repair products) and
unligated repair intermediates. (B) BER assay was carried out in the presence or absence of ATP and ATP generating agents
(lanes 1 and 2, respectively). Half part of the puriﬁed DNA was further incubated with T4 DNA ligase at 16 ◦C overnight
(lanes 3 and 4). (C) Western blot analysis of HaCaT mitochondrial extract before (lane 1) and after (lane 2) treatment of intact
mitochondria with 1mg/ml proteinase K. (D) BER analysis of HaCaT mitochondrial extract from proteinase K treated
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sitochondria.
f DNA fragments in Fig. 5B and C. Note that the repaired
ligated) DNA fragments were too long to be resolved in the
el after single digestion with EcoRI (Fig. 5D, the fragments
ver the dotted line). These results indicate that 5′ protruding
aps that may be formed during LP are cleaved from DNA by
itochondrial extract.
In the nuclei, single-stranded DNA ﬂaps that can be formed
uring LP BER are cleaved by the nuclear protein FEN-1.
otably, using Western blot analysis we did not detect FEN-1
n ourmitochondrial extract (Fig. 5E, lane 3). However, the abil-
ty of Western blot analysis to detect target proteins depends
n the sensitivity of antibodies used. To further assure that
he mitochondrial extract was not contaminated with FEN-1,
e carried out immunoprecipitation of possible FEN-1 from
itochondrial extract as described in Section 2, using nuclear
xtract as control.Westernblot analysis showed that immuno-
recipitation removed a substantial fraction of FEN-1 from the
uclear extract (Fig. 5E, compare lane 1 with 2). FEN-1 was
either detected in mitochondrial extract, nor in immuno-
recipitates from mitochondrial extract (Fig. 5E, lane 6) while
t was detected in immunoprecipitates from nuclear extract
Fig. 5E, lane 5).Next, we used the immunoprecipitated materials (anti-
EN-1) from nuclei and mitochondrial extracts in our
ap-removal assay. The pattern of DNA fragments in the
ample incubated with immunoprecipitated material frommitochondrial extract was identical to that of DNA substrate
alone (Fig. 5F, lanes 1, 2, 4, and 5). However, a substantial
increase in the intensity of the fragments II and IV was
observed in the sample incubated with the immunoprecipi-
tated FEN-1 from the nuclear extract (Fig. 5F, lane 3) similar to
what was observed with the mitochondrial extract (Fig. 5D).
We next examined whether the 5′ protruding DNA was
incised as a ﬂap or digested exonucleolytically. For this
purpose we end-labeled the oligo that contains ﬁve non-
complementary adenines and prepared double-strand DNA
substrates as above but in the absence of T4 DNA ligase
(Fig. 5A, F5, the underlined DNA sequence). Incubation of
the ﬂap containing substrate with mitochondrial and nuclear
extracts resulted in the release of 5-mer DNA (Fig. 5G, lanes
4 and 5, respectively). The reaction was carried out at 37 ◦C
for 2min. A fraction of the released DNA was degraded by
the extract. Longer incubation (5min) resulted in even more
degradation of DNA (not shown). To further test if the observed
fragment corresponded to 5-mer ﬂap and to avoid degradation
of the released ﬂap by the extract we used with immunopre-
cipitated FEN-1 from nuclear extract in the reaction (Fig. 5G,
lanes 6). The migration pattern of the released oligo (lane
6) corresponded to those of the extracts (lanes 4 and 5) and
as expected not degraded. The end-labeled “ﬂap-less” oligo
(Fig. 5A, F0, the underlined DNA fragment) was used as con-
trols (Fig. 5G, lanes 8–11). Addition of EDTA to the reaction
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Fig. 5 – Analysis of 5′ ﬂap-removal activity by HeLa mitochondrial extract. (A) Schematic illustration of the strategy for
analysis of removal of 5′ protruding ﬂaps by mitochondrial extract. The 33P end-labeled common oligo is shown in bold and
marked with * at the 5′ end position. (B) Schematic presentation of DNA fragments released after digestion of DNA
substrates with EcoRI and HindIII. Incomplete DNA synthesis (shown as dotted line) during the preparation of substrate
together with failure to ligate 33P end-labeled oligo at 3′ end position to the downstream “ﬂap” oligo results in the release of
fragment I. Fragment II corresponds to 33P end-labeled oligo ligated at 3′ end position to the downstream oligo, but not
ligated at the 5′ end position. Fragment III corresponds to 33P end-labeled oligo that is joined at the 5′ end to the
synthesized DNA (shown as dotted line). Fragment IV represents 33P end-labeled oligo that has become ligated at both ends.
(C) Lane 1, F0 (P) is the 5′ end phosphorylated form of F0 (ﬂap-less oligo). Lanes 1–10 show the migration pattern of DNA
substrates either digested with both EcoRI and HindIII or EcoRI alone as indicated. (D) The ﬂap-containing DNA substrates
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Fig. 6 – BER of normal and synthetic (THF) AP sites by HeLa mitochondrial and nuclear extracts. The strategy for BER
analysis is shown in Fig. 2A only in this experiment we used DNA substrates containing normal AP sites (normal AP) or
THF in place of nick. As control we used DNA substrate with normal nucleotides (lane 1). The reactions were carried out at
32 ◦C for the indicated times. At zero time point no signal was detected (not shown). After termination of the reaction, half
part of the puriﬁed DNA was incubated with XbaI and HindIII and analyzed for ligated products (total BER) and unligated
repair intermediates. The remaining DNA from samples corresponding to lanes 2–7 were further incubated with T4 DNA
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oigase at 16 ◦C overnight followed by digestion with XbaI and
ompletely inhibited the ﬂap cleavage activity in the samples
ndicating that it is MgCl2-dependent (not shown). Altogether,
hese results show that (a) mitochondrial extract is able to
ncise 5′ protruding ﬂaps from DNA and (b) this activity is not
result of contamination of the mitochondrial extract with
EN-1.
.6. Mitochondrial extract carries out repair of AP site
nalog tetrahydrofuran (THF)
NA polymerases  and  have lyase activity [13,35] enabling
hem to cleave the blocking 5′ terminal dRP moiety from
NA. The lyase activity of POL and POL implicates for-
ation of Schiff’s base intermediate in an -elimination
eaction mechanism [13]. The lyase activity of POL is, sim-
lar to reduced/oxidized AP sites, unable to remove the 5′
HF residue [17,35], because these lesions are resistant to -
limination. Repair of these lesions requires the action of a
ap-endonuclease and implicates LP-BER [36]. Therefore, we
sedTHF as amodel to test the ability ofmitochondrial extract
o repair modiﬁed AP sites compared with nuclear extract. For
omparison we included repair of normal AP sites (normal
P) in the experiment. We found that mitochondrial extract
epaired THF and normal AP sites with comparable efﬁciency
Fig. 6, lanes 2–7). An increasing amount of ligated products
as detectedwith prolonged incubation indicating that (a) the
ere incubated with mitochondrial extract in the absence or pres
xtract, half part of DNA was digested with both EcoRI and Hin
lanes 7–12). (E) Western blot analysis of the nuclear (lanes 1 and
re-IP) and after (Ext. post-IP) the FEN1 immunoprecipitation. And
he nuclear (lane 5) and the mitochondrial (lane 6) extracts. (F) F
uclear extract (lanes 3 and 6) and possible FEN-1 contaminant
NA substrate and carried out the reaction in the presence of ad
ap-DNA substrate included as control. (G) Flap-endonuclease a
EN1 immunoprecipitated from nuclear extract was assayed using
F5-subs.). As control we used circular DNA containing 5′-end labe
f the gel has been deleted to shorten the image.dIII (lanes 14–19).
proteinaseKwas inactivated and (b) strand-displacement can-
not account for the observed long-patch shown in Figs. 3 and 4.
An equal amount of nuclear extractsmeasured as total protein
concentration was used in a parallel experiment for compar-
ison. Like THF, NaHB4-reduced AP sites are not susceptible
to -elimination, making them resistant to dRP lyase activ-
ity of POL, thus implicating LP for repair [37]. We prepared
NaHB4-reduced AP sites as describe previously [37] using cir-
cular DNA shown in Fig. 3A. Mitochondrial extract was able
to repair NaHB4-reduced AP sites, further indicating the abil-
ity of mtBER to repair different types of modiﬁed AP sites (not
shown).
A fraction of repair products of both lesions (normal AP site
and THF) by mitochondrial extract, but not by nuclear extract,
was in the form of repair intermediates. To test if the pres-
ence of the repair intermediates was a result of unprocessed
5′ dRPs or 5′ ﬂaps in DNA we further incubated half of the
DNA from samples corresponding to lanes 2–7 with T4 DNA
ligase at 16 ◦C overnight. This treatment resulted in ligation
of repair intermediates (compare lanes 2–7 with lanes 14–19,
respectively). This indicates that the 5′ dRP ends and possibly
also 5′ ﬂaps that could have been formed during LP BER were
processed during repair.
In summary our results show that (a) our mitochondrial
extract is free of nuclear BER proteins, (b) UNG is the only
uracil-DNA glycosylase present in HeLa mitochondria, and (c)
ence of EDTA as shown. After puriﬁcation of DNA from the
dIII (lanes 1–6), and the other half was digested with EcoRI
2) and the mitochondrial (lanes 3 and 4) extracts before (Ext.
Western blot analysis of immunoprecipitated material from
lap-removal activity of the immunoprecipitated FEN-1 from
from the mitochondrial extract (lanes 2 and 5). We used 5F
ditional T4 DNA ligase. Lanes 1 and 4 show the untreated
ctivity of mitochondrial and the nuclear extracts as well as
circular DNA substrate containing 5′ end-labeled 5-mer ﬂap
led nick (F0-subs.). The broken line (- - -) indicates that a part
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the mitochondrial extract is able to carry out SP and LP BER
and displays ﬂap-endonuclease speciﬁc activity.
4. Discussion
A prerequisite for analysis of mtBER in vitro is the preparation
of mitochondrial extract free of nuclear BER proteins. During
the present study we tested several procedures for isolation
of mitochondria. Using Western blot analysis we found that a
fraction of nuclear proteins including PCNA, POL, and UNG2
associated with mitochondria, possibly by attaching to mito-
chondria upon disruption of the cells. In addition to the Percoll
gradient step that we routinely used in the present study, we
also applied a discontinuous density gradient method which
was reported to efﬁciently separate mitochondria from other
organelles [38]. Thus, the gradient step enables us to sep-
arate organelles, but was insufﬁcient for removing nuclear
proteins attached to mitochondria. Incubation of intact mito-
chondria with trypsin has been used to clear mitochondria
from nuclear proteins [27,39]. However, we found that some
nuclear proteins including PCNA and UNG2 were particu-
larly difﬁcult to completely digest by this treatment. Thus,
an additional or alternative step was necessary to clear mito-
chondria of nuclear proteins involved in long-patch BER in
order to examine potential long-patch BER in mitochondria.
Using proteinase K enabled preparation of a mitochondrial
fraction devoid of detectable nuclear proteins. Biochemical
analysis clearly demonstrated that the mitochondrial extracts
prepared in this way are proﬁcient in BER and therefore suit-
able for this line of analysis.
Our results indicate that UNG is the only DNA glyco-
sylase in mitochondria for removal of uracil from mtDNA.
Several reports support a role for UNG also in repair of oxida-
tive DNA damage [27,40–42]. Ung−/− mice showed increase
infarct size after focal-brain ischemia compared to control
animals and experiments indicated a role for mitochondrial
Ung in brain protection [41]. Recently, expression of UNG1
was shown to increase twofold after oxidative stress [27]. In
addition to uracil, UNG removes isodialuric acid, alloxan and
5-hydroxyuracil [43] although relatively inefﬁciently. These are
cytosine-derived products of oxidative base damage. Experi-
mental demonstration of these lesions in mtDNA, and a role
of UNG1 for their removal, remains to be examined.
Nuclear BERhas been extensively studied and found to take
place as both SP and LP BER [16]. By comparison, mtBER patch-
size has been far less studied. To our knowledge two reports
on this subject are available [18,19]. In the ﬁrst report a recon-
stituted BER with POL, AP-endonuclease, and DNA ligase,
all puriﬁed from Xenopus laevis mitochondria, was in form of
single-nucleotide insertion [18]. It is possible that factors con-
tributing to the processivity of POL and LP BER were absent
in the puriﬁed fractions. In the second study [19], difference
in reaction conditions including sensitivity and type of DNA
substrate used may explain the discrepancy in conclusions.
During nuclear LP BER, short 5′ single-stranded DNA
(ﬂaps) can be formed that is subsequently cleaved by ﬂap
endonuclease-1 (FEN-1) [44]. In Escherichia coli, the 5′ to 3′
nuclease activity of PolI carries out this action [44,45]. To
our knowledge a speciﬁc 5′ ﬂap endonuclease in human0 0 8 ) 605–616
mitochondria has not been identiﬁed. However, the results
presented in Fig. 5 show that 5′ protruding ﬂaps of length
between 1 and 5 nucleotides were removed from DNA by a
mitochondrial extract free of FEN-1. We are working on iden-
tifying the enzyme(s) responsible for this activity.
Exposure of DNA to ROS results in the formation of a vari-
ety of lesions, including oxidized AP sites [46]. Because of the
close proximity of mtDNA to the inner membrane, which is
the main site of ROS production in mitochondria, it is likely
that oxidative modiﬁcation of AP sites in mtDNA is a rather
frequent event. We tested the ability of mitochondrial extract
to repair modiﬁed AP sites using a DNA substrate contain-
ing THF which is resistant to lyase activity of POL [17] and
that requires LP pathway for repair [36,47]. We found that THF
and normal AP sites were repaired with equal efﬁciency by
mitochondrial extract. Whether a 5′–3′ exonuclease activity
or the lyase activity of POL is responsible for the removal 5′
THF or a hitherto unidentiﬁed mitochondrial-speciﬁc 5′ ﬂap
endonuclease carries out this action remains to be examined.
In conclusion in this study we show that UNG is the
predominant uracil-DNA glycosylase in mitochondria. Fur-
thermore, we show that mitochondrial extract is able to carry
out repair of modiﬁed AP sites, displays LP BER and speciﬁc
ﬂap-endonuclease activity. These data suggest thatmitochon-
dria repair a broad repertoire of DNA lesions that are expected
to occur frequently in mtDNA.
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a b s t r a c t
Uracil in DNA is repaired by base excision repair (BER) initiated by a DNA glycosylase, fol-
lowed by strand incision, trimming of ends, gap ﬁlling and ligation. Uracil in DNA comes in
two distinct forms; U:A pairs, typically resulting from replication errors, and mutagenic U:G
mismatches, arising from cytosine deamination. To identify proteins critical to the rate of
repair of these lesions, we quantiﬁed overall repair of U:A pairs, U:G mismatches and repair
intermediates (abasic sites and nicked abasic sites) in vitro. For this purpose we used circular
DNA substrates and nuclear extracts of eight human cell lines with wide variation in the
content of BER proteins. We identiﬁed the initiating uracil–DNA glycosylase UNG2 as the
major overall rate-limiting factor. UNG2 is apparently the sole glycosylase initiating BER of
U:A pairs and generally initiated repair of almost 90% of the U:G mismatches. Surprisingly,
TDG contributed at least as much as single-strand selective monofunctional uracil–DNA
glycosylase 1 (SMUG1) to BER of U:G mismatches. Furthermore, in a cell line that expressed
unusually high amounts of TDG, this glycosylase contributed to initiation of as much as
∼30% of U:G repair. Repair of U:G mismatches was generally faster than that of U:A pairs,
which agrees with the known substrate preference of UNG-type glycosylases. Unexpectedly,
repair of abasic sites opposite G was also generally faster than when opposite A, and this
could not be explained by the properties of the puriﬁed APE1 protein. It may rather reﬂect
differences in substrate recognition or repair by different complex(es). Lig III is apparently aminor rate-regulator for U:G repair. APE1, Pol , Pol , PCNA, XRCC1 and Lig I did not seem to
be rate-limiting for overall repair of any of the substrates. These results identify damaged
base removal as the major rate-limiting step in BER of uracil in human cells.
1
U
c
1
p
S
u
instead of dTMP during replication, resulting in U:A pairs [1,2].
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d. Introductionracil is a frequently occurring lesion in DNA and the largest
ontribution probably comes from incorporation of dUMP
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Theamount of incorporateduracil inDNAmaybeenhancedby
cytostatics that increase the dUTP/dTTP ratio [1,3]. Although
incorporated dUMP is thought to be non-mutagenic, it may
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perturb DNA metabolism by interfering with the sequence
speciﬁc binding of transcription factors [4]. Uracil in DNA may
also result from spontaneous hydrolytic deamination of cyto-
sine, generatingmutagenic U:Gmismatches at a rate of 70–200
events per day in each cell. In the absence of repair, this would
clearly result in an unacceptably high mutation rate, given the
perfect pairing of U with A [5,6].
In general, base excision repair (BER) of uracil in DNA is
initiated by a uracil–DNA glycosylase (UDG) that cleaves the
N-glycosidic bond between the base and deoxyribose, leaving
an abasic site (AP-site). In humans, four enzymes displaying
UDG-activity are known, among which nuclear UNG2 in the
conserved UNG-family and single-strand selective monofunc-
tional uracil–DNAglycosylase 1 (SMUG1) havebeen considered
the most important in BER. SMUG1 was reported to be cen-
tral in repair of U:G mismatches in mouse cells [7], but this is
not necessarily the case for human cells, where UNG2 may be
more important [8,9]. In fact, roles in BER of SMUG1 and partic-
ularly thymine–DNA glycosylase (TDG) which actually prefers
uracil, are unsettled. Essentially nothing is known about
the functional signiﬁcance in BER of the fourth mammalian
uracil–DNA glycosylases, methyl binding domain protein 4
(MBD4) [10]. Subsequent to base excision, AP-endonuclease
1 (APE1) cleaves DNA 5′ to the AP-site. BER may then follow
two distinct routes characterised by the insertion of either
one (short patch, SP) or several (long patch, LP) nucleotides.
Both pathways have been reconstituted in vitro with puriﬁed
enzymes. The SP pathway requires as a minimum a DNA gly-
cosylase,APE1, Pol,which removes 5′-deoxyribosephosphate
(dRP) and inserts a single nucleotide, and ﬁnally ligation by
DNA ligase III, usually in complex with XRCC1 [11]. If the AP-
site is modiﬁed to become resistant to the AP-lyase activity
of Pol , an alternative polymerase may displace a segment
of single-stranded DNA containing the lesion. The displaced
strand is then cleaved by the structure speciﬁc enzyme ﬂap
endonuclease 1 (FEN1) and the resulting nick is ligated, most
likely by DNA ligase I. The LP pathway has been reconsti-
tuted with APE1, DNA polymerase /, replication factor C
(RFC), proliferating cell nuclear antigen (PCNA), FEN1 and DNA
ligase I [12,13]. In vivo the mechanism is almost certainly
more complex due to apparent redundancy of proteins car-
rying out different steps, different expression of the proteins
during the cell cycle, compartmentalization of proteins, exten-
sive protein–protein interactions, as well as post-translational
modiﬁcations [2,14–18]. In addition, BER may under some
conditions involve several other proteins, such as poly-(ADP-
ribose) polymerase (PARP) [19], p53 [20] and WRN [21].
The ability to excise uracil among human cell lines was
previously found to vary several-fold; a variation which was
not caused by polymorphisms in the coding region of the
human UNG-gene [22]. This variation is not limited to cancer
cell lines, since substantial inter-individual variation in UDG-
activity has also been reported in human tumour tissues and
normal tissues [23,24]. The purpose of the present study was
to examine which of the known nuclear BER proteins, if any,
are bottle necks in the repair of uracil in DNA in human cell
lines. Previous studies have proposed removal of 5′dRP by Pol
 [25] or ligation [26] as rate-limiting step in mammalian BER.
We report here that UNG2, in spite of a very considerable vari-
ation in the level of several of the other proteins known to0 8 ) 1869–1881
be required for BER, is the major rate-limiting factor in repair
of U:A and U:G in nuclear DNA in human cell lines. However,
for U:G repair TDG and SMUG1 also contribute to the initia-
tion of BER. Surprisingly, TDG was at least as important for
U:G repair as SMUG1. Except for a possible rate-limiting effect
of low DNA ligase III content, we found no signiﬁcant corre-
lation between BER capacity and the content of several other
BER proteins, indicating that no single factor can be identiﬁed
as rate-limiting in human cancer cell lines.
2. Materials and methods
2.1. Cell culture and nuclear extracts
All cell lines were cultured in Dulbeccos modiﬁed Eagle
medium (4500mg/l glucose), with 10% fetal calf serum, 0.03%
glutamine and 0.1mg/ml gentamicin in 5% CO2. The cell lines
were harvested at 50–70% conﬂuence by trypsination, fol-
lowed by washing in ice-cold phosphate-buffered saline (PBS).
Nuclear extracts were prepared by swelling the cells in hypo-
tonic buffer (20mMHEPES-KOHpH 7.8, 1mMMgCl2, 5mMKCl,
1mM DTT and 1× Complete® EDTA-free protease inhibitor
cocktail (Roche)) for 45min followed by lysis of the cells using
a Dounce homogenizer with a tight ﬁtting pestle. Nuclei were
centrifuged at 180 g and resuspended in 10× packed nuclear
volume (PNV) of buffer I (10mM Tris–HCl pH 8.0, 200mM KCl,
2mM EDTA, 1mM DTT and 1× Complete® EDTA-free protease
inhibitor cocktail (Roche)), recentrifuged and resuspended in
2× PNV buffer II (same as buffer I, but also containing 0.5%
(v/v)NP-40 and40% (v/v) glycerol). Proteinwas extracted at 4 ◦C
for 2h and cell debris removed by centrifugation at 13,000× g
for 15min. Supernatants were aliquoted, snap frozen in liq-
uid nitrogen and stored at −80 ◦C. Protein concentrations were
measured using the Bradford method (BioRad).
2.2. Standard UDG-assays on nick-translated DNA
StandardUDG-assayswere performed essentially as described
[9]. The standard substrate in UDG-assays was calf thymus
DNA nick-translated in the presence of [3H]dUTP and unla-
belled dNTPs. Thus, the substrate contains labelled uracil
in a U:A context and the assay essentially measures activ-
ity encoded by the UNG-gene [27]. UDG-activity is given as
units/mg protein in nuclear extract, where one unit is the
amount of enzyme required to release 1nmol of uracil from
the UDG-substrate per minute at 30 ◦C [16]. The 20l reaction
mixtures contained ﬁnal concentrations of 40mM HEPES-KOH
pH 7.8, 70mM KCl, 1mM EDTA, 1mM DTT, 0.1g/l BSA,
1.8M [3H]dUMP-containing calf thymus DNA (speciﬁc activ-
ity 0.5mCi/mol) and diluted nuclear extracts.
2.3. Western blot analysis
50g protein from each nuclear extract were separated by
electrophoresis on NuPAGE® 4–12% Bis–Tris gradient gels
(Invitrogen) andblottedonto PVDFmembranes (ImmobilonTM,
Millipore) by standard procedure, followed by blocking in
5% fat-free dry milk in PBS containing 0.1% Tween®-20 and
hybridisation with primary and secondary antibodies, the lat-
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er conjugatedwith horseradish peroxidase (DAKO, Denmark).
or Western blot analysis of UNG we used an antibody recog-
ising the catalytic domain [27] at 0.5g/ml. TDGwas detected
ith anti-murine TDG serum at a 1:500 dilution (a kind gift
rom Primo Schär). Antibodies against PCNA (ab29), DNA poly-
erase  (ab2856), XRCC1 (ab1838), DNA ligase I (ab615) and
NA ligase III (ab587) were supplied by Abcam Ltd., UK. The
ntibody against APE1 (NB100–504) was from Novus Biolog-
cals Inc., Littleton, CO, USA and the antibody against DNA
olymerase  (D73020–050) from Transduction Laboratories,
exington, KY, USA and used as recommended by the sup-
lier. The membrane used for the visualisation of TDG had
reviously been used for the visualisation of DNA ligase III
∼100kDa), then stripped using 0.2M NaOH for 5min at room
emperature, washed in water, reblocked and reprobed. All
ther BER proteins were visualised on separate membranes.
e quantiﬁed the content of individual BER proteins in the
xtracts by luminometry using the SuperSignal West Femto
ubstrate (Pierce) a Kodak ImageStation 2000R and Kodak
olecular Imaging Software v4.0.1.
.4. In vitro BER-assays
ubstrates for the BER assay were prepared as described
16,28]. Brieﬂy, an uracil-containing oligonucleotide (5′-GAT
CT CTA GAG TUG ACC TGC A-3′) was annealed to ssDNAs
erived from the pGEM-3Zf(+) plasmid, containing either A or
opposite uracil. The lesions were positioned in otherwise
dentical sequence contexts in order to rule out any differ-
nces due to the sequence-dependency of uracil excision [29].
ollowing strand elongation and ligation, covalently closed
ircular DNA (cccDNA) was collected from a CsCl/ethidium
romide gradient, ethanol precipitated, washed and resus-
ended. These substrates will be referred to as U:A and U:G
ubstrates, respectively. Substrates containing anAP-sitewere
repared by treating U:A and U:G cccDNA with the puri-
ed recombinant catalytic domain of human UNG [27], while
ubstrates with nicked AP-sites (nAP) were prepared by addi-
ional treatment with recombinant puriﬁed human APE1. The
P-site substrate and the nAP-site substrate are therefore
dentical to natural intermediates in the BER process. Unless
therwise indicated, 250ng cccDNA substrate was incubated
t 30 ◦C for 30min with 10g protein in ﬁnal concentrations of
0mMHEPES-KOH, 70mMKCl, 5mMMgCl2, 0.5mMDTT, 2mM
TP, 20M dATP, 20M dGTP, 8M dCTP or dTTP depend-
ng on the radioactive isotope used, 4.4mM phosphocreatine,
2.5ng/l creatine kinase and 50nCi/l [-32P]dCTP or [-
2P]dTTP in a volume of 40l. The reactions were stopped
y the addition of EDTA (to 18mM) and 6g RNase A and
ncubated at 37 ◦C for 10min followed by the addition of SDS
to 0.5%) and 12g proteinase K. After a further incubation
or 30min at 37 ◦C, DNA was puriﬁed by phenol/chloroform-
xtraction and ethanol precipitation and unless otherwise
ndicated digested with XbaI and HincII (New England Bio-
abs). This generated an 8-mer fragment labelled with a single
ncorporated nucleotide at the position of the original lesion.
rovided that the ligation step was fairly efﬁcient, this frag-
ent was a quantitative measure of uracil-repair by both
hort patch and long patch pathways. Following 12% PAGE,
ands were visualised and quantiﬁed with arbitrary units) 1869–1881 1871
using ImageQuant software (Fujiﬁlm). We investigated rela-
tive contribution of SMUG1, TDG and UNG2 to the initiation
of uracil repair by pre-incubating extracts with a neutralising
antibody to SMUG1 (0.11g/l ﬁnal concentration) [9], UNG
(0.3g/l ﬁnal concentration), and/or neutralising anti-serum
towards TDG at (1:50 dilution) [30] on ice for 30min prior to
the reaction.
2.5. AP-site incision assay
APE1 activity was measured by monitoring the incision of an
oligonucleotide containing an AP-site opposite A or G. Brieﬂy,
a 22-mer oligonucleotide (5′-GAT CCT CTA GAG TUG ACC TGC
A-3′) was 5′ end-labelled using T4 polynucleotide kinase and
[-33P]ATP and annealed to a complementary 22-mer (5′-TGC
AGG TCX ACT CTA GAG GAT C-3′) containing either A or G
(X=A or G) opposite uracil. An AP-site was then generated
by treatment with the puriﬁed recombinant catalytic domain
of human UNG. Labelled duplex oligonucleotide (0.1 pmol)
and increasing concentrations of unlabelled duplex oligonu-
cleotide containing AP:A or AP:G were then incubated with
puriﬁed APE1 under conditions similar to those in the BER
assay (40mM HEPES-KOH pH 7.8, 5mM MgCl2, 70mM KCl,
1mM DTT, 0.1g/l BSA) at 30 ◦C for 5min. Reactions were
stopped by addition of formamide loading buffer containing
10mM EDTA, heated at 90 ◦C for 10min and oligonucleotides
separated by 12% PAGE.
2.6. Statistical analysis
Linear regression analysis was employed to determine best-ﬁt
curves and corresponding coefﬁcient of determination val-
ues (R2). P-values were calculated to determine whether the
slopes of the linear regression curves were signiﬁcantly dif-
ferent from zero, which would be the expected result if one
assumes no correlation between the content of the relevant
protein and repair capacity. Finally, t-tests were performed to
determine the statistical signiﬁcance of the apparent prefer-
ence for U, AP andnAP opposite G in the extracts. All statistical
analyses were done using Excel and GraphPad Prism.
3. Results
3.1. Preparation of nuclear extracts
Tobe able to directly compare results from in vitro repair assays
using nuclear extracts from different cell lines, we carried
out a series of experiments to establish conditions for extract
preparation that gave reproducible results for all cell lines
used. The criteria were reproducibility in terms of BER activity,
UDG-activity and yield of protein per 106 cells. In our hands,
isolation of nuclei after Dounce homogenization of hypo-
tonically swollen cells, followed by centrifugation at 180× g
and extraction in hypertonic buffer containing detergent and
200mM KCl gave reproducible results for all cell lines. Using
lower salt concentration (100mM KCl) for extraction under
otherwise identical conditions resulted in several-fold lower
protein yield, as well as lower BER activity. Higher salt (500mM
KCl) followed by dialysis increased the yield of protein, but
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Table 1 – Cell lines and their corresponding
UDG-activities in nuclear extracts
Cell line Type of cell UDG-activity±S.D.
CCD 1064 Human foreskin ﬁbroblast 0.19 ± 0.01
AGS Gastric adenocarcinoma 0.34 ± 0.01
SW480 Colon adenocarcinoma 0.80 ± 0.02
ZR-75-1 Breast carcinoma 0.83 ± 0.01
MDA-MB-231 Breast adenocarcinoma 0.95 ± 0.02
HCT-8 Ileoceal adenocarcinoma 0.99 ± 0.01
CX-1 Colon adenocarcinoma 1.60 ± 0.03
T-47D Breast carcinoma 2.40 ± 0.11One unit is deﬁned as nmol uracil released per mg protein per
minute, and standarddeviations are calculated basedon three inde-
pendent experiments.
BER activity was markedly reduced. Extraction with 500mM
KCl in the absence of detergent also resulted in lower BER
activity, and in addition resulted in more variation between
different experiments (data not shown). Speciﬁc UDG-activity
in nuclear extracts, measured using a substrate with uracil in
a U:A context, was found to vary 12.6-fold (Table 1). The data
presented for each cell line (UDG-activity) are from three inde-
pendent measurements on the same preparation of nuclear
extract (S.D. < 5%). However, we have also carried out simi-
lar measurements after preparation of three separate nuclear
extracts from the same batch of cells (S.D. = 5%), as well as
three separate nuclear extracts from different cell batches
(S.D. = 16%). These results are in good agreement with the
report that formed thebasis for selectionof cell lines [22].How-
ever, we found higher speciﬁc activities, since we have used
nuclear extracts rather than whole cell extracts of sonicated
cells.
3.2. Western blot analysis of BER proteins
The content of UNG2, TDG, APE1, Pol  and , XRCC1, PCNA
and DNA ligase I and III in the extracts was examined by
Western blot analysis, as displayed in Fig. 1A and Table 2.
The results displayed are from one experiment. However,
we have repeated Western blots using three independently
prepared nuclear extracts for UNG2, APE1, XRCC1 and Lig
III. Standard deviations were in the range 4.8–20%, demon-
strating that variation between extract preparations is much
smaller than between extracts from different cell lines. The
mitochondrial UNG1 protein was not detected in any of the
nuclear extracts, indicating that they were largely free of con-
taminants from mitochondria. We detected two bands for
TDG—one representing an unmodiﬁed protein at an apparent
molecular weight of ∼60kDa, and another that conforms to a
SUMOylated form at ∼84kDa [31]. Quantitative Western blot
analysiswas limited to the 60kDa form.We examined the pos-
sibility that expression of some of the proteins correlated with
each other. However, the only signiﬁcant correlation observed
was that between the replication-associated proteins DNA
polymerase  andDNA ligase I (R2 = 0.80 and P=0.0027). Regret-
tably, we were unable to visualise SMUG1 in the extracts. This
protein was only detectable following immuno-precipitation
(data not shown), so our failure to detect SMUG1 was presum-
ably due to low SMUG1 levels in the human nuclear extracts.0 8 ) 1869–1881
The relative protein content of UNG2 in the extractswas found
to correlate stronglywithUDG-activity (R2 = 0.92 and P=0.0002,
Fig. 1B). This suggests that UNG2 was mainly responsible for
the variation inUDG-activitymeasuredunder these assay con-
ditions. Importantly, it also indicates that our quantitative
Western analysis was suitable to gauge the content of BER
proteins in different extracts. We found that the content of
proteins frequently used as “loading control”, e.g. lamin A/C,
variedmuch between cell lines,making themuseless as a gen-
eral loading control in experiments involving several cell lines.
Instead, we relied on protein measurements and loaded 50g
of total protein from each nuclear extract.
3.3. DNA–uracil and BER intermediates are repaired at
different rates and the repair capacities vary among the
different extracts
Nuclear extracts were used to study repair of cccDNA con-
taining uracil, an AP-site or a nicked AP-site in a deﬁned
position (Fig. 1C). Each type of lesion was placed opposite A
in the complementary strand to mimic the substrate resulting
from incorporation of dUMP during replication, or opposite
G to mimic the substrate resulting from cytosine deamina-
tion. Following incubation with nuclear extracts, repair was
assessed by measuring the radioactivity incorporated into the
fragment between the XbaI and HincII restriction sites. This
is a good quantitative measure for BER, as exactly one radi-
olabelled nucleotide is incorporated into this fragment per
BER event regardless of whether repair takes place via SP or
LP subpathways. Technically, this does not provide informa-
tion about the ﬁnal ligation step of BER, as the product would
not be different after incomplete BER in the form of unligated
nick in the ﬁnal intermediate. However, we found that liga-
tion took place at high and largely similar efﬁciency in the
extracts investigated. This control was carried out by digest-
ing repair products with BamHI and PstI, which results in a
22-mer if the substrate is completely repaired and ligated,
and a 14-mer representing an unligated, nicked repair prod-
uct after one-nucleotide incorporation (Fig. 1D). We did not
observe a signiﬁcant accumulation of repair intermediates of
size between 14 and 22 nucleotides, indicating negligible accu-
mulation of repair intermediates other than the unligated 1
nucleotide extensionproduct. However,with themethodology
used, we cannot exclude the possibility that some interme-
diates containing an AP-site accumulated when starting BER
with substrates containing uracil in a U:A or U:G context.
Therefore, the intensity of the XbaI-HincII fragment was a
useful approximation to complete BER in this system. Further-
more, the BER reaction was linear beyond the incubation time
of 30min used in subsequent experiments. The conditions
used did not consume too much of the substrate for quan-
titative analysis, and the BER activity of the extract did not
decay signiﬁcantly during the incubation (Fig. 1E).
All extracts were capable of repairing the DNA sub-
strates, although with different efﬁciencies (Fig. 2A and B). As
expected, the substrates representing later stages in the BER
pathway were generally repaired more efﬁciently than those
representing earlier stages (U<AP<nAP), but the capacity of
the extracts to repair each lesion varied several-fold. Some
extracts repaired uracil and AP-sites with similar efﬁciencies
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Fig. 1 – BER proteins in nuclear extracts and measurement of BER activities. (A) Western blot analysis of BER proteins in
nuclear extracts. From left to right: (1) AGS, (2) CCD 1064, (3) CX-1, (4) HCT- 8, (5) MDA-MB-231, (6) SW480, (7) T-47D, (8)
ZR-75-1. TDG appears as two bands at ∼60kDa and ∼84kDa, the latter conforming to a SUMOylated form of TDG [31]. (B)
Correlation between relative UNG2 content and UDG-activity in nuclear extracts. UNG2 content was set relative to that in the
T-47D extract (100%), where UNG2 was most abundant. UDG-activity was measured by the standard UDG-assay (values
taken from Table 1). (C) Overview of strategy for analysing the BER process. A plasmid containing uracil or, alternatively, an
AP-site or a nAP-site (not shown in ﬁgure) in a deﬁned position is incubated with nuclear extracts. BER is then quantiﬁed in
restriction fragments (routinely XbaI and HincII) after incorporation of [32P]dTTP or [32P]dCTP in the position of the
original lesion. For ligation analysis we digested the substrate with BamHI and PstI. Potential incorporation sites for
radiolabelled [32P]dTTP and [32P]dCTP are indicated with asterisks. Y represents incorporation of dCMP or dTMP
following BER. For analysis of BER of uracil in a U:G context, the complementary strand contained G instead of A (not shown
in ﬁgure). (D) Fraction of ligated product (complete repair) after in vitro BER in nuclear extracts, measured as radioactivity in
BamHI-PstI fragments using U:A or U:G substrates. The lower 14-mer fragment represents an unligated single nucleotide
insertion intermediate while the upper 22-mer represents completely ligated product, resembling completed short- and
long patch repair products, alternatively unligated long patch repair with a patch size of eight nucleotides or above. Ligation
during U:A repair appeared to be slightly more efﬁcient than for U:G repair, with 72–83% versus 67–79%, respectively, of the
intensity in the upper fragment. (E) BER as function of time. Repair of U:G, AP:G and nAP:G substrates by SW480 nuclear
extract after 15min, 30min and 45min incubation, as monitored after digestion with XbaI and HincII.
1874 dna repa ir 7 ( 2 0 0 8 ) 1869–1881
Table 2 – Variation in the content of BER proteins among extracts
UNG2 TDG APE1 Pol  Pol  PCNA XRCC1 Ligase I Ligase III
AGS 14 100 91 64 61 76 52 72 58
CCD1064 5 18 100 33 15 83 24 15 17
CX-1 82 42 49 17 91 78 32 84 89
HCT 40 15 64 48 36 87 37 42 74
MDA-MD-231 30 12 90 44 66 92 54 37 100
Sw480 13 20 44 39 100 87 100 100 69
T-47D 100 32 50 91 73 100 81 60 96
proteZR-75-1 33 33 92 100
Protein content is given in percent relative to the extract in which the
Western analysis was limited to the non-SUMOylated form of TDG.
(T-47D and SW480), whereas others displayed up to 3–4-fold
more efﬁcient AP-site repair compared to uracil-repair (HCT-8
and CX-1). The most efﬁciently repaired substrate was gener-
ally the one containing nAP, which was repaired 1.4–5.6-fold
faster than AP-sites, and 1.5–12-fold faster than uracil in DNA.
3.4. BER of uracil in DNA correlates with UDG-activity
and UNG2 content
Generally, the extracts with the highest UDG-activity dis-
played the most efﬁcient repair of both U:A and U:G (Fig. 2C
Fig. 2 – BER of circular DNA containing uracil, AP-site or nAP-site
extracts along the X-axis are ordered according to ascending UD
UDG-activity values are taken from Table 1. (A) Repair of uracil (b
opposite A by nuclear extracts. (B) As in panel A, but lesion oppo
UDG-activity. (D) Correlation between BER of U:G substrate and U
and the error bars represent standard deviation of the mean. The52 81 38 38 69
in in question was found to be most abdundant (100%). Quantitative
and D, see also Fig. 4A). In particular, the repair of U:A corre-
lated well with UDG-activity (R2 = 0.84 and P=0.0013) as well
as with the relative content of UNG2 (R2 = 0.84 and P=0.0007).
As shown in Fig. 1A, there is no co-variation between the DNA
glycosylases or between these and other BER proteins. Thus,
this highly signiﬁcant linear relationship between BER and
UNG2 suggests that increased expression of UNG2 results in
more efﬁcient repair of U:A, and that the glycosylase step is
the rate-limiting step in BER of U:A. The correlation between
UDG-activity and U:G repair was also signiﬁcant, but weaker
(R2 = 0.67 and P=0.013) and the correlation between U:G repair
by nuclear extracts. Note that in panels A–D nuclear
G-activity, as measured in the standard UDG-assay. All
lack bars), AP-sites (grey bars) and nAP-sites (white bars)
site G. (C) Correlation between BER of U:A substrate and
DG-activity. Each experiment was conducted three times,
units for BER (along the Y-axis) are arbitrary.
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Fig. 3 – Contribution of UNG2, SMUG1 and TDG to initiation of BER of uracil in DNA. Effect of neutralising antibodies on BER
of (A) U:G, and (B) U:A in nuclear extract from AGS, SW480 and T-47D cell lines. The effects of neutralising antibodies
towards UNG2, SMUG1 and TDG were examined in otherwise standard BER assay. Detail on antibody dilutions are given in
Section 2.4. Each experiment was conducted three times. Error bars represent the standard deviation of the mean and units
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ire arbitrary. A representative image of the bands of one exp
nd the relative content of UNG2 (R2 = 0.64 and P=0.017) was
eaker aswell. Theweaker correlationwithU:G substratewas
ssentially caused by one outlier in Fig. 2D, the extract from
he AGS cell line. This extract displayed a signiﬁcantly higher
:G repair than expected from its measured UDG-activity, and
nterestingly also contained the highest content of TDG of all
he extracts. Because the UDG-activity assay measures exci-
ion of uracil from U:A base pairs, the contribution of other
lycosylases with a relative preference for U:G mispairs (i.e.
MUG1, TDG and MBD4, reviewed in [10]) is most likely under-
stimated using this assay. We therefore investigated whether
:G repair in the AGS extract could be initiated by other U:G
lycosylases to any signiﬁcant extent. By adding neutralising
ntibodies against UNG2, SMUG1 andTDG to the reactionmix-
ures, we were able to inhibit BER of U:G in the AGS extract
y ∼95% (Fig. 3A), indicating that these glycosylases are the
ain enzymes initiating repair of U:G under these experi-
ental conditions. The residual ∼5% activity could either be
ue to incomplete inhibition by the three antibodies or result
rom activity of MBD4, which we did not have the means
o selectively inhibit. By omitting one of the three neutral-
sing antibodies from the reaction mixture, we were able to
stimate the individual contribution to U:G repair from each
lycosylase. Our results indicate that in extract of AGS cells,
DG initiated ∼30% of the U:G repair, but even here UNG2
ppeared to be the major uracil-excising activity, initiating
60% of the repair events. SMUG1 appeared to initiate only
5% of total repair. However, in extracts from cell lines SW480
ndT-47D,which containedmoreUNG2 and less TDG than the
GS extract, UNG2 initiated almost 90% of U:G repair, whereas
DGandSMUG1 contributed roughly equally (∼5%each) to the
est of the BER initiations (Fig. 3A). To our knowledge, this is
he ﬁrst demonstration of a signiﬁcant contribution of TDG to
nitiation of BER of uracil in a system mimicking a more com-ent is shown.
plex cellular system. In agreementwith previous studies using
other methods [2,27,32], UNG2 was apparently the sole activ-
ity initiating repair of the U:A substrate in all three extracts
(Fig. 3B).
Next we analysed the relationship between the content of
individual BER proteins in the extract and the repair capac-
ity of uracil, AP-site and nAP substrates (Fig. 4) and examined
possible correlation to the rate of BER by linear regression
analysis. Resulting coefﬁcients of determination (R2) are dis-
played in Table 3. We quantiﬁed each protein relative to the
extract in which the protein in question was most abundant,
e.g. for UNG2, the reference extract was T-47D. Except for
UNG2, the most signiﬁcant correlation appeared to be that
between the content of DNA ligase III and U:G repair (R2 = 0.68
and P=0.012), thus suggesting that it was important for the
efﬁciency of U:G repair. However, we observed no general cor-
relation between the content of DNA ligase III (or any other
protein) and the ligation efﬁciency of U:A or U:G (Fig. 1D), and
the correlation between DNA ligase III and the repair of AP-
and nAP-substrates was also low. We did not observe any clear
relationships between the content of any of the other proteins
and repair of the other substrates, except for APE1 which dis-
played a weak negative correlation with U:A repair (R2 = 0.52
and P=0.045).
3.5. Uracil and AP-sites are repaired more rapidly
opposite G than opposite A
In six out of eight extracts U:G was repaired 1.7–3-fold more
efﬁciently than U:A (P<0.05), and AP-sites opposite G were
repaired 1.2–4.7-fold more efﬁcient than AP-sites opposite
A in ﬁve (P<0.05) (Fig. 5A and B). For repair of nAP-sites,
the preference for G opposite the lesion was less obvious
(Fig. 5C), with only four extracts displaying a signiﬁcantly
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Fig. 4 – Relationship between content of different BER proteins in nuclear extracts and BER. Data on BER protein content
(X-axis) is from Table 2 while data on repair (Y-axis) of U:A (open circles), AP:A (open squares), nAP:A (open triangles), U:G
(closed circles), AP:G (closed squares) or nAP:G (closed triangles) is from Fig. 2A and B. Protein levels for each BER protein are
as mgiven relative to the extract in which each speciﬁc protein w
extract was T-47D (see Table 2).
more efﬁcient nAP:G repair (1.3–1.8-fold, P<0.05). As the
differences between substrates containing A or G opposite
the lesion were more pronounced for uracil and AP-sites
this could suggest that the base opposite the AP-site may
affect binding and/or the activity of APE1. However, this
effect cannot be explained from the known properties ofost abundant (100%), e.g. for UNG2 the 100% reference
AP-endonuclease, the major one being APE1 in mammalian
cells [8,33]. Moreover, we found that the puriﬁed APE1 incised
AP-sites with equal efﬁciency in both contexts (Fig. 5D).
Equal incision opposite A and G has also been observed by
others using the synthetic AP-site analog tetrahydrofuran
[34].
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Table 3 – Correlations between relative protein content and base excision repair capacities of nuclear extracts
U:A AP:A nAP:A U:G AP:G nAP:G
UNG2 0.87**(0.85)* 0.44 0.45 0.64*(0.85)* 0.08 0.14
TDG 0.00 0.07 0.12 0.06 0.10 0.11
APE1 0.52* 0.15 0.28 0.35 0.03 0.08
DNA Polymerase  0.02 0.08 0.02 0.17 0.06 0.04
DNA Polymerase  0.40 0.09 0.41 0.31 0.17 0.06
PCNA 0.09 0.06 0.07 0.10 0.00 0.08
XRCC1 0.08 0.11 0.15 0.13 0.28 0.05
DNA Ligase I 0.26 0.10 0.32 0.22 0.24 0.08
DNA Ligase III 0.43 0.25 0.38 0.68* 0.07 0.18
Correlation is displayed as coefﬁcient of determination (R2)-values of best-ﬁt linear regression curves. **P<0.001 and *0.001<P<0.05. Values
within parentheses represent R2 from a data set in which the AGS extract is excluded on the basis of its high TDG content (outlier).
Fig. 5 – Effect of opposite base in BER of circular DNA containing U, AP-site or nAP-site opposite A (grey bars) or G (black
bars). From left to right in panels A–C—1: CCD1064 (0.19), 2: AGS (0.34), 3: SW480 (0.80), 4: ZR-75-1 (0.83), 5: MDA-MB-231
(0.95), 6: HCT-8 (0.99), 7: CX-1 (1.6), 8: T-47D (2.4). (A) Repair of U positioned opposite A or G. (B) Repair of AP-site opposite A
or G. (C) Repair of nAP-site opposite A or G. The units for repair are arbitrary. All experiments were performed in triplicates,
and error bars represent standard deviations of the mean.*0.01<P<0.05 and **P<0.01. (D) A ﬁxed amount of puriﬁed APE1
was incubated with 0.1pmol labelled 22-mer oligonucleotide containing an AP-site opposite A or G as well as increasing
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roduct.
. Discussion
e aimed at identifying rate-limiting factor(s) in BER of uracil
nd the roles of uracil-excising glycosylases UNG2, SMUG1
nd TDG in this process. For this purpose, we used nuclear
xtracts from eight human cell lines and a BER system that
arries out all the steps in the repair process. Uracil in DNA is
ound in two very different contexts, U:A pairs as a result of
replication errors and U:G mismatches as a consequence of
ytosine deamination. There is no a priori reason to assumesion of the 22-mer at the AP-site results in the 14-mer
that the processing of these structurally and biologically quite
different lesions should involve the same proteins or protein
complexes. However, we found that UNG2 is the major glyco-
sylase for initiation of BER of both lesions. Furthermore, the
concentration of DNA–uracil substrate (1 lesion per plasmid)
in our studies is only approximately 3nM, while the KM for
UNG2 is approximately 1000-foldhigher [9]. The substrate con-
centration is therefore far below saturating conditions, but in
spite of this UNG2 is a major rate-limiting factor in overall
BER of uracil in DNA. Our results also indicate that, at least
for proliferating human cells, measurements of UDG-activity
( 2 0
as well, but it is not. In addition, if data from the AGS extract1878 dna repa ir 7
on DNA nick-translated in the presence of 3H-labelled dUTP,
in which U is found in a U:A context, is a good biomarker for
the capacity of a cell to repair uracil in DNA. As mentioned
above, other studies have proposed removal of 5′dRP by Pol 
[25] or ligation [26] as the rate-limiting step inmammalianBER.
However, in the ﬁrst study [25], BER was reconstituted using
equimolar amounts of recombinant BER proteins, which may
not resemble physiological conditions. In the second study
the initial steps were not examined [26]. A third study using
extracts from male germ cells demonstrated that uracil–DNA
glycosylase was rate-limiting for BER in extracts from young
mice, but not from old. In contrast, APE1 was apparently
rate-limiting in old mice, but not in young [35]. Thus, the rate-
limiting step in BER may change with age, at least in male
murine germ cells. In addition, the rate-limiting step may vary
depending on the type of lesion involved. The very strong
correlation between uracil repair and the content/activity of
UNG2 observed here indicates that in human cancer cells, the
rate of uracil BER is controlled by the initiating glycosylase. In
line with this, another study observed virtually no detectable
repair intermediates during repair of uracil, 8-oxoguanine and
hypoxanthinewhen examining complete repair [36]. This sug-
gests that repair intermediates are very rapidly processed,
and supports our data demonstrating that the rate-limiting
step for repair of uracil resides in the ﬁrst step of the BER
pathway. This would seem to make sense, since constriction
of repair at a later step could cause accumulation of repair
intermediates that are more cytotoxic than the original lesion.
This is thought to be the mechanism behind the cytotoxicity
observed when glycosylases are highly overexpressed in the
presence of agents which damage DNA, as demonstrated for
N-methylpurine DNA glycosylase, 8-oxoguanine-DNA glyco-
sylase 1 and human homologue of endonuclease III [37–39].
Generally, UNG2 initiates all U:A repair and the largest
fraction of U:G repair. However, in the gastric carcinoma cell
line AGS that contained very high TDG levels this glycosylase
contributed to initiation of ∼30% of U:G repair, as demon-
strated using neutralising antibodies. Even here, UNG2 was
the major contributor to BER initiation (∼60%), while SMUG1
contributed far less (∼5%) to U:G repair. In other cell lines
(SW480 with medium level of UNG2, medium level of TDG,
and T-47D with high UNG2, medium TDG) the contribution of
TDG and SMUG1 to initiation of U:G BER was roughly equal
(5–10%), but small compared with UNG2 (∼90%). TDG has pre-
viously been thought to have a specialised or quantitatively
minor role in U:G repair, due to the very low turnover num-
ber of the puriﬁed enzyme compared to UNG2 and SMUG1
[10,40], but here we ﬁnd that it is quantitatively at least as
important as SMUG1 in human cells. The catalytic turnover
of TDG is strongly inhibited by binding to the product AP-site,
but factors that displace TDG from the AP-site stimulate its
turnover. Such factors include the cell cycle checkpoint com-
plex Rad9-Rad1-Hus1 [41], the XPC-RAD23B protein complex
[42], APE1 [43] and SUMOylation [31]. These factors may well
contribute to increase the catalytic efﬁciency of TDG in the BER
system employed here, and in intact cells. To our knowledge
the present work is the ﬁrst study to demonstrate a consider-
able contribution from TDG to BER of uracil in DNA, although
U:G repair activity independent of UNG and SMUG1 has been
reported [9,16]. In conclusion, UNG2 appears as the sole glyco-0 8 ) 1869–1881
sylase initiating BER in a U:A context, and the major initiator
of U:G repair, but if UNG2 is poorly expressed TDG and SMUG1
may signiﬁcantly complement UNG2.
UNG2 has the highest level of expression in the S-phase
[18], and TDG peaks in the G1-phase of the cell cycle [44]. How-
ever, since all cells were harvested during exponential growth
(50–70% conﬂuency) and there was no inverse correlation
between the content of UNG2 and that of TDG among the cell
lines, the low UNG2 and high TDG content in the AGS extract
likely reﬂect an intrinsic property of the cell line. Furthermore,
the low UDG-activity (measured on a U:A substrate) in AGS
cells was also reported in a previous study [45] and reproduced
in independent experiments here. It was reported that TDG is
12–300-fold more active on U:G than on T:G mispairs, depend-
ing on surrounding sequence context [46]. Considering this
result and data on cell cycle expression [44], TDG may well
represent a major activity for repair of U:G mispairs outside
the S-phase in human cells, a task that is likely to be shared
by SMUG1, which is equally expressed in all phases of the cell
cycle (unpublished data). UNG2 is present in BER complexes in
replication foci during S-phase [2,14] and also probably in pre-
assembled BER complexes [16]. Rapid post-replicative removal
of incorporated dUMP depends on functional UNG2-activity
[2,32]. In addition, the rate of removal of uracil in U:A pairs by
puriﬁed UNG2 [9] (and also from U:G and U in single-stranded
DNA) is orders of magnitude higher than that of TDG [30] and
SMUG1 [9]. UNG2 is therefore an ideal enzyme for removal
of incorporated dUMP-residues at a speed keeping up with
the movement of the replication fork. It is conceivable that
complexes containingUNG2may be evolutionary optimised to
process uracil in one of the two main lesion contexts, while all
three glycosylases contribute to U:G repair. Generation of U:G
mispairs from deamination is largely independent of the cell
cycle, and probably infrequent compared with dUMP incorpo-
ration [1]. U:G mispairs present in the S-phase may need to
be repaired relatively rapidly to avoid mutations and UNG2
may be a good candidate for this task. In agreement with this,
MEFs from Ung knockout mice display ∼5.2-fold increase in
mutation rates, but SMUG1-deﬁcient cells also show ∼2.4-fold
increase. For both cell types G:C to A:T transition mutations
were the most common changes observed. This strongly indi-
cates that both UNG2 and SMUG1 contribute to U:G repair and
that they are not redundant. One possible explanation for this
could be that they act mainly in different cell cycle phases,
which also ﬁtswith the additive, rather than synergistic, effect
of deﬁciency in both glycosylases in MEFs [47]. Little is known
about the repair phenotype of Tdg knockout mice, as they lose
viability midway through the gestation period [48].
We also found that the content of DNA ligase III correlates
signiﬁcantly with U:G repair (R2 = 0.68 and P=0.012) and must
therefore be considered as a possible rate-limiting factor in
U:G repair as well. This idea has considerable biological merit,
as several studies have implicated the XRCC1–DNA ligase III
complex in BER [11,49,50]. However, if the rate-limiting step
for U:G repair resided at the ligation step, one might have
expected that this would be the case for AP:G and nAP:G repairare excluded on the basis of its high TDG content, we ﬁnd
that the correlation between UDG-activity/UNG2 content and
U:G repair is as strong as that observed for U:A (R2 = 0.85 and
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=0.003 for both, Table 3). Moreover, we did not observe accu-
ulation of unligated fragments during U:G repair, nor did
e ﬁnd a strong correlation between the content of DNA lig-
se III and the proportion of ligated to unligated fragment
R2 = 0.16, Fig. 1D). We did not observe correlation between
he content of any other BER protein and repair, except in the
ase of APE1, which has a weak inverse correlation with U:A
epair (R2 = 0.52 and P=0.045). Our failure to ﬁnd correlation
etween the content of BER proteins and AP-site or nAP-site
epair may have several explanations. The rate-limiting step
f AP and nAP repair may be controlled by some factor not
onsidered here, and/or the Western blot analysis may not
eﬂect the content of functional protein in the extracts. For
xample 30% of cancers characterised to date, somewhat sur-
risingly, express variant forms of DNA polymerase , some of
hich contain altered polymerase and dRPase activity [51,52].
urthermore, Bcl-2 was recently shown to modulate the activ-
ty of APE1 [53], indicating that AP-site processing is a rather
omplex issue. In addition, numerous protein–protein interac-
ions and post-translational modiﬁcations are known to occur
n the BER pathway and may be important in AP-site process-
ng [2,14–18]. One of the unexpected features observed here
as that AP-sites (and uracil) were generally more efﬁciently
epaired when opposite G compared to opposite A. This was
pparently not due to the properties of APE1 since incision
t AP:A and AP:G by puriﬁed APE1 (Fig. 5D) was equally efﬁ-
ient in both contexts. This has also been observed by others
34], albeit with the AP-site analogue tetrahydrofuran. It thus
ppears likely that other factors may contribute to more efﬁ-
ient repair of AP-sites opposite G in most extracts.
Cancer cells are reported to be genetically unstable [54],
nd our results from a relatively modest number of cell lines
emonstrate a wide variation in DNA repair protein expres-
ion and DNA repair capacity. Because of this variation results
rom one cell line may not be extrapolated to cancer cells
n general. It is likely that both too low expression, too high
xpression and unbalanced expression may contribute to
enetic instability. Unbalanced expression may contribute to
ariable responses to cytostatic drugs, including resistance.
dentiﬁcation of factor(s) governing the rate of DNA repair in
ancer cells may therefore improve diagnosis and treatment
f cancer.
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ABSTRACT 
The cytotoxicity of 5-fluorouracil (5-FU) is thought to be mediated via thymidylate synthase 
inhibition by 5-FdUMP, and by incorporation of 5-FdUTP and 5-FUTP into DNA and RNA, 
respectively. Recently, cytotoxicity due to repair of 5-FU-containing DNA and subsequent 
DNA fragmentation has received considerable attention. This may involve mismatch repair 
(MMR) and base excision repair (BER) initiated by uracil-DNA glycosylases UNG2, 
SMUG1, TDG and MBD4, but their relative significance has not been examined. In extracts 
from human cancer cells (HeLa, SW480), we find that only BER repairs 5-FU:A, while BER 
and MMR both repair 5-FU:G. The major mechanism in vitro is BER initiated by UNG2. 
However, cytotoxicity was neither affected by siRNA-knock-down of either glycosylase, nor 
by inhibition of the common steps in BER. Furthermore, accumulation of 5-FU was ~3000-
fold higher in RNA than in DNA in 5-FU treated cells. Although the mechanisms contributing 
to cytotoxicity were different for 5-FU, 5-F(rU) and 5-F(dU), reversal experiments by dT, dU 
and rU indicated that cytotoxic effects of fluoropyrimidines are mainly attributed to RNA 
effects and thymidylate synthase inhibition. BER apparently has a minor role in cytotoxicity 
and DNA repair by MMR is limited to a 5-FU:G context in human cancer cells.  
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 INTRODUCTION 
5-fluorouracil (5-FU) is one of the most widely used drugs in the treatment of cancer, 
including breast cancer, colorectal cancer and other gastrointestinal malignancies. It has been 
used as an anti-cancer drug for five decades, and presently some 2 million patients are treated 
each year. However, for approximately one-half of the patients given 5-FU based combination 
therapies the treatment has no positive effect, highlighting the need for more knowledge of its 
complex mechanism of action. 5-FU is a prodrug that is converted to several active 
metabolites that are thought to mediate cytotoxicity directly and indirectly by interfering with 
RNA and DNA functions. (Fig. 1) (1). Incorporation of 5-fluorouridine triphosphate (5-
FUTP) into RNA causes disruption of rRNAs (2,3), tRNAs (4) and snRNA processing (5) and 
inhibits the conversion of uridine to pseudouridine in RNA (6). DNA metabolism is perturbed 
by 5-fluorodeoxyuridine monophosphate (5-FdUMP), which inhibits thymidylate synthase 
(TS) and thereby de novo synthesis of dTMP, resulting in dTTP deficiency, imbalanced 
nucleotide pools, and an increased incorporation of dUTP and 5-FdUTP into DNA (7).  
 
Genomic uracil and 5-fluorouracil are repaired by base excision repair (BER) initiated by 
DNA-glycosylases. Purified recombinant forms of all four known human uracil-DNA 
glycosylases are able to excise 5-FU from DNA in vitro. Uracil-DNA glycosylase (UNG2), 
Single-strand selective monofunctional uracil-DNA glycosylase 1 (SMUG1) and thymine-
DNA glycosylase (TDG) may all excise 5-FU in 5-FU:A- and 5-FU:G contexts, while 
Methyl-binding domain 4 protein (MBD4) is active only on 5-FU:G (8-11). In addition, 
mismatch repair (MMR) can process 5-FU:G in a nicked plasmid in vitro, and has been 
suggested to be able to repair 5-FU:A base pairs as well (12). However, the quantitative 
contribution from MMR and BER, as well as the possible role of individual DNA 
glycosylases, remain obscure.   
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Deficiency in DNA repair is associated with tolerance to 5-FU in several cell systems, indeed 
suggesting a role of DNA-repair in cytotoxicity. Accumulated repair intermediates in BER, 
such as abasic sites and cleaved DNA strands, are more cytotoxic than the original base 
lesion, and may therefore contribute to cell killing (13). Furthermore, synthesis of long repair 
tracts during MMR may be cytotoxic and mutagenic in cells having imbalanced and dTTP-
depleted nucleotide pools (7,14). MMR may also act as a DNA damage sensor, inducing a 
rapid G2 arrest following 5-F(dU) treatment (15). A 5-FU-tolerant phenotype has been 
reported for both human and murine cells deficient in MMR (15,16). The evidence linking 
BER to fluoropyrimidine cytotoxicity is more ambiguous. Mouse embryonic fibroblasts 
(MEFs) derived from gene-targeted knockouts of the genes encoding TDG, MBD4 and DNA 
polymerase β did show an increased tolerance to fluoropyrimidines (17-20). In contrast, 
siRNA knock-down of Smug1 in MEFs reduced the tolerance to fluoropyrimidines while Ung-
/- MEFs displayed essentially identical sensitivity to fluoropyrimidines as wild type (11,21). 
This was also the case for human cells expressing the UNG-specific inhibitor Ugi, and down-
regulation of human DNA polymerase β had no effect on 5-FU cytotoxicity (11,22). One open 
question is whether MEF knockout cells, yeast mutants, and indeed individual human cancer 
cell lines in culture, are good models to study the mechanism of 5-FU in human cancer, since 
they may convert this prodrug to different levels of active metabolites.  
 
In this paper we analyse the relative contribution of the BER- and MMR pathways to 5-FU 
DNA-repair in extracts of human cancer cells and intact cells. Furthermore, we determine the 
relative efficiency of each DNA glycosylase in initiating BER of 5-FU in DNA. In addition, 
we investigate the effect on cytotoxicity of BER inhibitors and down-regulation of individual 
DNA glycosylases by siRNA. Finally, we examine the ability of deoxy- and ribonucleosides 
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to reverse the effect of 5-fluoropyrimidines, and the incorporation of 5-FU into DNA and 
RNA. We find that BER is not likely to be a major factor mediating toxicity, and a role for 
DNA fragmentation to MMR would be initiated through a 5-FU:A context. Our results also 
suggest that cytotoxic mechanisms involving perturbation of RNA functions and TS 
inhibition hold up as major contributors to toxicity of 5-FU and its metabolites in human 
cancer cells.  
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MATERIALS AND METHODS 
Cell lines, chemicals and enzymes 
The human cancer cell lines HeLa S3 (cervix adenocarcinoma), SW480 (colon 
adenocarcinoma) and CX-1 (colon adenocarcinoma) were purchased from ATCC and 
cultured in DMEM (4500 mg/l glucose) with 10% FCS, 0.03% L-glutamine, 0.1 mg/ml 
gentamicin and 2.3 µg/ml fungizone at 37°C and 5% CO2. MEFs were cultured as described 
(21). 5-FU, 5-F(dU), 5-F(rU), 5-hm(dU), methoxyamine, 4-amino-1,8-naphthalimide, 
nucleosides and oligodeoxynucleotides were from Sigma-Aldrich. siRNA targeting UNG 
(Assay ID: 36376), SMUG1 (AM16708A, ID: 21193, 140141, 21109) and TDG (Assay ID: 
12923) were purchased from Ambion. Radionucleotides were from Perkin-Elmer. Restriction 
endonucleases were from New England Biolabs. Recombinant human His-tagged APE1, 
UNG2, SMUG1 and TDG were purified as described (9,23). 
  
Preparation of nuclear extracts 
Cultured cells were harvested at 50-70% confluency by trypsination, followed by washing in 
ice-cold PBS. Nuclear extracts were prepared as described (24). Protein concentrations were 
measured using the Bradford method (BioRad).  
 
Combined MMR and BER assay 
To generate a substrate for both BER and MMR a unique Nt.BbvCI site was introduced into 
the substrate plasmid (pGEM-3Zf+) at position 388 using the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene) protocol. This allowed the introduction of a nick that serves as a 
strand distinguishing signal for MMR. Substrates for BER and MMR containing 5-FU 
opposite A or G in otherwise identical sequence contexts were then prepared essentially as 
described (24). 
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Substrate (300 ng cccDNA pretreated with 5 U Nt.BbvCI when indicated) were incubated 
with 40 µg nuclear extract (TDG depleted and preincubated with Ugi and neutralizing 
SMUG1 antibodies when indicated) in BER buffer (40 mM HEPES-KOH pH 7.8, 70 mM (or 
110mM) KCl, 5 mM MgCl2, 0.5 mM DTT, 250 µM NAD+, 2 mM ATP, 50 µM of each 
dNTP, 4.4 mM phosphocreatine, 2.5 µg creatine phosphokinase) at 37oC for the times 
indicated. The reactions were stopped by addition of 25 mM EDTA , 0.5% SDS, 150 µg/µl 
proteinase K and incubation at 55°C for 30 min. DNA was purified by phenol-chloroform 
extraction and ethanol precipitation with 10 µg glycogen as carrier. DNA was then treated 
with purified recombinant UNG (0.1 µg/µl)(25) (U- and 5-FU-substrates) or purified human 
TDG (0.5 µg/µl) (T:G substrates), as well as 50 mM methoxyamine (MX) and 0.2 µg/µl 
RNaseA (NEB buffer 2 +0.1 µg/µl BSA) for one hour at 37°C, followed by treatment with 
restriction endonucleases XmnI and HincII (5U each) for one hour. Restriction fragments 
were analysed on 2% agarose gels, stained with ethidium bromide and band intensities were 
quantified using ImageJ software (http://rsb.info.nlh.gov/ij/). 
 
DNA-glycosylase activity assays 
5-FU- and 5-hmU-DNA excision activities were measured using a 22-mer oligonucleotide 
containing a centrally positioned modified base (5'GATCCTCTAGAGT-X-GACCTGCA-3', 
where X = 5-FU, 5-hmU or U). The oligonucleotides were labelled on the 5' end with FAM or 
33P. Double-stranded substrates were prepared by annealing the labelled strand to a 
complementary strand containing either A or G opposite the modified base. Base excision 
activity was measured in a an assay mixture containing 5 µg nuclear extract (or 10 µg total 
extract or various amount of recombinant human His-tagged UNG2, SMUG1, TDG), 0.1 
pmol oligonucleotide substrate, 20mM Tris-HCl pH 7.5, 50 mM NaCl, 1mM EDTA, 1mM 
DDT, 0.5 mg/ml BSA (UDG buffer) and 0.1 pmol recombinant human APE1 at 37°C for 30 
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min. The extracts were pre-incubated on ice with 0.1 µg UGI, 0.1 µg neutralizing SMUG1 
antibody (PSM1) (8) and 1 µl anti-TDG antiserum (diluted 1:3) (26) when indicated. The 
reactions were stopped and analyzed as previously described (8).  
UDG activity assays using [3H]-labelled calf thymus DNA substrates (U:A substrate) were 
performed in UDG buffer with 3 µg whole cell extract at 30oC for 10 min essentially as 
described (8) 
 
BER incorporation assay 
The assay were performed as described (24). Briefly, 300 ng cccDNA substrate and 10 µg 
nuclear extract were incubated in BER buffer, supplemented with 50 nM dCTP and 3 µCi 
[α33P]dCTP for substrates containing 5-FU and 5-hmU opposite G, and 50 nM dTTP and 
3µCi [α33P]dTTP for substrates containing 5-FU opposite A. Ugi (0.1 µg), neutralizing 
SMUG1 antibody (0.1 µg) and 1 µl anti-TDG antiserum (diluted 1:3) where added when 
indicated. For PARP-1 inhibition increasing concentrations of 4-amino-1,8-naphtalimide (4-
AN) were included for the indicated times. Reactions were stopped by addition of EDTA (25 
mM), SDS (0.5%) and proteinase K (150 µg/µl). DNA was purified and treated with 
restriction endonucleases XbaI and HincII to release radiolabelled fragments.  
  
AP-site incision assay 
An AP-site substrate was generated by incubating 0.2 µM (20 pmol) 5'FAM-labelled 19mer 
double-stranded uracil containing oligonucleotide (U141A) (8) with 5 ng/µl (0.5 µg) purified 
recombinant UNG (25) in 100 µl UDG buffer at 30ºC for 20 minutes Subsequently, 30 ng/µl 
(0.3 µg) Ugi was added to inactivate the glycosylase. Methoxyamine-modified AP-sites were 
generated by incubating AP-site substrate (0.2 pmol) in 0.5, 5 and 50 mM MX pH 7.2 
(adjusted with NaOH) or corresponding concentrations of NaCl for 20 minutes at 30ºC. AP-
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site cleavage assays was performed using100 fmol purified human AP endonuclease 1 (27) 
for 10 minutes at 30ºC in 10 µl UDG buffer, supplemented with 7.5 mM MgCl2. Reactions 
were stopped by adding 15 µl 95 % formamide. 
 
Transfection with siRNA 
160000 cells per well were plated in a 6 well dish in 1600 µl antibiotic free DMEM (4500 
mg/l glucose) with 10% FCS and 0.03% L-glutamine, and cultured over night. siRNA 
targeting SMUG1 (a mix of three, final concentration 30 nM each), UNG (60 nM final), and 
TDG (60 nM final) was dissolved in OptiMEM (Invitrogen) and incubated with 4 µl/well 
Dharmafect transfection agent (Dharmacon) for 20 min, before adding the mixture to the 
culture, according to the manufacturers protocol. After 24 h cells were treated with trypsin, 
counted and replated in medium with antibiotics.  
 
Preparation of whole cell extracts from siRNA transfected cells 
Cells from 6 well dishes were harvested by trypsination 48 h post transfection. Cell pellets 
were dissolved in 100 µl buffer containing 20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM 
EDTA, 1xComplete protease inhibitor (Roche), and 0,5 % NP-40 and sonicated for 3 x 30 
seconds at 4ºC. Cell debris was removed by centrifugation at 13000 x g for 15 min. 
Supernatants were snap-frozen in liquid nitrogen and stored at -80°C.  
 
Western analysis 
50-100 µg whole cell extract were treated with DNase and RNase for 10 min at room 
temperature, denatured at 70°C in LPS loading buffer, separated on the NuPage 
electrophoresis system (Invitrogen) and electro-blotted onto Immobilon PVDF membranes 
(Millipore). UNG was detected using the polyclonal UNG antibody PU059 (25), SMUG1 by 
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the polyclonal SMUG1 antibody PSM1 (8), TDG by hTDG-antiserum (26), and β-actin was 
detected using mouse monoclonal ab8226 (AbCam). The membranes were analyzed using 
HRP swine anti-rabbit (1:5000; DakoCytomation) and HRP rabbit anti-mouse (1:5000, 
DakoCytomation) secondary antibodies and Super Signal West Femto substrate (Pierce) on a 
KODAK Image Station 2000R. 
 
Cytotoxicity assays 
2000-4000 cells/well were plated on a 96 well plate in complete DMEM (10 % FBS, L-
glutamine, gentamicin, and amphotericin B). Cells were exposed to the cytostatic drugs and 
nucleosides 24 hours after plating and cultured for further 96 hours. Living cells were then 
quantified using the MTT-assay. Growth medium was replaced with 100 µl fresh medium 
containing 0.5 mg/ml MTT, and the plates were further incubated at 37°C for 4 h. 50 µl of 
medium was subsequently removed, and 100 µl 2-propanol with HCl (0.1 M) were added. 
Plates were transferred to a mechanical shaker until the MTT-formazan was dissolved. The 
optical density of each well was read on a Titertek Multiscan Plus Reader at wavelength 
588 nm.  
 
FACS analysis of cell cycle 
Cells were plated in a 6-well dish at approximately 25 % confluence and grown for 24 h 
followed by exposure to cytostatic drugs for 48 hours. Cells were harvested by trypsination, 
fixed by 70 % methanol and washed twice with PBS. Then cells were treated with 50 µl 
RNaseA (100 µg/ml in PBS) at 37 ºC for 30 min before DNA staining using 200 µl propidium 
iodide (50 µg/ml in PBS) at 37ºC for 30 min. Cell cycle analyses were performed using a 
FACS Canto flow cytometer (BD-Life Science). 
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Thymidylate synthase assay 
TS activity was measured as previously described (28) with minor modifications. Cells were 
seeded in 24-well plates at a density of 70.000 cells per well. Following overnight incubation, 
each well was treated with fluoropyrimidines, and/or varying concentrations of rU diluted in 
growth medium for one hour, followed by the addition of 1 µCi [5-3H]deoxyuridine (specific 
activity 20 Ci/mmol, Moravek Biochemicals Inc.) and incubated for 90 min, in a final volume 
of 500 µl. The reaction was stopped by transferring 400 µl of the growth medium to an equal 
volume 150 mg/ml activated charcoal suspension in 5% trichloroacetic acid. The samples 
were vortexed and centrifuged at 16.000 x g at 4°C for 15 min or more. Radioactivity in a 400 
µl aliquot of the supernatant was counted using a liquid scintillation counter, and each value 
was corrected for background counts. 
 
Quantitation of 5-FU in DNA and RNA by LC/MS/MS  
Nucleic acids were isolated from fluoropyrimidine-treated cells by the Blood and cell culture 
mini DNA isolation kit (Qiagen) and by the mirVana RNA-isolation kit (Ambion). The DNA 
or RNA samples were enzymatically hydrolyzed to nucleosides using nuclease P1, 
phosphodiesterase I from Crotalus adamanteus venom, and alkaline phosphatase (all from 
Sigma-Aldrich) as described (29), followed by addition of 3 vol of methanol and 
centrifugation (16000 × g, 30 min). The supernatants were dried under vacuum and the 
resulting residues dissolved in 50 µl 5% methanol in water (v/v) for analysis of 5-F(dU) and 
5-F(rU) by LC/MS/MS. A portion of each sample was diluted for the quantitation of the 
unmodified nucleosides (dA, dC, dG, dT, rA, rC, rG, and rU). Chromatographic separation of 
nucleosides was performed on a Shimadzu Prominence HPLC system with a Zorbax SB-C18 
2.1x150 mm i.d. (3.5 µm) reverse phase column equipped with an Eclipse XDB-C8 2.1x12.5 
mm i.d. (5 µm) guard column (all from Agilent Technologies), at ambient temperature and a 
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flow rate of 0.2 ml/min. For 5-F(dU) and 5-F(rU) separation the mobile phase consisted of 
water and methanol, starting with a 3.5-min linear gradient of 5-70% methanol, followed by 1 
min with 70% methanol and 6.5 min re-equilibration with the initial mobile phase conditions. 
Chromatography of unmodified nucleosides was performed under isocratic conditions with 
water/methanol/formic acid in ratio 85/15/0.1% for deoxyribonucleosides, or 92/8/0.1% for 
ribonucleosides. Online mass spectrometry detection was performed using an Applied 
Biosystems/MDS Sciex 5000 triple quadrupole mass spectrometer (Applied Biosystems) with 
TurboIonSpray probe operating in negative electrospray ionization mode for 5-F(dU) and 5-
F(rU), or positive electrospray ionization mode for unmodified nucleosides. LC/MS/MS 
chromatograms showing 5-F(dU) in DNA and 5-F(rU) in RNA hydrolysates are shown in the 
supplementary figure 1. The nucleosides were monitored by multiple reaction monitoring 
using the mass transitions 245.2→129.1 (5-F(dU)), 261.2→129.1 (5-F(rU), 252.2→136.1 
(dA), 228.2→112.1 (dC), 268.2→152.1 (dG), 243.2→127.1 (dT), 268.2→136.1 (rA), 
244.2→112.1 (rC), 284.2→152.2 (rG), and 245.2→113.1 (rU). Quantitation was 
accomplished by comparison with pure nucleoside standards run intermediate the samples.  
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RESULTS 
BER is the dominant pathway for repair of genomic 5-FU in human cancer cell lines in 
vitro, and contribution by MMR is limited to a 5-FU:G context 
In vitro studies suggest that both BER and MMR contribute to repair 5-FU in DNA. However, 
their relative contribution has not been established (12). We examined the contribution of 
BER and MMR to repair of 5-FU:A and 5-FU:G in DNA in nuclear extracts from human 
cancer cell lines. For this purpose we employed an in vitro assay using a circular covalently 
closed DNA substrate (cccDNA) containing a single 5-FU at a defined position, as well as a 
unique recognition sequence for the nicking endonuclease Nt.BbvCI positioned at 298 bp 3' to 
the lesion (Fig. 2A). Any mismatch in the plasmid can be repaired by the MMR system when 
the plasmid is nicked (12). Distinction between substrate and product in in vitro MMR assays 
has traditionally been obtained using restriction endonucleases unable to cut mismatched 
recognition sequences. To study MMR-mediated 5-FU:A repair by this approach is not 
straight-forward, because restriction endonucleases that discriminate between 5-FU:A in the 
substrate from T:A in the product are not available (12). Thus, we exploited the fact that 
restriction endonuclease HincII (GTY^RAC, Y=C/T, R= A/G) is unable to digest a 
recognition sequence containing a centrally positioned abasic site (AP-site). By treating the 
incubated substrate DNA with a DNA glycosylase that excises the damaged base prior to 
HincII digestion, all unrepaired substrate is converted to non-cleavable substrate (due to the 
AP-site in the HincII recognition site). If the lesion is repaired, however, it will not be 
recognized by the glycosylase, thus the product (T:A or C:G in the HincII recognition site) 
will be cleaved by HincII (Fig. 2B). To validate the assay we used nuclear extract from 
SW480 and verified repair of a T:G mismatch in a nick-dependent manner, consistent with an 
active MMR system. The same extract under identical assay conditions also carried out repair 
of cccDNA-U:A substrate, but this process was completely inhibited by the UNG inhibitor 
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Ugi, consistent with BER initiated by UNG (Fig. 2C). Thus, these substrates can be used to 
measure both BER and MMR. One or both pathways can be specifically inactivated; BER by 
directly inhibiting the initiating glycosylase, and MMR by removing the strand-break that 
repair is critically dependent on. We then measured repair in nuclear extracts from SW480 
and HeLa on a cccDNA-5-FU:A substrate. Repair of 5-FU:A was completely inhibited by the 
presence of the UNG2 inhibitor Ugi and anti-SMUG1 antibodies in extract from both cell 
lines. This was also the case for the nicked substrate, with no detectable repair after 60 min in 
the presence of Ugi and neutralizing SMUG1 antibodies, both at 70 mM KCl (Fig. 2D) and 
110 mM KCl (data not shown). This indicates that BER is the main, possibly sole, pathway 
for repair of 5-FU:A. Surprisingly, we could not detect any contribution from TDG on 5-
FU:A repair in either extract. The repair of 5-FU:G was also mainly performed by BER, as 
most of the cccDNA 5-FU:G substrate was repaired after 15 min whether it was nicked or not 
(Fig. 2E). Inhibition of BER by the addition of Ugi and anti-SMUG1 antibody to a TDG-
depleted extract (12) inhibited all detectable repair of 5-FU:G (un-nicked) substrate, while a 
marked reduction was observed when using nicked substrate. These results indicate a 
dominant role for BER in repair of 5-FU in DNA, with a smaller contribution of MMR to 5-
FU:G repair. 
 
DNA repair of 5-FU in human cancer cells is predominantly initiated by UNG2, while 
SMUG1 and TDG are more important in mouse embryonic fibroblasts 
Purified recombinant UNG2, SMUG1, TDG and MBD4 have all been reported to excise 5-FU 
from DNA in vitro (8-10,12). However, their relative importance in 5-FU-DNA repair in 
different cells has so far not been investigated. We analysed the contribution of UNG2, 
SMUG1, and TDG to the excision of 5-FU from DNA in nuclear extracts from three human 
cancer cell lines (SW480, HeLa and CX-1) as well as in MEFs. Nuclear extracts were 
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incubated with duplex oligonucleotides with a central 5-FU paired with adenine (5-FU:A), 
guanine (5-FU:G), or as single-stranded DNA (5-FU). SMUG1 and TDG activities in the 
extracts were inhibited using neutralising antibodies as described (8,26), while UNG2 activity 
was inhibited with Ugi. Note that MBD4 did not appear to be significantly involved 
quantitatively, as inhibition of UNG2, SMUG1 and TDG was sufficient to abolish essentially 
all measurable 5-FU excision in the extracts (Fig. 3A, line 5). UNG2 was the dominant 
activity with all the 5-FU substrates in extracts from human cancer cell lines (SW480, HeLa 
and CX1), while SMUG1 and TDG activities were measurable only on the 5-FU:G substrate 
(Fig 3A). In contrast, 5-FU excision by UNG2 was hardly detectable in the MEF extract, 
where it was dependent mainly on SMUG1 and TDG. Moreover, excision activity in a 5-
FU:A context and in 5-FU  in single stranded substrate was very low (Fig. 3A). In accordance 
with this, measurements of UDG activity in the extracts using a 3H-labelled calf thymus U:A-
DNA substrate (which detects mainly UNG-activity) revealed very low UDG activity in the 
MEF extract compared to extracts of human cancer cells (Fig. 3B). This difference is 
interesting because results from 5-FU treatment of MEF cell systems are often assumed to be 
valid for human cells as well. We have, in fact, found that these differences apply to murine 
tumour cell lines as well (Doseth et al., unpublished data). To determine substrate preference 
and specific activity, experiments with purified recombinant human UNG2, SMUG1 and 
TDG were performed under identical conditions. The results confirmed that 5-FU is substrate 
for all three UDGs, with UNG2 as the most efficient enzyme on 5-FU:A and especially on 5-
FU in a single-stranded context, while SMUG1 was the most efficient enzyme on 5-FU:G. As 
expected, TDG excised 5-FU efficiently from a 5-FU:G context (Fig. 3C), in accordance with 
the analysis of 5-FU-excision in nuclear extracts. A dominant role for UNG2 in BER of 5-
FU:A was also substantiated by assays measuring complete BER incorporation assays in 
SW480 and HeLa extracts, since all detectable 5-FU:A repair activity was abolished when 
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Ugi was added to the nuclear extracts (Fig. 2D). On the other hand, UNG2, SMUG1 and TDG 
were all able to initiate 5-FU:G repair, although with varying efficiency.  
 
Cellular sensitivity to fluoropyrimidines is not affected by siRNA knock-down of UNG, 
SMUG1 or TDG and 5-FU accumulates abundantly in RNA compared with DNA  
Our in vitro data from nuclear extracts suggested that 5-FU in DNA was predominantly 
repaired by BER, initiated by UNG2, SMUG1 or TDG. We therefore used specific siRNAs to 
examine the in vivo effects of these UDGs in mediating fluoropyrimidine cytotoxicity in 
SW480 and HeLa cells. To avoid selection bias and phenotypic drift, we employed transient 
siRNA-mediated silencing. UNG, SMUG1 and TDG activities were reduced at least 70-90% 
48 h after transfection (Fig. 4A), and western blots verified knock-down at the protein level 
(Fig. 4B). Generally, the knock-down effect was stronges at 48 hrs after transfection and then 
gradually faded out towards 50 to 75 % residual activity after six days (data not shown). Thus, 
we exposed SW480 and HeLa cells to 5-FU and its metabolites 5-F(dU) and 5-F(rU) 48 h 
post transfection. 
 
The DNA-directed effects of fluoropyrimidines would be analogous to the effect of 5-
hydroxymethyl-2'-deoxyuridine (5-hm(dU)), which is incorporated into DNA, which in turn 
may lead to DNA strand breaks and apoptosis through excessive 5-hm(dU) excision by 
SMUG1 (8,30-32). Thus, since 5-hmdUMP does not inhibit thymidylate synthase (33), has no 
known RNA-directed effects, and is removed by a distinct DNA glycosylase, it constitutes an 
ideal positive control for the concept of DNA repair-directed cytotoxicity of 
fluoropyrimidines. We tested hmU-excision in nuclear extracts from SW480, HeLa and CX-1 
and verified that SMUG1 was the only glycosylase having detectable activity on this substrate 
(Figure 4C). In accordance with this, SW480 SMUG1-knock down cells were more tolerant to 
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5-hm(dU) than control cells, while UNG and TDG knock downs had no effect on relative 
cytotoxicity after exposure to 5-hm(dU) (Fig. 5). These results demonstrate that BER can in 
principle enhance cytotoxicity of pyrimidine antimetabolites incorporated into DNA. HeLa 
tolerated very high doses of 5-hm(dU), but the SMUG1 knock-down effect was still detected 
at high concentrations also in this cell line.  
 
To differentiate between the different proposed cytotoxic mechanisms of 5-FU, we also 
exposed the knock-down cells to varying concentrations of 5-F(dU) and 5-F(rU) to 
predominantly induce DNA- and RNA-mediated cytotoxicity, respectively (Fig. 1). However, 
we were not able to observe any significant change in sensitivity to 5-FU, 5-F(dU) or 5-F(rU) 
in UNG, SMUG1 or TDG knock down cells (Fig. 5).  
 
Furthermore, while 5-hm(dU)-exposed cells were shifted from G1/S arrest towards G2/M 
arrest in SMUG1 knock-down cells, the cell cycle profiles after 5-FU and 5-F(dU) treatment 
were unaffected by knock-down of the glycosylases (Fig. 6A). The G1/S cell cycle arrest 
induced by both 5-FU, 5-F(dU), and 5-F(rU) was completely reversed by thymidine, both in 
SW480 and HeLa cells (Fig. 6B), indicating that the G1/S cell cycle arrest is due to thymidine 
starvation (presumably induced via TS inhibition). Importantly, both 5-FU- and 5-F(dU)-
treated cells contained measurable quantities of 5-FU in DNA. However, 5-FU was more 
abundant in RNA compared to DNA, both after 5-FU treatment (~2000-3000-fold) and 
surprisingly also after 5-F(dU) treatment (~6 fold) (Table 1). 
 
5-FU, 5-F(dU) and 5-F(rU) inhibit TS with similar efficiency in HeLa and SW480 cells 
To further elucidate how the different fluoropyrimidines mediates cytotoxicity, we measured 
the activity of TS in HeLa and SW480 in the presence of varying concentrations of 5-FU, 5-
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F(dU) and 5-F(rU) (Fig. 7). 5-F(dU) was by far the most potent inhibitor, inhibiting  50% of 
the TS activity (IC50) at 2.0 and 2.7 nM for HeLa and SW480, respectively. The IC50-values 
for 5-F(rU) were 0.45 and  0.63 µM for HeLa and SW480, respectively, while the 
corresponding values for 5-FU were 98 and 32 µM. Thus, as 5-FU, 5-F(dU) and 5-F(rU) 
inhibit TS with a rather similar efficiency in HeLa cells and SW480 cells, it seems that TS 
inhibition is insufficient to explain the large variations in cytotoxicity observed in Fig. 5. 
 
Inhibition of PARP-1 and AP-site processing does not affect 5-F(dU) cytotoxicity 
Lack of detectable effects on fluoropyrimidine cytotoxicity after knock-down of the 
individual 5-FU-DNA glycosylases may be due to redundancy, in which the different DNA 
glycosylases may substitute for each other in the repair process. Thus, to further explore 
whether BER mediates 5-F(dU) cytotoxicity we employed inhibitors that target the common 
steps of BER. Methoxyamine (MX) reacts with and inhibits processing of AP-sites by APE1 
(34) and 4-AN is a potent inhibitor of PARP-1 polyribosylation (35). These inhibitors have 
previously been shown to affect cytotoxicity mediated by BER (36,37). The effect of MX on 
AP-site cleavage was tested in vitro by hAPE1 activity measurements. We employed an AP-
site-containing duplex oligonucleotide pre-treated for 20 min with pH adjusted MX (~1:1 
molarity of MX-HCl and NaOH to pH 7), and used corresponding NaCl concentrations as 
controls. MX treatment of AP-sites clearly inhibited cleavage by APE1 in a concentration 
dependent manner (Fig. 8A). From the results in Fig. 8A we decided to use 20 mM MX in the 
following cell culture experiments. To verify the effect of 4-AN on BER in vitro, we utilized 
a BER incorporation assay with HmU opposite G in the cccDNA substrate. More than 50 % 
inhibition of BER was achieved in presence of 10 µM 4-AN (Fig. 8B). 
 
 19
We further tested MX and 4-AN in vivo by concurrent 5-hm(dU) and 5-F(dU) exposure of 
SW480 and HeLa cells. The cytotoxicity of MX and 4-AN treatment in itself had an 
approximately 10–20 % growth inhibitory effect on the cells, for which the data were 
normalized. The presence of 20 mM MX clearly enhanced the cytotoxicity of 5-hm(dU) in 
both SW480 and HeLa cells (Fig. 8C). Similarly, treatment with 10 µM 4-AN resulted in an 
enhanced 5-hm(dU) cytotoxicity at low concentrations. The effect of 4-AN was most 
pronounced in HeLa cells. At higher concentrations of 5-hm(dU) , 4-AN had a protective, 
rather than aggravating effect on cytotoxicity. Importantly, however, both MX and 4-AN 
failed to affect the cytotoxicity of 5-F(dU)-treated cells in any discernible way (Fig. 8D). 
These results indicate that BER mediates the cytotoxicity of 5-hm(dU) cytotoxicity, but not 
that of 5-F(dU). 
 
Cytotoxicity of 5-FU, 5-F(dU) and 5-F(rU) is differentially reversed by dT, dU and rU, 
indicating quantitatively different mechanisms of action 
Since BER did not affect fluoropyrimidine sensitivity significantly, we wanted to explore the 
mechanisms further by attempting to reverse cytotoxicity by ribonucleosides (rU) and 
deoxynucleosides (dT, dU). For these reversal experiments, we exposed HeLa- and SW480 
cells to fixed concentrations of 5-F(dU), 5-F(rU) and 5-FU and varying concentrations of 
thymidine (dT), deoxyuridine (dU), and uridine (rU) for four days. The cytotoxic effect of 5-
F(dU) was partially reversed by thymidine (dT), and to a lesser extent deoxyuridine (dU), but 
not uridine (rU). The effects were, however, significantly different in the two cell lines (Fig. 
9A). The cytotoxicity of 5-F(rU) was reversed by rU in both cell lines, but not by dU or dT 
(Fig. 9B). However, 5-FU toxicity was only marginally reversed by rU, and not by dU or dT 
(Fig. 9C). This was somewhat unexpected since dT reversed the G1/S cell cycle arrest of cells 
treated with either 5-FU, 5-F(dU) or 5-F(rU) (Fig. 5B). Consistent with the above results, 
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addition of rU strongly reduced the content of 5-FU in RNA for cells exposed to 5-F(rU), but 
not after exposure to 5-FU (Table 2). Since ribonucleosides may be converted to 
deoxyribonucleotides, we also examined the possible effect of rU on 5-F(rU)-mediated TS 
inhibition. Here, rU had two apparent effects. First, addition of rU alone resulted in a small to 
moderate decrease in apparent TS activity, which might be explained by pool effects. 
Secondly, and more importantly, rU alleviated TS-inhibition by 5-F(rU) at much lower 
concentrations than those required to reverse cytotoxicity in both cell lines (Fig. 9D). 
Therefore, it appears that 5-F(rU) more likely mediates cytotoxicity through interfering with 
RNA-functions than by inhibiting TS, in agreement with in inability of dT to reverse 5-F(rU) 
cytotoxicity (Fig. 9B).   
 
In summary, cytotoxicity of 5´-subsituted pyrimidines from BER processes is a plausible 
mechanism, as demonstrated here in the case of 5-hm(dU). However, our results also strongly 
indicate that BER is not a major contributor to cytotoxicity of 5´-fluoropyrimidines in human 
cancer cells (HeLa and SW480), and a possible role of MMR would most likely be limited to 
a 5-FU:G context. Cytotoxicity of these agents appears to be mainly be attributed to TS-
inhibition and dTTP-deficiency for 5-F(dU) and incorporation into RNA for 5-F(rU) and 5-
FU, rather than a consequence of excessive DNA repair.  
 21
DISCUSSION 
5-FU has been in clinical use for half a century and although several cytotoxic mechanisms 
have been proposed for the drug, their relative significance in killing cancer cells is not well 
understood. Several papers report that cells deficient in BER or MMR are more resistant to 5-
FU or 5-F(dU) than the wild type. However, the relative quantitative contributions of these 
repair pathways have not been investigated. In this paper we report that BER, rather than 
MMR, was the sole repair activity of 5-FU in a 5-FU:A context in vitro, and also the 
dominant activity on nicked 5-FU:G substrate in nuclear extracts from human cancer cell lines 
(Fig. 2D&E). This may appear to be in contrast to a previous study, which found that MMR-
proficient extracts incorporated more radio-labelled deoxynucleotides into nicked 5-FU:A 
substrates than MMR-deficient (12). However, it does not necessarily follow from this that 
MMR is involved in 5-FU:A repair, especially as an undamaged control substrate was not 
included in the study. MMR did, however, repair 5-FU:G, although MMR, at least in vitro, 
proceeded at a far lower rate than BER, which repaired ~70% of the substrate after only 15 
min. It should be kept in mind that the presence of a nick in DNA is crucial for strand-
discrimination, and hence for the activity of MMR. Since multiple ligases may seal the nick 
directly, the amount of substrate available for MMR may decline rapidly during incubation. 
Consequently, the relative contribution from MMR may be underestimated using this assay. 
In addition, it should be underlined that we have not examined the contribution of MMR to 5-
FU:G repair in intact cells. While several studies have demonstrated that MMR-deficient cells 
are more tolerant to fluoropyrimidines than MMR-proficient, the identity of the DNA lesion 
that provokes MMR is not known. Our results and the inability of MMR proteins to recognise 
5-FU:A in gel shift assays (12,15), indicate that MMR may act on mismatches involving 5-
FU:G or alternatively mismatches introduced by DNA polymerases due to dNTP pool 
imbalances during TS inhibition. It is important to note that even if we only observe a 
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relatively modest contribution from MMR to repair of 5-FU in vitro, this does not exclude 
that MMR mediates cytotoxicity of 5-FU in vivo or in the clinic. Some 10-15% of colon 
cancers are MMR-deficient due to inactivating mutations or epigenetic silencing (38). 
Clinically, these patients generally respond well to 5-FU treatment (39,40), although 
resistance to 5-FU has been reported in cancer cell lines deficient in the MMR damage 
recognition proteins MSH2 (16) and MLH1 (20,41). Thus, while we observe a quantitative 
modest role of MMR in vitro, our results do not exclude a significant involvement of MMR in 
the 5-FU response in vivo. 
 
Our results clearly demonstrate that UNG2 is the dominant glycosylase activity initiating 5-
FU:A repair, at least in vitro. Given that UNG2 is downregulated in G1 (and vice versa for 
TDG) (42,43), 5-FU:A that escapes repair in S-phase may not be efficiently processed in G1. 
As a consequence, aberrant bases may well be present in the template strand during the 
subsequent S-phase. 5-FU:G, on the other hand, may be repaired by UNG2 or SMUG1 in S-
phase and TDG or SMUG1 in G1, alternatively by MMR. We were not able to measure any 
contribution from MBD4. Our in vitro experiments with 5-hm(dU) demonstrate that the DNA 
fragmentation-hypothesis involving excision repair is a feasible idea. Furthermore, given our 
in vitro results, and that 5-FU is mainly incorporated opposite A, fragmentation of DNA by 
excessive glycosylase activity would be a more likely candidate than MMR. We therefore 
tested this hypothesis using intact human cancer cell lines, in which the different DNA 
glycosylases had been knocked down using siRNA, using 5-hm(dU) as a positive control for 
BER-mediated cytotoxicity. Knock-down of SMUG1 in cells exposed to 5-hm(dU) lead to a 
shift from G1/S to G2/M arrest and also reduced cytotoxicity. Furthermore, the cytotoxicity 
was modulated by BER inhibitors and reversed by the addition of thymidine to the medium. 
While this is consistent with a cytotoxic mechanism involving BER, the 5-hm(dU) results 
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were in stark contrast to those obtained with fluoropyrimidines. Here, the knock-down of 
individual glycosylases did not affect cytotoxicity or cell cycle arrest, and the addition of BER 
inhibitors had no apparent effect on cytotoxicity. Collectively, these experiments indicate that 
BER processes are neither substantially enhancing cytotoxicity due to DNA fragmentation, 
nor reducing cytotoxicity due to removal of 5-FU from DNA. Taken together, our results 
indicate that incorporation of a 5'-substituted thymine-analogue followed by excessive 
excision by a DNA glycosylase most likely explains the cytotoxicity of 5-hm(dU), but not that 
of fluoropyrimidines. The nucleoside reversal experiments suggest that TS-inhibition and 
RNA-incorporation are the most likely the dominant modes of cytotoxicity for 
fluoropyrimidines (Fig. 9).  
 
These results may appear to be in conflict with results from MEFs demonstrating that 
resistance to 5-FU depends upon SMUG1, since SMUG1 knock-down increased sensitivity 
(11). However, our studies indicate that the divergent results may be explained by species 
differences, since we find that SMUG1 has a much more prominent role in removal of 5-FU 
in mouse cells, compared with human cells (Fig. 3A). Another apparent species and/or cell 
type difference was the observed ~3000:1 preferential incorporation of 5-FU into RNA in 
stead of DNA in HeLa (Table 1), compared to ~11:1 reported for wild type MEFs (11). 
Furthermore, Tdg-/- mouse embryonic stem cells and fibroblasts have an increased tolerance to 
5-FU, while knock-down of endogenous levels of TDG in HeLa has a much smaller effect 
(19). Similarly, MEFs carrying gene-targeted disruptions in the gene encoding DNA 
polymerase β are more resistant to 5-FU compared to wild type (18), while knock-down of the 
human orthologue in two human cancer cell lines did not alter the sensitivity to 5-FU (22). It 
is likely that DNA repair may well mediate fluoropyrimidine cytotoxicity in MEFs, but these 
results may not be easily extended to human cancer cell lines. In contrast, silencing of UNG in 
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a human cervix cancer cell line (HeLa) was reported to increase resistance to 5-F(dU) 
treatment (17). Apart from technical differences in cell culture, incubation times and assay 
strategies, we find it hard to reconcile this result with ours. Nevertheless, the inclusion of a 
positive control in the form of 5-hm(dU) in our study lends strength to the argument that the 
contribution of BER-mediated cytotoxicity is rather modest in human cancer cells. The fact 
that the prodrug 5-FU is converted to several metabolites that may affect DNA and RNA 
transactions is most likely the basic reason for the apparently diverse mechanisms of action of 
the drug. There is little doubt that several of the proposed mechanisms may play a role under 
different conditions, but the problem is rather to identify the practical significance of each of 
them for therapy. Thus, the cytotoxic mechanism of 5-FU may vary between species, cell 
types and even individuals. It is certainly also different for various 5-fluoropyrimidines, as 
clearly demonstrated here. Consequently, the research literature is filled with conflicting 
reports, and the quantitative contribution of different RNA and DNA-related mechanisms of 
cytotoxicity remains elusive.  
 
In summary, our results and other recent results allow the conclusion that the main 
mechanisms that mediate 5-FU cytotoxicity in human cells are TS-inhibition and RNA 
incorporation rather than BER of 5-FU. Our results do not exclude a role of MMR in toxicity 
of 5-FU, particularly since we have only carried out in vitro studies. Repair patches in MMR 
are long, frequently several thousand nucleotides, and may therefore be more sensitive to 
dNTP pool imbalances decreasing repair efficiency and increasing risks of polymerase errors 
introducing mismatches. The importance of TS-inhibition is further corroborated by the 
clinical success of combining 5-FU with leucovorin that stabilizes the TS:5-FdUMP complex 
(44). 5-FU, 5-F(dU) and 5-F(rU) inhibited TS with similar efficiencies in HeLa and SW480 
(Fig. 7), but the these cell lines displayed very different sensitivities, especially to 5-F(dU), 
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(Fig. 5), indicating that additional factors modulate the cytotoxicity mediated by TS-
inhibition. Interestingly, in a comprehensive drug activity gene expression study, 5-FU 
clustered with RNA synthesis inhibitors, suggesting that a major mechanism of action is 
RNA-directed (45). Finally, microarray profiling of 5-FU resistant cell lines tend not to find 
BER genes to be differentially regulated, as one might expect if BER were an important 
mediator of cytotoxicity (46-51). 
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 FIGURE LEGENDS 
 
Figure 1. Metabolism of 5-FU and mechanisms of cytotoxicity.  
5-FU cytotoxicity is thought to be conveyed by four active metabolites (underlined in the 
figure); 5-FUTP (RNA incorporation), 5-FdUMP (TS-inhibition), 5-FdUTP and dUTP (DNA 
incorporation). The nucleotide metabolizing pathways which effectuate 5-FU cytotoxicity are 
indicated by full drawn arrows. Possible routes to 5-FU deactivation are indicated by dotted 
arrows. dUMP/dUTP (2'-deoxyuridine mono-/triphosphate), 5-F(dU) (5-fluoro-2'-
deoxyuridine), 5-FU (5-fluorouracil), 5-F(rU) (5-fluorouridine), BER (base excision repair), 
dUTPase (deoxyuridinetriphosphatase), DHFU (dihydrofluorouracil), DHF (dihydrofolate), 
DPD (dihydropyrimidine dehydrogenase), MMR (mismatch repair), OPRT (orotic acid 
phosphoribosyl transferase), RR (ribonucleotide reductase), THF (tetrahydrofolate), TK 
(thymidine kinase), TP (thymidine phosphorylase), TS (thymidylate synthase), UK (uridine 
kinase), UP (uridine phosphorylase), 5-FUTP (5-fluorouridine triphosphate), 5-FdUMP and 5-
FdUTP (5-fluoro-2'-deoxyuridine mono- and triphosphate). 
 
 
Figure 2. Repair of 5-FU-DNA by BER and MMR in nuclear extracts.  
A. Cartoon showing the cccDNA substrate designed to measure 5-FU:A and 5-FU:G repair by 
both BER and MMR. 5-FU is positioned in the HincII recognition sequence. Only the lesion 
containing strand is shown. The nicking endonuclease Nt.BbvCI cleaves one strand 298 bp 3' 
to the lesion, thus providing a strand-discrimination signal for MMR. B. Agarose gel showing 
HincII+XmnI treated cccDNA substrates containing either 5-FU:A, T:A, 5-FU:G or C:G in 
the HincII recognition site. Distinction between substrates (5-FU:A, 5-FU:G) and products 
(T:A, C:G) are performed by 5-FU excision by UNG generating AP-sites that are not cleaved 
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by HincII . C. Positive controls for MMR and BER and their inhibition. cccDNA substrate 
(T:G, T:G-nicked, U:A) were incubated with SW480 nuclear extract (40 µg) for 60 min, 
followed by treatment with recombinant TDG (T:G) or UNG (U:A) and MX before 
purification and HincII + XmnI digestion. Ugi was added to the U:A reactions when 
indicated. D. 5-FU:A repair by SW480 and HeLa nuclear extracts. Nuclear extracts (40 µg) 
were incubated with cccDNA (5-FU:A, 5-FU:A-nicked) substrates and incubated for 15, 30, 
45 and 60 min. Ugi and anti-SMUG1 antibodies were added to the reactions when indicated. 
E. 5-FU:G repair by SW480 and HeLa nuclear extracts. Nuclear extracts and TDG depleted 
nuclear extracts were incubated with cccDNA (5-FU:G, 5-FU:G nicked) substrates for 15, 30, 
45, and 60 min. Ugi and anti-SMUG1 antibodies were added to the reactions when indicated. 
BER + MMR is quantified from the reactions with cccDNA 5-FU:G nicked substrate, BER is 
quantified from the panel with cccDNA 5-FU:G substrate, MMR is quantified from the 
reactions with cccDNA 5-FU:G nicked substrate and TDG-depleted nuclear extract with Ugi 
and neutralizing SMUG1 antibody. The background (no repair) is quantified from the panel 
with cccDNA 5-FU:G-nicked substrate and TDG-depleted nuclear extract with Ugi and 
neutralizing SMUG1 antibody.  
 
Figure 3. 5-FU and 5-hmU excision by human uracil-DNA glycosylases. 
 A. 5-FU excision by uracil-DNA glycosylases in nuclear extracts from human cancer cell 
lines (SW480, HeLa, CX1) and MEFs. Nuclear extracts (5 µg) were pre-incubated with Ugi, 
neutralizing SMUG1 (αSMUG1), and neutralizing TDG (αTDG) antibodies as indicated and 
assayed with oligonucleotide substrates containing 5-FU:A, 5-FU:G, or in a single-stranded 
context (5-FU). Excision of 5-FU allows piperidine cleavage of the 22-mer oligonucleotide 
substrate, resulting in a 13-mer product fragment. U, S and T indicate the individual activities 
of UNG2, SMUG1 and TDG, respectively. B. UDG activity in nuclear extracts nuclear 
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extracts from human cancer cell lines (SW480, HeLa, CX1) and MEFs. UDG activity was 
measured by the release of [3H]uracil from labelled calf thymus DNA (U:A substrate). C. 
Varying amounts (0-1000 fmol) of purified recombinant hUNG2, hSMUG1 and hTDG 
assayed with oligonucleotide substrates containing 5-FU in different contexts (5-FU:A, 5-
FU:G, 5-FU). D. BER incorporation assay using a cccDNA substrate containing 5-FU 
opposite A (5-FU:A) or G (5-FU:G). Nuclear extracts (10 µg) from SW480 and HeLa were 
pre-incubated with Ugi, neutralizing SMUG1 (αSMUG1), and neutralizing TDG (αTDG) 
antibodies as indicated, and BER were detected by measuring incorporation of radio-labelled 
nucleotides.  
 
Figure 4. Verification of siRNA down regulation of UNG, SMUG1 and TDG in SW480 
and HeLa cell lines.  
A. Measurement of siRNA down regulation by specific enzyme activity assays. Whole cell 
extracts of SW480 and HeLa UNG, SMUG1 and TDG knock-downs (48 h post-transfection) 
were assayed for UNG, SMUG1 and TDG activity, respectively and compared to control 
cells. UNG activity was measured by the release of [3H]uracil from labelled calf thymus DNA 
(U:A substrate). SMUG1 activity in the extract (10 µg) was measured with a uracil containing 
oligonucleotide annealed to a complementary strand containing G opposite U (U:G substrate ) 
in the presence of Ugi and neutralizing TDG antibodies (37°C, 1 hour). TDG activity was 
measured in 10 µg extract on the same substrate, but in the presence of Ugi and neutralizing 
SMUG1 antibodies, and the samples were incubated at 37°C for 20 hours. B. Efficiency of 
siRNA down regulation verified by Western analysis. Western analysis of UNG, SMUG and 
TDG knock-down compared to control. Total extracts were prepared 48 hour post 
transfection. β-actin was included as loading control. C. hmU-excision activity of SW480, 
HeLa, and CX-1 nuclear extracts. Extracts (5 µg) were incubated with an oligonucleotide 
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containing a centrally positioned 5-hmU opposite A (5-hmU:A), opposite G (5-hmU:G) or in 
a single-stranded context (5-hmU) in presence or absence of neutralizing SMUG1 anti bodies.  
 
Figure 5. Relative cytotoxicity of UNG, SMUG1, and TDG knock-down cells after 
continuous treatment with 5-hm(dU), 5-FU, 5-F(dU), and 5-F(rU). HeLa and SW480 
transfected with SMUG1↓ (green), UNG↓ (blue), TDG↓ (red) and control siRNA (black) 
were treated for four days with varying concentrations of 5-hm(dU), 5-FU, 5-F(dU), or 5-
F(rU). Cytotoxicity was measured by the MTT assay. The curves represent relative 
cytotoxicity compared to untreated cells. The data points represent the mean ± SD of at least 
two parallel experiments. 
 
Figure 6. FACS analysis of cell cycle distribution.  
A. FACS analysis (cell cycle profiles) of SW480 control and knock-down cells (UNG↓, 
SMUG1↓, TDG↓) after treatment with 100µM 5-hm(dU), 25 µM 5-FU, and 25µM 5-F(dU) 
for 48 hours. B. FACS analysis (cell cycle profiles) of SW480 and HeLa cells treated with of 
5-hm(dU), 5-FU, 5-F(dU) and 5-F(rU) for 48 hours in the absence or presence of 100 µM dT. 
PI (Propidium Iodide). 
 
Figure 7. Inhibition of thymidylate synthase by 5-F(dU), 5-F(rU) and 5-FU. 
HeLa and SW480 was treated with varying concentrations of fluoropyrimidines. Thymidylate 
synthase activity was measured by counting [3H]H2O released into the growth medium, and is 
plotted relative to the activity of untreated samples. The values represent the mean ± SD of at 
least three parallel experiments.  
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Figure 8. Effect of BER inhibitors on 5-hm(dU) and 5-F(dU) treated cells. 
 A. APE1 cleavage of MX-modified AP-sites. A double-stranded oligonucleotide containing 
an AP-site was pre-treated for 20 min with various concentrations of MX, and then incubated 
with purified hAPE1. The upper bands observed after denaturing PAGE represent uncleaved 
19-mer substrate, whereas the lower bands represent the APE1 cleaved products. B. BER of 
5-hmU:G in the presence of increasing concentrations of the PARP-1 inhibitor 4-AN. Nuclear 
extract from the SW480 cell line was pre-incubated with various concentration of 4-AN and 
assayed with the BER incorporation assay using cccDNA plasmid with a single HmU 
opposite G. BER was measured by monitoring the incorporation of [α33P]dCTP at the position 
of hmU. C. Effect of BER inhibitors on the cytotoxicity of 5-hm(dU). HeLa and SW480 cells 
were treated for four days with varying concentrations of 5-hm(dU) in the presence of either 
20 mM MX, 10 µM 4-AN or normal medium (control). The data represent the mean ± SD of 
at least two parallel experiments. D. Effect of BER inhibitors on the cytotoxicity of 5-F(dU). 
HeLa and SW480 cells were treated for four days with varying concentrations of 5-F(dU) in 
the presence of either 20 mM MX, 10 µM 4-AN or normal medium (control). The data 
represent the mean ± SD of at least two parallel experiments.  
 
Figure 9. Cytotoxicity reversal experiments.  
A. Relative cytotoxicity of SW480 and HeLa cells treated for four days with fixed doses of 5-
F(dU) and varying concentrations of dT, dU, and rU. B.  Relative cytotoxicity of SW480 and 
HeLa treated with fixed doses of 5-F(rU) and varying amounts of nucleosides. C. Relative 
cytotoxicity of SW480 and HeLa treated with fixed doses of 5-FU and varying amounts of 
nucleosides. The data represent the mean ± SD of at least three parallel measurements. D. 
Thymidylate synthase activity in HeLa and SW480 cells treated with varying amounts of rU 
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in the absence or presence of 2.5 µM 5-F(rU). The data represent the mean ± SD of three 
parallel measurements. 
 
Supplementary figure 1: LC/MS/MS chromatograms showing 5-F(dU) in DNA and 5-
F(rU) in RNA hydrolysates from 5-FU- or 5-F(dU)-treated HeLa cells. 5-FU:A cccDNA was 
employed as a positive control for 5-FU in DNA. For each mass transition the signal 
intensities are normalized according to the most abundant peak in the present samples. The 
arrows indicate the expected elution positions of the respective nucleosides. 
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Table 1: Incorporation of 5-FU in DNA and RNA from HeLa cells exposed to 
different concentrations of 5-FU or 5-F(dU) for 24 hours.  
 
 Conc. 
(µM) 
DNA 
(5-F(dU)/106 nt) 
RNA 
(5-F(rU)/106 nt) 
Ratio 5-FU 
(RNA/DNA) 
 
5-FU 
 
10 
 
2.4 ±1.0 
 
5419 ±90 
 
2260 
 20 2.4 ±0.22 8262 ±420 3451 
 40 5.1 ±0.11 15046 ±1083 2967 
     
5-F(dU) 1 27.5 ±5.6 169 ±8.8 6.2 
 2 46.0 ±3.6 303 ±0.7 6.2 
 4 72.0 ±3.4 457 ±51 6.3 
 
 
Table 2: Incorporation of 5-FU in RNA from 
HeLa cells exposed to 5-FU or 5-F(rU) combined 
with increasing concentration of uridine 
 
Uridine 5-FU in RNA (5-F(rU)/106 nt) 
 (µM) 5-FU (10 µM) 5-F(rU) (2µM) 
 
0 
 
3501 ±119 
 
35166 ±2920 
10 4339 ±263 33486 ±534 
100 3651 ±110   7001 ±130 
1000 3417 ±22   1222 ±7 
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